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Abstract 
Activation of complement and its terminal pathway leads to the formation and insertion of 
the membrane attack complex (MAC) in the membranes of target cells. Complement is 
activated in tumours as is clear from the presence of complement activation products in 
cancer tissues. Over-expression of membrane bound complement regulators on tumour 
cells together with endogenous recovery mechanisms restricts complement activity and 
results in escape from lytic killing; nevertheless, sublytic MAC deposition is not without 
consequence. Sublytic MAC assembly on nucleated cells causes cell activation, secretion 
of extracellular matrix and pro-inflammatory cytokines and may cause protection from 
apoptosis. Signalling of these events is unclear.  
The global effects of sublytic MAC were addressed in the murine colon carcinoma cell line 
(CT26) through the use of microarray technology. Cells were exposed to sublytic 
complement attack using pooled normal human serum (pNHS) and compared to MAC-
inhibited controls generated using pNHS containing the C5 inhibitor OmCI.  Total RNA 
was extracted at 0, 1 and 12 hours post-exposure and subjected to microarray analysis 
using the Illumina platform. Top statistically significant changes were then identified and a 
list of genes upregulated at both time points was uploaded to MetaCore and a gene 
network generated. From this a number of co-regulated genes which converged on the 
EGFR were highlighted. These were cxcl1, amphiregulin and matrix metalloproteinases 
(Mmp) 3 and 13. Both the top statistically significant and network derived genes were 
validated using qPCR. Changes in protein levels were then tested using western blot 
analyses for Mmp3 and Areg. Inhibition of the MEK/ERK, and to a lesser extent PI3K/Akt, 
signalling suppressed the gene upregulation that occurred in response to MAC but 
inhibition of p38 and JNK had no effect, implicating a MEK/ERK- PI3K co-activation. MAC 
deposition and not C5a/C5aR axis signalling was shown to be responsible for the mmp3 
gene upregulation response. 
Identification of MAC-mediated events and the signalling pathways involved may provide 
insight into the mechanisms by which complement activation influences tumour growth. In 
particular the data suggest that sublytic MAC deposition might promote a gene expression 
response which pushes the cells to a more aggressive phenotype by the upregulation of 
proliferative, survival, invasion and migratory signals. This in turn will inform strategies that 
seek to harness complement or complement regulation in tumour immunotherapy. 
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1 Introduction 
1.1 Complement System 
1.1.1 Introduction 
A bacteriolytic activity of serum first described by Hans EA Buchner had been extensively 
studied at the end of the 19th century and was shown to have heat labile and heat stable 
components. The heat labile component was later referred to as complement (C) by Paul 
Ehrlich in the late 1890s, a term deriving from its apparent ‘complementation’ of antibody 
action, but it is Jules Bordet who is generally credited with C’s discovery (Morley & 
Walport, 2000). Bordet’s observation was that heat treated immune serum (from an 
immunized animal) lost its bacteriolytic capacity but, when combined with a non-immune 
unheated serum, could cause bacteriolysis in the same way as unheated immune serum 
(Laurell, 1990). 
C is a key part of innate immunity, providing an early warning signal and fast response 
upon encountering a foreign antigen. It is a system of proteins found in the serum which 
function as a proteolytic cascade amplifying an initial signal. The system is populated by 
roughly 30 proteins found in the fluid phase and on cell surfaces (Walport, 2001a). 
The role that C plays in immunity is multifaceted and complex. It functions in infection 
control through cytolysis of invading pathogens, opsonization for phagocytosis and 
release of anaphylatoxins which recruit and activate immune cells (Walport, 2001a).  It is 
also important in immune complex clearance (Schreibe.Ad & Frank, 1972). C can act as a 
bridge between innate and adaptive immunity helping to regulate B and T cell responses 
(Carroll, 2000; Dunkelberger & Song, 2010). Apart from these key immune functions it is 
implicated in processes including regulation during development of neuronal networks 
(Schafer et al, 2012). 
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Figure 1.1.1.1 C cascade is activated through three triggering pathways which respond to 
antibody/antigen (classical), mannose sugars (MBL) and foreign surfaces/spontaneous tickover 
(alternative).  The pathways converge on a C3 convertase which forms on the triggering surface and 
cleaves C3 into C3b and C3a. C3b deposits on local membrane allowing the further formation of C3-
convertase enzymes and leading to the alteration of substrate specificity of the convertase from C3 to 
C5. C5 convertase then cleaves C5 into C5b and C5a. C5a is a potent anaphylatoxin capable of 
attracting and activating local immune cells. C5b is then able to bind C6 and be released from the 
surface. C5b6 once bound to C7 and C8 begins to deposit and puncture the membrane and allow C9 
polymerisation and formation of a MAC pore. 
1.1.2 Activation 
C activates in response to several stimuli and is initiated by three activation pathways, the 
classical pathway which is primarily initiated by antibody:antigen complexes, the 
alternative pathway activated spontaneously by a tickover mechanism independently of 
antibody or as an amplification loop, and the mannose binding lectin pathway activated by 
mannose containing proteins or carbohydrates (Walport, 2001a). 
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1.1.2.1 Classical Pathway 
Antibody bound with antigen is capable of binding the C1 complex which is then activated. 
The C1 complex is made up of the large collagen like C1q molecule interacting with a 
C1r2C1s2 oligomer. Once the C1q-C1r2C1s2 complex binds with an antibody-antigen 
complex it is activated; C1r molecules cleave each other in sequence and then cleave the 
neighbouring C1s molecules. Once cleaved and activated, C1s can extend out from the 
C1q scaffold allowing it to interact with the next molecules of the cascade, C4 and C2. C4 
is cleaved by C1s releasing the C4a fragment and exposing an internal thioester moiety 
on the larger fragment C4b. This allows the C4b fragment to bind covalently with available 
amino or hydroxyl groups on local surfaces. C2 is then able to associate with the bound 
C4b in a metal-dependent manner where it is cleaved by C1s in an adjacent C1 complex, 
releasing the C2b fragment. The resulting C4b2a complex is the classical C3 convertase 
(Müller-Eberhard, 1988). 
1.1.2.2 Lectin pathway 
The lectin pathway is activated on the binding of either mannan binding lectin (MBL) to 
carbohydrate molecular patterns or one of three ficolins (L, M or H) to patterns of acetyl 
groups (Thiel, 2007). Activation is mediated, like the classical pathway, by serine 
proteases. There are three MBL associated serine proteases (MASPs) MASP-1, 2 and 3. 
Of these MASP-2 is key in the cleavage of C4 and C2, progressing in much the same way 
as the classical pathway (Vorup-Jensen et al, 1998). MASP-1 appears to activate MASP-2 
in a homologous manner to C1r and C1s and recent evidence suggests that MASP-3 may 
activate fD thus regulating alternative pathway activation (Sekine et al, 2013).  
1.1.2.3 Alternative pathway 
The alternative pathway can be considered both an activating pathway and an 
amplification mechanism. A non-cleaved C3 molecule hydrolysed at the thioester bond, 
designated C3(H2O), is capable of behaving like C3b and forming a C3 convertase thus 
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acting as a constantly activated tickover mechanism (Bexborn et al, 2008; Fishelson et al, 
1984). C3(H2O) binds factor B in the fluid phase, permitting factor B cleavage by the 
plasma enzyme factor D; Ba is released and the resulting C3(H2O)Bb complex is an 
alternative pathway C3 convertase. When C3 is cleaved by C3 convertase or by 
proteases into C3b (and C3a), C3b can become covalently bound to surfaces and with the 
binding of factor B and its cleavage by factor D, C3bBb can form and create a surface-
bound alternative C3 convertase enzyme (Fearon et al, 1973; Fishelson et al, 1984). The 
capability of C3b to form new convertase enzymes allows a small activation event to 
become amplified many fold thus forming a positive feedback amplification loop; properdin 
which binds and stabilizes the enzyme enhances amplification (Lachmann, 2009; 
Schwaeble & Reid, 1999). 
1.1.2.4 C3 
C3 is one of the most abundant proteins in plasma at 1.2 mg/mL (Kohler & Müller-
Eberhard, 1967; Morley & Walport, 2000). Each of the activation pathways converge on 
the central C3 component which is cleaved into two fragments; the smaller C3a 
anaphylatoxin and the larger C3b opsonin (Walport, 2001a). C3b in plasma or deposited 
on target surfaces is rapidly cleaved in sequence by regulators to form, first iC3b, then 
C3c and C3dg (Liszewski et al, 2008). Surfaces enriched in deposited C3b and its 
cleavage products can adhere to and illicit signals to immune cells expressing relevant 
receptors, acting as tags (Lambris & Müller-Eberhard, 1986).  
1.1.2.5 C5 convertase 
Activation of C results in a C3 convertase enzyme being formed, generally the 
classical/lectin pathway enzyme is C4b2a and the alternative pathway enzyme is either 
C3bBb or C3(H2O)Bb. For C activation to progress beyond this point the enzyme must 
alter specificity from cleavage of C3 to cleavage of C5. Alteration of specificity is 
dependent on the density of C3b deposited on the target surface, monomeric (C3bBb) 
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enzymes have a higher affinity for C3b only weakly interacting with C5,  but when there is 
a high density of C3b this affinity shifts towards C5, thought to require the presence of 
more than one C3b and referred to as C3bBbC3b (Rawal & Pangburn, 2001). Cleavage of 
C5 into C5b (the larger fragment) and C5a (the smaller anaphylatoxic fragment) marks a 
key event in C progression (Walport, 2001a; Walport, 2001b). Both fragments have 
significant roles in C function and immunity. C5a is a potent anaphylatoxic protein 
released locally, attracting and activating immune cells which express the receptor, C5aR 
(Monk et al, 2007). C5b marks the start of the terminal pathway. 
1.1.3 Terminal Pathway 
C5b formed from cleavage of C5 is initially in its nascent form C5b*. This short-lived 
conformation binds to C6 in a stable hydrophilic interaction to form C5b6. The C5b6 
complex remains loosely associated with C3b until it binds C7 to create C5b67 complex 
which initiates a hydrophilic-amphiphilic transition causing its release from the convertase 
and making it capable of forming a metastable interaction with surface phospholipids. 
Once bound to the surface, C5b67 recruits and binds C8 which begins the insertion into 
the membrane via its α chain. C8 now recruits and acts a catalyst for C9 polymerisation; 
C9 undergoes hydrophilic-amphiphilic transition, unfolding into the membrane and 
exposing fresh sites for further C9 binding. Polymerization of C9 results in the classical 
cylindrical pore of the membrane attack complex (MAC) (Müller-Eberhard, 1986). 
1.1.4 Anaphylatoxins and their receptors 
Activation of C results in the formation and release of three anaphylatoxic cleavage 
products, C4a, C3a and C5a, the smaller fragments of C4, C3 and C5 cleavage 
respectively. These proteins are each around 10 kDa in mass and have 74-77 amino acid 
(aa) sequence. They are rapidly inactivated by carboxypeptidases to their desarginine 
forms (DesArg). Hierarchically the potency of the anaphylatoxins are ordered C5a > C3a 
>C4a  (Hugli, 1984; Zhou, 2012). The anaphylatoxins are named due to their induction of 
anaphylactic responses when generated in excess, they function on local tissue and cells 
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by causing contraction of smooth muscle, histamine release, increase in capillary 
permeability, adhesion of leukocytes to vascular endothelium, leukocyte chemotaxis, and 
aggregation of platelets and leukocytes (Vogt, 1986). 
Specific roles of C3a on ligation to its receptor include eliciting histamine release from 
mast cells, eosinophils, neutrophils and basophils, thromboxane A release from 
macrophages, and the secretion of lysosomal enzymes from neutrophils (Lambris, 1988). 
C3a is capable of inducing vascular permeability and increasing contractility of vessels 
(Ember et al, 1992) as well as vasodilating activity (Schumacher et al, 1991). It has also 
been shown to trigger respiratory burst in neutrophils, releasing reactive oxygen species 
(ROS) and H2O2 in response to C3a exposure (Elsner et al, 1994b). C3a also causes 
respiratory burst in macrophages (Murakami et al, 1993) and eosinophils (Elsner et al, 
1994a) and can act as a chemoattractant for eosinophils (Daffern et al, 1995) and mast 
cells (Nilsson et al, 1996). As a pro-inflammatory mediator, C3a is also capable of 
triggering cytokine release. In response to C3a in vitro, adherent PBMCs released 
interleukin (IL) -1β, tumour necrosis factor (TNF) -α and IL-6 (Takabayashi et al, 1998; 
Takabayashi et al, 1996). C3a can also exert influence on tissue cells, inducing IL-8 
expression in epithelial cells and both IL-8 and IL-1β in endothelial cells (Monsinjon et al, 
2003; Monsinjon et al, 2001).  
C5a has influence on neutrophils and macrophages at nanomolar concentrations and is 
thus significantly more potent than C3a, though it shares many of its functions such as 
increasing vessel contractility (Ember et al, 1992). C5a has potent neutrophil 
chemoattractant activity, also influencing macrophages and monocytes (Marder et al, 
1985). C5a has been shown to induce oxidative burst in neutrophils as well as enhancing 
phagocytosis of opsonised bacteria via C receptor (CR) type 3 upregulation (Mollnes et al, 
2002; Sacks et al, 1978). It has also been described as having vasodilating activity in a 
canine model (Schumacher et al, 1991). C5a can modulate expression of cytokines such 
as macrophage inflammatory protein-2 (MIP-2) and monocyte chemoattractant protein-1 
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(MCP-1) induced by IL-6 in endothelial cells (Laudes et al, 2002) and TNF-alpha, MIP-2, 
and cytokine-induced neutrophil chemoattractant-1 (CINC-1) in epithelial cells response to 
LPS (Riedemann et al, 2002). 
C3a and C5a effects are exerted via their ligation to receptors present on the surface of 
expressing cells. A receptor for C4a has not been described; although originally thought to 
exert effects through C3aR binding, it is now generally accepted that C4a does not have 
an important biological function. C3aR, C5aR (CD88) and C5L2 are the three receptors 
associated with anaphylatoxin responses. Both the C3aR and C5aR are members of the 
rhodopsin subfamily of G protein-coupled receptors (Gerard & Gerard, 1994). C5aR 
mediates the majority of responses attributed to C5a with C5L2, a structurally similar 
receptor but thought to lack signalling activity. C5L2 is only weakly phosphorylated upon 
binding but has a higher affinity for C5a than C5aR and thus may act as a decoy or 
scavenger receptor, regulating in vivo responses to C5a (Gao et al, 2005; Okinaga et al, 
2003). 
1.1.5 Regulation 
C activation is a proteolytic cascade in continual tick-over and is thus capable of 
enormous amplification. With the powerful results of C activation mediated by the 
anaphylatoxins and potential for tissue damage mediated by MAC, there is a need for tight 
control. Around a third of all proteins belonging to the C system are regulatory in function. 
1.1.5.1 Soluble regulators 
The soluble regulators maintain fluid phase homeostasis, controlling release of 
inflammatory mediators and preventing depletion of the necessary components.  
C1-Inhibitor (C1-INH) is a member of the serpin family of protease inhibitors and is the 
only classical pathway protease inhibitor present in serum (Ziccardi, 1981). C1-INH 
regulates activation of the classical pathway primarily by dissociating C1s and C1r from 
the activated C1 molecule (Davis et al, 2008). Apart from its classical pathway inhibition, 
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C1-INH is also capable of regulation of the lectin pathway via its inhibition of MASP-2, and 
has been suggested to cause a non-protease mediated inhibition of alternative pathway 
activation (Jiang et al, 2001; Kerr et al, 2008). 
C4b-binding protein (C4BP) is a large glycoprotein of 500 kDa with regulatory activity for  
both the classical and lectin pathways (Blom et al, 2004). C4BP possesses factor I (FI) 
cofactor activity, inactivating soluble and surface bound C4b by catalysing its cleavage to 
C4c and C4d, thus regulating the formation of the classical C3-convertase enzyme (Fujita 
et al, 1978). C4BP binds C4b preventing the formation of the classical C3 convertase 
enzyme as well as acting as a decay accelerator to the forming C4b2a complex (Daha & 
van Es, 1980; Gigli et al, 1979). 
FI is an 88 kDa serine protease and regulator of C3 convertase containing either C3b or 
C3(H2O) (Davis, 1981; Hsiung et al, 1982). FI requires a co-factor to cleave C3b and 
C3(H2O) into their inactivated forms iC3b and iC3(H2O) through the cleavage of the α 
chain into a smaller and larger fragment which remain associated by a disulphide bridge 
(Pangburn & Müller-Eberhard, 1983). Co-factors, including factor H (FH), C4BP, 
membrane co-factor protein (MCP/CD46) and CR1 (CD35), direct substrate specificity to 
either C3b or C4b (Minta et al, 1998). iC3b can be further cleaved to C3c and C3dg when 
CR1 acts as cofactor (Ross et al, 1983) 
FH is a 155 kDa glycoprotein with 20 repeated short consensus repeat (SCR) units 
making up its 1213 aa sequence (Ripoche et al, 1988; Sim & Discipio, 1982). FH functions 
as a regulator of the alternative pathway and its C3 convertase via its decay accelerating 
activity as well as its co-factor activity mediating FI cleavage of C3b as described above 
(Pangburn et al, 1977; Weiler et al, 1976; Whaley & Ruddy, 1976). FH functions as decay 
accelerator for alternative and classical C3-convertase enzymes as well as their 
corresponding C5 convertases (Heinen et al, 2009; Jokiranta et al, 1996). 
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1.1.5.2 Membrane associated regulators 
CD46, also known as MCP is a membrane bound C regulatory protein ~ 60 kDa in size 
and comprised mainly of 4 SCRs. Variability in size is due to a number of splice variants 
and glycosylation patterns (Ballard et al, 1988; Post et al, 1991). MCP is widely distributed 
being expressed by platelets, granulocytes, Thelper, Treg, B-cells, NK cells and 
monocytes as well as fibroblasts, epithelial and endothelial cells but not by erythrocytes 
(McNearney et al, 1989; Seya et al, 1988). MCP was first described as a C3b/iC3b 
binding protein and later shown to possess co-factor activity for FI degradation of C3b and 
C4b into their inactivated forms (iC3b, iC4b) (Seya et al, 1986). Expression of MCP on the 
cell surface protects cells from C attack by intrinsic regulation, i.e. it is unable to act as co-
factor for C3b deposited on bystander cells (Oglesby et al, 1992). 
CD55, also known as decay accelerating factor (DAF), was first described as a 70 kDa 
glycoprotein isolated from human erythrocytes displaying decay acceleration of both the 
classical and alternative C3-convertases (Nicholsonweller et al, 1982). Membrane 
association of CD55 is dependent on its glycophosphatidyl (GPI) anchor which is attached 
during post-translational modification, the anchor allows it to be easily incorporated by 
exogenous addition and thus confers greater freedom of translocation on the outer leaflet 
of the membrane bilayer (Davitz et al, 1986; Medof et al, 1984; Thomas et al, 1987). The 
protein is expressed as a single aa chain containing a highly glycosylated region, GPI 
anchor site and 4 SCRs  (Lublin & Atkinson, 1989). CD55 regulation is mediated partly by 
its binding of intrinsically bound C3b and C4b, preventing FB and C2 respectively from 
binding and forming the convertase enzymes, this happens without modification of either 
C3b or C4b (Medof et al, 1984). DAF is capable of dissociating C2a or Bb from preformed 
C3 convertases thereby rendering them inactive, this is achieved with no biochemical 
alterations to either C2a or Bb (Fujita et al, 1987). 
CD35, also known as CR1, functions both as a receptor to C3b/C4b opsonised particles 
and as an efficient regulator of C. The CD35 protein is made up of 30 extracellular SCR 
10 
 
domains arranged into 4 long homologous repeats (LHRs) containing 7 SCRs each 
(Klickstein et al, 1987). Ligand binding sites for C3b and C4b are located in SCRs 8-9 and 
1-2 respectively (Krych et al, 1991). The binding of each site to their respective ligands 
mediates both CR1 co-factor activity (Krych et al, 1994) and decay accelerating activity for 
both the C3 and C5 convertases of the alternative and classical pathways (Krych-
Goldberg et al, 1999). Apart from its versatile regulatory functions, CD35 has important 
roles in C mediated phagocytosis and immune complex handling. CD35 is expressed on 
erythrocytes, polymorphonuclear leukocytes, B-cells T-cells, and monocytes (Fearon, 
1980; Wilson et al, 1983). CR1 expressed on erythrocytes binds C3b/C4b labelled 
immune complexes so that they can be transported to the liver and cleared (Cornacoff et 
al, 1983). CR1 also causes adhesion of neutrophils to opsonised particles to promote their 
phagocytosis (Fallman et al, 1993). 
CD59, once referred to as protectin, but now only known by its CD designation, was 
described as the antigen to which the antibody YTH 53.1 bound, potentiating lysis of cells 
to homologous C; the antigen was characterised as a 20 kDa glycoprotein with homology 
to Ly-6 antigens (Davies et al, 1989). CD59 is expressed as a 128 aa polypeptide chain 
which is processed to a 77 aa mature form. This mature protein  is a single globular, 
cysteine rich extracellular domain, linked to the plasma membrane by a GPI anchor and 
has a single N-glycosylation site and several potential O-glycosylation sites (Holguin et al, 
1990; Kimberley et al, 2007). CD59 regulates the terminal pathway of C; specifically 
inhibiting C9 polymerisation and membrane insertion by its binding of the C5b-8 complex 
and thus preventing MAC formation (Meri et al, 1990). 
1.1.6 Mouse complement 
The murine complement system shares much of the components of the human system 
albeit with varying degrees of homology. The mouse complement system is known to be 
significantly less active compared to its human counterpart. There are several molecular 
differences, both in the components of the cascade and regulators of the cascade. Murine 
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C4 is not capable of forming part of a classical C5 convertase i.e. C4bC2bC3b complex, 
as is known to occur in the human system, contributing a significant reduction in 
haemolytic activity (Ebanks & Isenman, 1996). With no C5 cleavage occurring during 
classical pathway activation the alternative pathway C5 convertase compensates for 
terminal pathway activation to occur. In fact the C5 component itself is lacking in 61% of 
in-bred mouse strains due to the synthesis of an abnormal protein through a post-
translational defect (Ooi & Colten, 1979).  Deficiency of the C8β sub-unit has also been 
recorded in MSM and Mae strains resulting in a severely reduced haemolytic activity 
which can be increased with supplementation with purified human C8 (Tanaka et al, 
1991). A well known phenomenon has also been described pertaining to a difference 
between male and female haemolytic activity in mice. This difference is associated with 
lower titres of C4, C5 and C6 as well as C4BP in the serum of female mice comparing to 
males (Churchil.Wh et al, 1967; Ferreira et al, 1978; Shreffler, 1976). Some of this 
difference is due to androgen control of expression (Churchil.Wh et al, 1967; Shreffler, 
1976). 
Other than the differing serum activity, the murine system differs in its regulatory 
components. The mouse has structural and functional homologues for CR1, CD59, CD46 
and CD55 (Holers et al, 1994; Kinoshita et al, 1985; Powell et al, 1997; Tsujimura et al, 
1998). CD59 in the mouse exists in two forms, a and b, with differing tissue distribution; 
CD59a is widely distributed acting as the main terminal pathway regulator but CD59b is 
restricted to the testis with roles in spermatozoal acrosome activation(Baalasubramanian 
et al, 2004; Donev et al, 2008; Qian et al, 2000). There is also a duplication of the CD55 
gene giving rise to a transmembrane and a GPI anchored form (Harris et al, 1999). In 
addition to these homologues mice also express the complement regulator complement 
receptor 1-related gene/protein-y (Crry) which is exclusive to rodents with the regulatory 
mechanisms of both MCP and CD55 (Kim et al, 1995; Molina, 2002). 
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Crry is considered the major complement regulator in mice, a fact which is demonstrated 
by the embryonic lethality of its deletion which can be reversed with C3 deficiency (Molina, 
2002). Lethality could also be reversed with the treatment of the mother with anti-C5 Ab 
further demonstrating the importance of Crry as a complement regulator in mice (Ruseva 
et al, 2009). Given the mechanism by which Crry regulates complement it has been found 
to be a major contributor to the maintenance of complement homeostasis, controlling the 
constant turnover of C3 in tick-over (Wu et al, 2008). 
1.2 Cancer and inflammation 
1.2.1 Introduction 
There has long been debate within the field of tumour immunology as to the role immunity 
has in tumour formation and progression. Infiltrating leukocytes within developing 
neoplasms were first described by Rudolf Virchow (Virchow & Chance, 1971) in the 19th 
century providing a key indicator of the link between inflammation and immunity in 
tumours. Over the last half century a great deal of progress has been made in 
understanding this link.   
Inflammation in response to tissue damage is a normal physiological process. The 
process begins with the release of an array of inflammatory signals to initiate the early 
response. First responders to the site are neutrophils from the circulation, these release 
chemokines and cytokines required for recruitment and activation of effector cells. 
Monocytes arrive next and  differentiate into macrophages upon activation becoming the 
main source of growth factor and cytokines. Released factors guide the remainder of the 
response, exerting influence on endothelial, epithelial and mesenchymal cells in the 
surrounding tissue (Coussens & Werb, 2002). 
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1.2.2 Inflammatory tumour infiltrates 
Tumour tissue throughout its development has a significant infiltration of leukocytes, 
innate inflammatory cells including neutrophils, dendritic cells, macrophages, eosinophils 
and mast cells, and an adaptive immune cell infiltrate of lymphocytes (Coussens & Werb, 
2002). A key mechanism responsible for recruitment of such cells is the tumour cell 
expression of chemokines and various chemoattractant factors like MCP-1 and CSF-1, 
thought to promote macrophage infiltration (Lin et al, 2001). Once recruited the diverse 
population provide a number of inflammatory factors including cytokines, chemokines, 
metallo/cysteine/serine-proteases, membrane perforating agents and mediators of cell 
death including TNFα, ILs, and IFNs (Coussens & Werb, 2001). The presence of immune 
infiltrates drives chronic inflammation which has the effect of triggering and promoting 
tumorigenesis through various mechanisms. 
1.2.3 Inflammation triggered cancer 
Chronic infections with a specific causative organism are known to be linked with cancer, 
accounting for at least 18% of all cases (Parkin, 2006). The common gastric infectious 
agent H. Pylori is closely associated with gastric adenocarcinomas (Franco et al, 2008). 
The best explanation for this association is its ability to drive a chronic inflammatory 
response given that infection with the more virulent cag-A/vacA expressing strains closely 
correlates with the incidence of pre-cancerous lesions (Plummer et al, 2007). Also, human 
patients suffering from colorectal tumours had a higher prevalence of the commensal 
enterotoxigenic Bacteroides fragilis bacterium (ETBF), an association supported by 
evidence suggesting a Th17 mediated inflammatory response is directly responsible for 
ETBF mediated tumour formation (Toprak et al, 2006; Wu et al, 2009). Other infectious 
agents with known links to cancer incidence include viral pathogens: Human papilloma 
virus (HPV) is linked to cervical cancer, Hepatitis B and C viruses (HBV and HCV) are 
linked to hepatocarcinoma and non-Hodgkin lymphoma, Epstein-Barr virus (EBV) is linked 
to Burkitt’s lymphoma, nasopharyngeal carcinoma and  Hodgkin’s lymphoma, Human 
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herpes virus 8 (HHV-8) and Human T-cell leukaemia virus type I (HTLV-1) are linked to T-
cell leukaemia (de Martel & Franceschi, 2009). 
Chronic inflammation induced by environmental exposure to metals such as beryllium, 
chromium and nickel and to the fibrous agents making up asbestos, contribute to their 
known links to incidence of cancer (IARC, 2012). Exposure to asbestos leads to pleural 
mesothelioma an otherwise rare neoplasm. Asbestos fibre exposure and its 
carcinogenicity is proposed to be associated with inflammation via its biopersistence and 
induction of phagocytosis triggered activation of the NLRP-3 inflammasome and 
subsequent release of IL 1β (Dostert et al, 2008). Other environmental triggers of 
inflammation include tobacco smoke which can induce chronic inflammation via IKKβ and 
JNK1 and contribute to tumour promotion (Takahashi et al, 2010).  
Conditions which are characterised by autoimmune mediated chronic inflammation are 
also associated with increased risk of cancer. Patients diagnosed with Crohn’s disease 
have a higher risk of developing colorectal cancer and those diagnosed at a younger age 
were more at risk than those diagnosed later in life (Ekbom et al, 1990a). The same 
association was found in patients suffering from ulcerative colitis (Ekbom et al, 1990b). 
Inflammatory mechanisms of tumour promotion are various. Primarily it is thought that 
activated cells in the leukocyte infiltrate release reactive oxygen and nitrogen species 
(RNS/ROS) which attack nucleic acids and mediate damage to DNA and other key 
molecules (reviewed (Hussain et al, 2003)). Briefly, activated cells release RNS; nitric 
oxide (NO•) and peroxynitrite (ONOO-) and ROS; hydroxyl radical (OH•) and  superoxide 
(O2-•), via the activity of the enzymes myeloperoxidase, NADPH oxidase, and nitric oxide 
synthase. These cause oxidative damage and nitration of DNA bases leading to mutations 
in DNA sequence, error-prone repair and genetic instability (Rassool et al, 2007). 
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Tumour initiation via inflammation can be mediated by acquisition of p53 mutations which 
in ulcerative colitis patients was found to precede dysplasia and cancer formation, 
suggesting an inflammation associated genomic alteration (Lashner et al, 1999). 
1.2.4 Tumour promoting inflammation 
These associations represent a direct tumorigenic role for the inflammatory response with 
a clear mechanistic manifestation. It is, however, often the case that inflammation is 
secondary in tumour formation assisting in development, as in the case of chemically 
induced liver tumorigenesis mediated by diethylnitrosamine (DEN). DEN caused DNA 
damage and cell death but induced tumorigenesis through an indirect, IKKβ mediated 
inflammatory response which resulted in cytokine and growth factor induced 
compensatory proliferation and tumour development (Maeda et al, 2005). The role for 
IKKβ implicates NFκB in the inflammatory response. IL-1α release caused necrotic death 
and induced a proliferative response confirming the importance of cell death in 
inflammation driven tumorigenesis (Sakurai et al, 2008). 
Cyclooxygenase (COX) 2 is upregulated in several human cancers and is responsible for 
the high levels of prostaglandin in the tumour microenvironment which in the case of 
neuroblastoma promote proliferation and survival of tumour cells (Rasmuson et al, 2012). 
Indeed, the key role this inflammatory mediator and other arachidonic acid (AA) pathway 
metabolites play in tumorigenesis is highlighted by the success in the use of the COX 
inhibitors. The non-steroidal anti-inflammatory drugs (NSAID) diclofenac, which increased 
apoptosis and inhibited tumour growth (Johnsen et al, 2004), and celecoxib which 
prevented tumour growth and increased cell susceptibility to chemotherapeutic drugs 
(Ponthan et al, 2007), were antitumour in in vivo models. 
TNFα expression is thought to be key in the transition from chronic inflammation to 
tumorigenicity in the case of ulcerative colitis in which its increase was correlated with 
malignant transformation in a mouse model. This correlation was associated with 
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inflammatory cell trafficking and COX-2 expression. Blocking of TNFα signalling prevented 
transformation and could reverse progression of formed carcinomas (Popivanova et al, 
2008). IL-6 trans-signalling (regulated by transforming growth factor (TNF) β), TNFα, IL-11 
and IL-1β have each been implicated in colitis associated cancer tumorigenesis (Becker et 
al, 2004; Bollrath et al, 2009; Grivennikov et al, 2009).  
Implication of IKKβ dependent NFκB activation in colitis associated cancer provides an 
indication of the molecular mechanisms of tumour promoting inflammation. Specific 
removal  of IKKβ and thus NFκB activation in myeloid cells in a mouse model reduced 
tumour growth, correlating with reduced expression of IL-1α and β, IL-6, CXC motif ligand 
(CXCL) 1, macrophage inflammatory protein 2 (MIP-2), TNFα, COX-2, and intercellular 
adhesion molecule 1 (ICAM-1) in response to colitis induction (Greten et al, 2004).  
1.2.5 C and cancer 
1.2.5.1 Cancerous cells activate homologous C 
When focussing on C in the context of cancer and transformed cells it is important to 
establish whether they are capable of activating endogenous C in vivo. Some of the first 
evidence of C activation by malignant transformed cells was found using 
immunohistochemistry of breast cancer tissue which showed deposition of the MAC and 
the components C3 and C4, in contrast to the lack of such components in adjacent benign 
breast tissue (Niculescu et al, 1992). These data indicate that transformed cells are 
capable of C activation as far as the terminal pathway and also suggest that this is due to 
classical pathway activation. Similar results were found in papillary thyroid carcinoma on 
which deposits of MAC, C3d, C4d, C5, IgG1 and IgG4 were detected (Lucas et al, 1996; 
Yamakawa et al, 1994). The concentration and activity of MBL in the plasma of colorectal 
cancer patients was higher when compared with normal controls, suggesting MBL may be 
activated in response to malignant transformation (Ytting et al, 2004). The presence of 
C3a and soluble MAC in the ascitic fluid taken from ovarian cancer patients also indicates 
activation of the alternative and classical pathways in this tumour type, supported by the 
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deposition of some activation products, for example C3d and C1q, on the surface of 
tumour cells (Bjorge et al, 2005). The exact trigger for C activation upon transformation is 
still not fully understood, although activation through immune complexes, antibody binding 
or direct C1q binding to necrotic/apoptotic cellular components are all possibilities. The 
relative contribution made by each activation pathway is unclear but data implicate all 
three pathways. 
1.2.5.2 C in immunotherapeutic mAb 
C activation is a contributor to the efficacy of a number of immunotherapeutic mAb used to 
treat cancers. C activation has been shown to contribute to tumour clearance for rituximab 
in vitro (Harjunpaa et al, 2000; Zhou et al, 2008), in vivo (Cragg & Glennie, 2004; Di 
Gaetano et al, 2003) and in treatment of patients (Kennedy et al, 2004). Taken together 
these data suggest a central role for C as an effector mechanism in therapeutic mAbs. 
1.2.5.3 Cancer cell expression of mCRegs 
It is widely thought that C activation on and around tumours is minimal due in part to the 
ubiquitous expression of C regulators (Fishelson et al, 2003; Jurianz et al, 2001). Most 
importantly, tumours abundantly express membrane bound C regulators (mCRegs). 
The inhibition of C activation by the mCRegs expressed by cancer cells is in some cases 
bolstered by their upregulation on these cells, thus protecting the transformed cells from 
attack (McConnell et al, 1978). This interpretation is complicated by the apparent 
variability in expression levels of the mCRegs in several different cancers, but the 
overwhelming view is that in the majority of cancers investigated expression of one or 
more of the mCRegs is increased relative to healthy cells (Fishelson et al, 2003). 
The possible role these regulators have in protecting tumours has been of great interest to 
those studying resistance to C fixing antibody in immunotherapy and can be demonstrated 
in in vitro studies in which mCReg protection is removed. The abrogation of regulatory 
activity invariably leads to significant increases in tumour cell sensitivity to C lysis (Yan et 
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al, 2008). Strategies include blocking with mAbs, for example with anti-CD55 in B-cell 
tumours, erythroleukaemic, melanoma, and renal tumour lines (Cheung et al, 1988; Gorter 
et al, 1996; Jurianz et al, 2001; Kuraya et al, 1992), and anti-CD59 in B-cell tumours, 
erythroleukaemic, mammary, ovarian, prostate, breast and renal cell lines (Donin et al, 
2003; Ellison et al, 2007; Gorter et al, 1996; Jurianz et al, 2001; Kuraya et al, 1992).  
The sensitization to killing by inhibiting mCRegs can be demonstrated in vivo giving 
results which reflect those in in vitro work. In an animal model, the human ovarian cancer 
cell line, A2780, was infected with recombinant retroviral particles containing a siRNA 
sequence designed to efficiently knock-down CD59 expression. Cells were then injected 
subcutaneously into nude mice. The CD59 knockdown cells formed significantly smaller 
xenograft tumours than a non-knocked-down infected cell control (Shi et al, 2009). Cells of 
the prostate cancer cell line PC-3 which demonstrate high expression of CD55 were 
transfected with the siRNA construct (CD55-3) targeted to knockdown CD55 expression. 
Cells were then injected into SCID mice. Mice injected with the PC-3 CD55-3 cells had 
significantly lower tumour burden compared to those injected with the PC-3 cells 
transfected with scrambled control (Loberg et al, 2006). Similar results were found when 
tumour cells isolated from breast cancer patients were xenotransplanted into SCID mice; 
mice injected with cells expressing high levels of CD59 developed larger tumours 
compared to those injected with cells expressing low levels of CD59 (Ikeda et al, 2008).  
The level of CD55 expression in human breast cancers was found to correlate with 
disease prognosis; high CD55 expression correlated to a higher tumour size and poor 
outcome (Ikeda et al, 2008). Over-expression of CD55 in human cervical cancer tissue 
was shown to correlate with reduced deposition of C3b compared to surrounding tissue, 
suggesting C inhibition is relevant in vivo (Gao et al, 2009). In the same way levels of 
CD59 expression have been correlated with tumour grade and survival in colorectal 
cancer patients (Watson et al, 2006). The expression of both these mCRegs was also 
found to correlate to prognosis in non-small cell lung cancer (NSCLC) and contribute to 
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disease resistance to herceptin, an anti-Her2/neu mAb, treatment whose efficacy relies 
upon C activation (Zhao et al, 2009). The correlation between prognosis and expression 
of the mCRegs in multiple tumour types suggests a key role for C during tumorigenesis 
where levels are critical. 
1.2.5.4 C activation influences tumour growth 
Given the evidence that C activation occurs in tumour tissues and that C evasion 
strategies are used by tumour cells to avoid damage, it has long been thought that C 
activation is bad for tumours. This has fuelled recent work aimed at targeting antibodies 
for C fixation and dampening the inhibitory influence of expressed regulators.  
There have, however, been a number of studies which suggest that C may promote 
cancer. A landmark study suggested a tumour promoting role for C5a (Markiewski et al, 
2008). Growth of TC-1 injectable tumours was slower in C3, C4 and C5aR syngeneic 
knockout mice and the administration of a C5aR antagonist had a similar effect in the wild 
type mouse. Together, the data indicate that C, likely classical pathway activation, drives 
tumour progression and that the effect requires C5aR signalling. The principal finding of 
this study was that C5a released by C activation in the tumour micro-environment 
recruited myeloid derived suppressor cells (MDSCs) which once in the tumour worked to 
dampen a CD8+ T-cell mediated immune response by releasing ROS and RNS. 
C activation as a tumour promoting influence is a new but plausible idea given the well-
known and powerful effect of inflammatory responses during tumour progression. A 
powerful effector of C activation is the MAC complex. Sublytic  MAC effects may present a 
novel pro-tumour role for C. 
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1.3 Sublytic MAC 
1.3.1 Mechanism of MAC induced lysis 
The one-hit theory of cellular lysis by complement long held precedence because of 
kinetic and statistical studies which showed that a single C2 molecule could lead to lysis 
(Mayer et al, 1970). It is now understood that a single C2 does not restrict the number of 
terminal events because the formed C3 convertase showers the membrane with C3b 
(Müller-Eberhard et al, 1967).  Cytolysis of an inert target, such as the aged erythrocyte, 
with a single MAC is theoretically possible as shown via C5b6 titrations (Yamamoto & 
Gewurz, 1978). It is however a different story with a metabolically active nucleated cell. 
1.3.2 MAC resistance in nucleated cells 
Deposition of the MAC on a nucleated cell can lead to disruption to membrane 
permeability as evidenced by calcium influx (Campbell et al, 1981; Michaels et al, 1976). 
However, nucleated cells display much greater resistance to MAC lysis compared to the 
aged erythrocyte, displaying multi-hit characteristics as shown in U937 cells exposed to 
C6 restricted serum (Koski et al, 1983). It was also apparent that this resistance to lysis 
was tightly associated with the cells metabolic activity, demonstrated by the increase in 
lipid synthesis induced in antibody sensitized tumour cells treated with C (Schlager et al, 
1978). Beyond this association, previous observations had demonstrated that the phase 
of the cell cycle had a profound influence on susceptibility to MAC lysis; in general cells 
were least susceptible in their exponential phase and most susceptible in their stationary 
phase (Cikes & Friberg, 1971). Though this was associated with changes in antigen 
density the number of C components involved in activation was unrelated to susceptibility 
suggesting the effect was dependant on the cells metabolic status (Cooper et al, 1974; 
Ohanian & Borsos, 1975). Treatment with metabolic inhibitors enhanced susceptibility to 
MAC lysis (Ohanian & Schlager, 1981). These data implied that resistance was due to 
active mechanisms arising from within the cell.  
21 
 
Nucleated cells are protected from bystander damage by C activation via passive and 
active mechanisms. The first and primary defence is that of the membrane bound 
regulators including CD46, CD55 and CD59 (Morgan & Harris, 1999). CD59 is especially 
important as the last line of passive protection, inhibiting the formation of MAC (Meri et al, 
1990). Protection from MAC beyond this involves internal processes which require 
expenditure of energy as evidenced by the effects of depletion of intracellular energy 
sources such as phosphocreatine and ATP (Tirosh et al, 1984). Ion pumps have even 
been implicated in the resistance of erythrocytes to MAC, activation of Ca2+ activated K+ 
pumps, counteracting the Na+ influx, was protective (Halperin et al, 1993b). 
Nucleated cells are capable of removing MAC from their surface in order to survive an 
attack. Deposited MAC on U937 cells was shown in functional studies to have a half-life of 
2 mins at 30°C and was increased to 2 hours at 2°C suggesting that the functional MAC 
was being removed from the membrane by an unknown mechanism (Ramm et al, 1983). 
The phenomenon was directly observed in Ehrlich cells where colloidal gold tagged 
complexes were internalised by endocytosis (Carney et al, 1985). In polymorphonuclear 
cells the MAC was shown to be removed by vesiculation (Campbell & Morgan, 1985). In 
1987 Morgan et al. elegantly demonstrated both mechanisms to be involved in resistance 
of human neutrophils to homologous MAC. Supernatants of attacked cells were enriched 
with vesicles coated in MAC, accounting for 65% of the total. The remaining 35% of 
complexes remained on the cell but were not accessible to the detecting antibody and 
radio labelled C8 was found to be internalised for degradation (Morgan et al, 1987).  
The phenomenon has since been reported to occur in many tumour and normal cells, 
including U937 monocytic cell line (Morgan et al, 1986), Ehrlich ascites tumour cells 
(Carney et al, 1985), K562 (Moskovich & Fishelson, 2007), glomerular epithelial cells 
(GECs) (Kerjaschki et al, 1989), blood platelets (Sims & Wiedmer, 1986) and  
oligodendrocytes (OLGs) (Scolding et al, 1989). 
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Using C9 labelled with AF488, Moskovich and colleagues were able to track deposited 
MAC on K562 cells, demonstrating outward emission of C9-AF488 via ectosomes and 
exosomes within 10 minutes (Moskovich & Fishelson, 2007). After 10 minutes, C9-AF488 
entered the early endosomal compartment then later entered the perinuclear compartment 
where it co-localised with transferrin. The vesicles were then packed into multivesicular 
bodies and exocytosed or proteolytically degraded. The mitochondrial hsp70 chaperone 
known as mortalin promotes elimination of the MAC enriched vesicles on which it co-
localises. When mortalin is blocked or silenced, the rate of vesiculation is reduced leaving 
the cell more sensitive to MAC lysis (Pilzer & Fishelson, 2005; Pilzer et al, 2010). The 
data suggests that mortalin could be involved in detection of MAC insertion and initiation 
of vesiculation. 
1.3.3 Resistance and signalling events 
Resistance to C is likely to be initiated by signalling cascades triggered at the surface. 
Levels of cyclic adenosine monophosphate (cAMP) the first second messenger to be 
discovered, are closely associated with levels of resistance with decreased levels being 
indicative of increased sensitivity (Lo & Boyle, 1979). Indeed, increased intracellular cAMP 
confers protection and can rescue cells from lysis (Boyle et al, 1976; Kaliner & Austen, 
1974).  
The first detectable event following MAC deposition is an immediate rise in intracellular 
free Ca2+ concentration ([Ca2+]i). Calcium influx was first shown using pigeon erythrocyte 
ghosts containing obelin, demonstrating that MAC allowed Ca2+ to enter the cell along the 
marked gradient maintained across the membrane (Campbell et al, 1979). The rapid influx 
of Ca2+ increased intracellular concentrations from 0.3 µM to between 5 and 30 µM within 
40 seconds (Campbell et al, 1981). Although first described in pigeon erythrocytes, a 
calcium influx upon MAC deposition was also shown in neutrophils. The study 
demonstrated using the Ca2+ chelator ethylene glycol tetra acetic acid (EGTA) that MAC 
deposition could induce release from intracellular stores in the absence of extracellular 
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Ca2+ and that rises in Ca2+ were key in the elimination of MAC from the membrane 
(Morgan & Campbell, 1985). Elimination of MAC from human platelets by exocytosis and 
from Ehrlich ascites by endocytosis are also Ca2+ dependent (Carney et al, 1986; 
Wiedmer et al, 1987).  
K562 cells exposed to sublytic doses of C were subsequently exposed to what would 
otherwise would have been lytic doses, but were protected; a phenomenon known as 
induced protection (Reiter et al, 1992). The mechanisms mobilized to protect the cell from 
lysis in response to MAC deposition could protect the cell from subsequent lytic doses of 
MAC and other pore forming proteins; although the precise nature of these mechanisms 
remains uncertain, they were shown to be calcium dependent (Reiter et al, 1995). 
The apparent importance of Ca2+ and cAMP suggested the mechanisms of recovery were 
dependent on signal transduction via either or both messengers and points to the potent 
influence MAC deposition has on host cells given the varied cellular processes regulated 
via these second messengers. This influence extends beyond cell protection and 
recovery. 
1.4 Sublytic MAC effects 
1.4.1 Introduction 
What has become apparent is that MAC elimination and recovery are only the start of a 
huge range of cellular effects exerted by MAC. These effects also have important 
implications in the roles that C activation plays in disease. The effects of MAC which occur 
without lysis are known as nonlytic effects and doses of MAC which achieve this are 
considered sublytic. The next section will discuss the effects of sublytic MAC and create a 
picture of the signalling events involved. 
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1.4.2 Expression 
Sublytic MAC is capable of profoundly influencing cell behaviour through cell activation 
and gene expression changes that can cause release of inflammatory mediators, 
cytokines, growth factors, adhesion molecules and extracellular matrix components and 
regulators. 
1.4.2.1  Inflammatory mediators 
The earliest described nonlytic effect of MAC was the release of reactive oxygen 
metabolites by neutrophils in response to doses of MAC which were below that required 
for lysis (Campbell et al, 1981; Campbell & Hallett, 1983). 
 
Figure 1.4.2.1 MAC assembly on nucleated cells has various effects on cellular processes. MAC 
deposition triggers signalling through Ca
2+
 and G-proteins at the cell surface leading to effects on 
expression; inflammatory mediators, adhesion molecules, extracellular matrix components and 
regulators, proliferation; triggering entry into the cell cycle, DNA synthesis and proliferation, 
apoptosis; protection from apoptosis via a BAD/Bcl2/xl mediated mechanism.  
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Beyond the oxidative burst, MAC can also affect the production and release of various AA 
metabolites, including leukotriene B4 by neutrophils and oligodendrocytes, thromboxane 
B2 by platelets and prostaglandin E2 by monocytes, glomerular epithelial (GECs) and 
mesangial (GMCs) cells and synoviocytes (Morgan, 1989).  
MAC assembly on GECs results in a Ca2+ flux  associated with release of AA and 
diacylglycerol (DAG) followed by prostaglandin F2α and thromboxane A2 production 
(Cybulsky, 1991). MAC activates phospholipase A2 (cPLA2) mediating the increase in 
free AA and thus prostaglandin E2 production via PKC signalling (Cybulsky et al, 1995; 
Cybulsky et al, 1998). Eicosanoid release by cultured GECs in response to MAC is 
thought to be driven by an upregulation of COX-2 protein although both COX-1 and -2 
were involved in vivo (Takano & Cybulsky, 2000).  
1.4.2.2 Cytokines 
Sublytic MAC can also induce inflammatory cytokine production, the first example 
described was in monocytes which released IL-1(Hansch et al, 1987). In human GMCs, 
deposition of MAC caused the release of prostaglandin E2 along with IL-1 and TNFα 
(Schonermark et al, 1991). In response to MAC, HUVECs released IL-8 and MCP-1 with a 
detectable upregulation of both at mRNA and protein (Kilgore et al, 1996). It was later 
discovered this effect was dependant on the translocation of NFκB from the cytosol to the 
nuclear compartment (Kilgore et al, 1997). Transcription and release of IL-6 by human 
smooth muscle cells in response to MAC was induced by Gi-protein activation and 
mediated by NFκB and AP-1 although the effect was prevented upon treatment with an 
antioxidant suggesting a significant ROS contribution (Viedt et al, 2000).  
1.4.2.3 Adhesion molecules 
An example of the co-operative effect of MAC is the induction of neutrophil adhesion 
molecules in response to the combination of TNFα and MAC treatment of human umbilical 
vein endothelial cells (HUVECs) (Kilgore et al, 1995). MAC was demonstrated to enhance 
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the TNFα induced expression of E-selectin and intracellular adhesion molecule-1 (ICAM-
1) and increase the neutrophil adhesion beyond that induced by TNFα and MAC alone. P-
selectin has also been shown to be induced by MAC directly in HUVECs (Hattori et al, 
1989). More recent work has suggested that inactive terminal C complex (iTCC), formed 
in fluid phase and often considered biologically inactive, is capable of upregulating 
expression of endothelial leukocyte adhesion molecule (ELAM)-1, ICAM-1 and vascular 
cell adhesion molecule (VCAM)-1 (Tedesco et al, 1997). 
 
1.4.2.4 Growth factors 
MAC has also been shown to effect the release of growth factors. Bovine aortic 
endothelial cell (AECs) and HUVECs released basic fibroblast growth factor (bFGF) and 
platelet-derived growth factor (PDGF) in response to MAC deposition and conditioned 
medium from these cells in turn caused increased proliferation rate in 3T3 cells 
(Benzaquen et al, 1994). 
Assembly of MAC on human AECs induced release of a number of chemokines, cytokines 
and growth factors, including epidermal growth factor (EGF), CXCL5, CXCL1, IL-6, IL-8, 
MCP-1, placental growth factor 1 (PIGF), regulated on activation normal T cell expressed 
and secreted (RANTES) and angiogenin. IL-6, PIGF, and RANTES release were inhibited 
upon knockdown of Akt and FOXO1 suggesting their involvement in AAC-induced growth 
factor release (Fosbrink et al, 2006). 
1.4.2.5 Extracellular Matrix (ECM) components and regulators 
The earliest record of sublytic MAC effect on ECM expression was in GECs where it 
induced synthesis and release of collagen IV (Torbohm et al, 1990). GMCs also 
upregulated collagen IV as well as fibronectin in response to MAC (Wagner et al, 1994). 
Tubular epithelial cells were shown to up-regulate collagen IV coinciding with an increase 
in expression of  its chaperone HSP47 (Abe et al, 2004). In retinal pigment epithelial cells 
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(RPEs) the ECM regulatory matrix metalloproteinases (MMP) 2 and 9 were upregulated in 
response to MAC deposition suggesting an opposing role in ECM degradation (Lueck et 
al, 2011). 
1.4.3 Cell fate 
Apart from altered gene expression and release of the various described factors and 
components, MAC deposition on nucleated cells can significantly alter their behaviour, for 
example, MAC can induce entry into cell cycle, alter rate of proliferation and modulate 
apoptosis. 
1.4.3.1 Cell-cycle and proliferation 
One of the first reports of a mitogenic activity for MAC was in Mouse Swiss 3T3 cells 
where MAC formed using purified C components induced significantly increased DNA 
synthesis when compared to controls. The MAC mitogenic effect also enhanced the 
effects of growth factors and could be demonstrated in their absence (Halperin et al, 
1993a).  
Further indication of a proliferative effect of MAC came from studying C6 deficient PVG 
rats which displayed reduced phenotype in experimental mesangioproliferative 
glomerulonephritis, including reduced proliferation of mesangial cells, an effect attributed 
to their inability to form MAC (Brandt et al, 1996). 
C activation and sublytic MAC deposition on oligodendrocytes induced cell cycle entry 
marked by an increase of cdc2 activity in G1 progression and increased cdk4 complexed 
with cyclin D2 during G1/S transition. S phase entry was mediated by c-jun induction via 
JNK . MAC  also induced the expression of the oncogenes junD and c-fos as well as 
increasing proliferation (Rus et al, 1996). Investigation of the mechanism revealed 
dependency on MAPK signalling pathways specifically activating ERK1 and JNK1. ERK1 
activation was dependent on Raf-1 and MEK1 activity upstream (Rus et al, 1997). 
Activation of MAPK signal transduction was later shown to be triggered by Gβɣ subunits; 
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accompanied by increased GTPase-bound Pas and Ras in JY25  B cell line (Niculescu et 
al, 1997).  In Schwann cells, a proliferative effect was mediated by ERK1, Gi proteins and 
PKC (Dashiell et al, 2000).  
Activation of PI3K/Akt was responsible for a proliferative response to sublytic MAC in 
human aortic smooth muscle cells (ASMCs) (Niculescu et al, 1999). The PI3K/Akt 
proliferation response was shown to require phosphorylation and inactivation of forkhead 
transcription factor FOXO1 (Fosbrink et al, 2006) 
The response gene to C 32 (RGC-32), first discovered by differential display analysis of 
gene expression response to C activation in oligodendrocytes, was associated with an 
increase in DNA synthesis pointing to its influence on the cell cycle (Badea et al, 1998). In 
ASMCs RGC-32 is upregulated in response to MAC and causes entry into the cell cycle 
by virtue of its binding and activation of p34CDC2 kinase an association which is dependent 
on phosphorylation by p34CDC2 itself (Badea et al, 2002).  
1.4.3.2 Apoptosis 
One of the more intriguing effects of sublytic MAC deposition in nucleated cells is its 
influence on the apoptotic fate of a cell.  
OLGs undergo apoptosis subsequent to the removal of growth factors from defined 
media, a response which is ameliorated when OLG cells are exposed to sublytic MAC 
deposition; thus MAC rescues the cells from apoptosis (Rus et al, 1996). Apoptosis 
induced by growth factor withdrawal is thought to occur through the cytochrome c pathway 
initiated by mitochondrial dysfunction triggering caspase 3 and 9 activation. Protection of 
OLG from apoptosis by MAC was shown to be mediated by an increase in Bcl-2 protein 
which prevented cytochrome c release and inhibited the activation of caspase 3.  The 
protection also extended to apoptosis induced by TNF-α suggesting the involvement of 
caspase 9 inhibition (Soane et al, 1999). Protection was reversed upon treatment with 
LY294002 and PTX pointing to a dependency of the effect on a Giα/PI3K/Akt signalling 
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pathway; PI3K phosphorylation of Bad resulted in its dissociation from the Bad/Bcl-xL 
which was dependent on Giα (Soane et al, 2001). This mechanism has also been shown 
to depend upon caspase 8 inhibition and increased levels of FLIP, thus suggesting that 
MAC interferes with Fas mediated apoptotic pathways (Cudrici et al, 2006). A Gβɣ 
mediated activation of the ERK1 pathway has also been implicated (Rus et al, 1997; Rus 
et al, 1996). A similar protective effect has been described for MAC in Schwann cells, 
protection from apoptosis subsequent to growth factor withdrawal, mediated by PI3K 
phosphorylation of BAD (Hila et al, 2001). 
Conversely, MAC has been shown to induce apoptosis in GECs in the Thy-1N model, 
though the mechanism involved was not elucidated (Hughes et al, 2000). Later MAC 
induced apoptosis in GMCs was shown to be through upregulation of IRF1 which bound 
the caspase 8 promoter and upregulated it’s expression (Liu et al, 2012). 
1.5 Aims and Hypothesis 
The view that C activation on and around tumours is anti-cancer in nature is under 
increasing scrutiny. The assumption relies heavily on the classical effector view of the 
system and its role as an immune defence; indeed in the case of mCReg over-expression 
in limiting the efficacy of treatment using anti-cancer mAb, it carries some truth. However, 
the inflammatory component in driving tumour development is now an accepted hallmark 
of cancer and the role that C, a major pro-inflammatory system, plays in this has largely 
been ignored. Recently, a limited number of studies have implicated some C components 
including C3 and C5a in tumour development but MAC has received limited attention, a 
situation which this thesis proposes to address. 
The potent effects that MAC can exert on nucleated cells presents a mechanism by which 
C may influence tumour development and progression. This thesis will examine how a 
tumour promoting role for MAC may manifest as gene expression changes exerted by 
sublytic C on tumour cells.  
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The hypothesis to be tested is that tumour cells may respond to sublytic C by up-
regulating genes which bestow upon the tumour a more metastatic and proliferative 
phenotype. 
The key aims of the study are: 
1. To optimise conditions for sublytic C membrane attack on selected cell lines and 
investigate suitable controls. 
2. To identify, using microarray analysis, gene expression changes induced by 
exposure of tumour cells to sublytic C membrane attack, focussing on genes 
associated with tumour progression and metastasis. 
3. To validate these gene expression responses at both the transcript and protein 
levels. 
4. To determine the key C factor/s exerting the effect. 
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2 Materials and methods 
2.1 Reagents 
2.1.1 Antibodies 
2.1.1.1 Primary antibodies 
Name Clonality Species Against 
Purchased 
from 
Technique 
Working 
concentration 
mCD59a7 Monoclonal Rat IgG 
Murine 
CD59a 
In-house 
generated 
FACS 10 µg/mL 
αMCF-7 
antiserum 
Polyclonal Rabbit 
MCF-7 
cell line 
In-house 
generated 
FACS/CDC 1/100 
27d1 Monoclonal 
Mouse 
IgG 
Human 
C6 
In-house 
generated 
FPLC/WB 1 µg/mL 
αMMP-3 Polyclonal 
Goat 
IgG 
Murine 
MMP-3 
R&D W/B 1 µg/mL 
αMMP-13 Polyclonal 
Rabbit 
IgG 
Murine 
MMP-13 
Abcam W/B 1 µg/mL 
αCXCL-1 Polyclonal 
Rabbit 
IgG 
Murine 
CXCL1 
Abcam W/B 1 µg/mL 
αAR Polyclonal 
Goat 
IgG 
Murine 
AR 
R&D W/B 1 µg/mL 
αC5aR Polyclonal 
Rat 
IgG 
Murine 
C5aR 
AbD 
Serotec 
W/B 1 µg/mL 
 
2.1.1.2 Secondary antibodies 
Name Clonality Species Against 
Purchased 
from 
Conjugate Technique 
Working 
concentration 
αRat FITC 
F(ab)2 
Polyclonal Donkey 
Rat 
IgG 
Jackson FITC FACS 1/500 
αRabbit 
FITC 
F(ab)2 
Polyclonal Donkey 
Rabbit 
IgG 
Jackson FITC FACS 1/500 
αMouse 
HRP 
Polyclonal Rabbit 
Mouse 
IgG 
Dako HRP WB 1/1000 
αGoat 
HRP 
Polyclonal Rabbit 
Goat 
IgG 
Dako HRP WB 1/1000 
αRabbit 
HRP 
Polyclonal Goat 
Rabbit 
IgG 
Dako HRP WB 1/1000 
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2.1.2 Primers 
All primers were purchased from Biomers (Ulm, Germany) and upon arrival reconstituted 
in ultrapure (up) H2O to a concentration of 100 µM. Reconstituted primers were stored at -
20°C and when in use kept on ice at all times. 
Name 
For/Rev 
Primer sequence Length 
Tm 
˚C 
Used for 
Cd59a  Forward ATATCTAGAGCCACCATGAGAGCTCAGAG 29 62 Cloning/PCR 
 Reverse CCGTCTAGATTAGAGATGACTTAAGAAAC 29 57  
pDR2  Forward CAAGCCTCAGACAGTGGTTC 20 54 Sequencing/PCR 
 Reverse ATGTCTGGATCGGTGCGGGC 20 58 
Polr2a Forward CCCGCTGCGCACCATCAAGA 20 60.04 qPCR 
 Reverse GGGCGACCTCCCTCCGTTGT 20 60.53  
Actb Forward ACGGCCAGGTCATCACTATTG 21 60.13 qPCR 
 Reverse AGTTTCATGGATGCCACAGGAT 20 60.02  
OPN Forward ATTGCCTCCTCCCTCCCGGTGA 22 61.04 qPCR 
 Reverse GATGGGTCAGGCACCAGCCATG 22 59.79  
Ki67 Forward TCAAGCGGAGCGGCGATGAC 20 59.84 qPCR 
 Reverse TGACACTACAGGCAGCTGGATACG 24 58.31  
uPA Forward AATGCTGTGTGCTGCGGACCCA 22 61.52 qPCR 
 Reverse GAGTTGGGCGGCCTTCGATGTT 22 59.73  
PCNA Forward TGCAAGTGGAGAGCTTGGCAATGG 24 59.94 qPCR 
 Reverse GAGCAAACGTTAGGTGAACAGGCT 24 57.67  
Rgs16 Forward GGTACTTGCTACTCGCTTTTCC 22 60.9 qPCR 
 Reverse CAGCCGCGTCTTGAACTCT 19 62.3  
Fam110c Forward GGCCAAAGAAACCCCCAGCCAG 22 60.18 qPCR 
 Reverse GGCTCTGGAGTTTCAGACGCCTA 23 58.16  
Irf1 Forward ATGCCAATCACTCGAATGCG 20 61.1 qPCR 
 Reverse TTGTATCGGCCTGTGTGAATG 21 60.4  
Hbb-bh1 Forward GAAACCCCCGGATTAGAGCC 20 62 qPCR 
 Reverse GAGCAAAGGTCTCCTTGAGGT 21 61.4  
Mmp3 Forward ACATGGAGACTTTGTCCCTTTTG 23 60.7 qPCR 
 Reverse TTGGCTGAGTGGTAGAGTCCC 21 62.9  
Mmp13 Forward TGTTTGCAGAGCACTACTTGAA 22 60.1 qPCR 
 Reverse CAGTCACCTCTAAGCCAAAGAAA 23 60.2  
Areg Forward GGTCTTAGGCTCAGGCCATTA 21 61 qPCR 
 Reverse CGCTTATGGTGGAAACCTCTC 21 60.4  
Cxcl1 Forward ACTGCACCCAAACCGAAGTC 20 60.04 qPCR 
 Reverse TGGGGACACCTTTTAGCATCTT 22 60.53  
C5aR Forward CAAGACGCTCAAAGTGGTGA 20 58.42 qPCR 
 Reverse TATGATGCTGGGGAGAGACC 20 58.28  
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2.2 Cell Culture  
Name Contents 
Serum free medium 
1×RPMI 1640, 2mM L-glutamine, 50 U/mL 
penicillin G, 50 µg/mL streptomycin 
sulphate, 1mM sodium pyruvate. 
Normal growth medium  
Serum free medium + 10% (v/v) heat 
inactivated FBS. 
Freezing medium 
60% (v/v) serum free medium, 30% (v/v) 
FBS and 10% (v/v) DMSO. 
2.2.1 Maintenance 
CT26 mouse colon carcinoma cells were cultured in normal growth medium. For 
transfected cells, 100 μg/mL hygromycin (Invitrogen) was also included. Cells were 
maintained in 75cm2 tissue culture flasks and kept in a humidified tissue culture incubator 
at 37°C, 5% CO2. Cells were maintained in culture for 2 months, ~16 passages, before 
being discarded. 
2.2.2 Initiating from liquid N2 stocks 
Frozen cells were thawed rapidly at 37°C in a water bath then gently transferred into 5 mL 
fresh, warmed normal growth medium. This suspension was pelletted by centrifugation at 
300×g for 5 minutes at room temperature (RT) and the cells resuspended in 20 mL normal 
growth medium and placed into culture flasks. 
2.2.3 Passaging for maintenance  
For routine maintenance cells were passaged roughly twice a week. Cells were grown to 
80% confluence in 75cm2 flasks and the spent medium discarded. Monolayers were 
washed in saline and incubated with 0.05% trypsin, 0.53 mM EDTA (Gibco) solution until 
fully detached. Cell suspensions were diluted in saline and transferred to 20 mL universal 
containers. Cells were pelleted by centrifugation at 300×g for 5 minutes at RT and 
resuspended in normal growth medium. Routinely cells were seeded for maintenance 
cultures at a ratio of 1/20 into 15 mL normal growth medium in 75cm2 flasks. 
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2.2.4  Preparation of frozen stocks 
Cells were grown to 80% confluence in 175cm2 tissue culture flasks and the spent 
medium discarded. Monolayers were then washed in saline and incubated with trypsin-
EDTA (Gibco) solution until fully detached. Cell suspensions were diluted in saline and 
transferred to 20 mL universal container. Cells were pelleted by centrifugation at 300×g for 
5 minutes at RT and re-suspended in 5 mL freezing medium so that cells were at a rough 
density of 1×107 per mL. Aliquots of 1 mL were prepared in cryo-vials and placed in an 
isopropanol freezer box which was stored at -80°C overnight to allow slow cooling (~1°C 
degree/min). Vials were then transferred to liquid nitrogen storage. Extensive frozen 
stocks were maintained so that experimental cells had undergone as few passages as 
possible.  
2.2.5 Trypan blue exclusion assay for cell counting 
Cell density was measured by trypan blue (TB) (Sigma-Aldrich, Dorset , UK) exclusion 
assay. To do this 20 µL of a cell suspension was diluted ½ in 0.4% (w/v) TB in PBS and 
mixed gently by repeat pipetting. The haemocytometer was assembled by affixing a glass 
coverslip. The cell suspension/trypan blue mixture was pipetted to the edge of the affixed 
coverslip and the mixture allowed to fill the area beneath the coverslip. The 
haemocytometer was placed under a microscope and the central grid located. Cells 
excluding the trypan blue dye were deemed viable and those that did not and stained blue 
were deemed non-viable. Viable cells within the grid were counted using a click counter 
and recorded. Cell density was calculated using the following formula: 
                                            
2.3 Serum preparation 
For preparation of pooled normal human serum (pNHS) whole blood was collected from 
consenting volunteers and placed in 20 mL glass vials. Blood was allowed to clot at RT for 
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1 hour and then placed on ice for 1 hour to contract the clot. The clotted blood was 
transferred to a 50 mL falcon tube and centrifuged at 800×g for 10 minutes at 4°C with no 
braking. The serum was then transferred to a second falcon tube and centrifuged at 
800×g for a further 10 minutes then supernatants pooled and mixed. Serum was decanted 
carefully to a fresh tube and sterile filtered through 0.22 µm syringe filter. Filtered serum 
was kept on ice while making appropriate aliquots for storage at -80°C. 
2.4 Sublytic C experiments 
In sublytic C experiments the required cells were seeded onto plates and allowed to form 
a monolayer over 20 hours in normal growth conditions. For sublytic attack experiments 
cells were grown to 80% confluence and spent media discarded. The monolayers were 
then washed in saline and incubated with trypsin-EDTA (Gibco) solution until fully 
detached. Cells were washed twice in 5 mL warmed serum free medium and cell density 
ascertained using the trypan blue exclusion assay. Cells were then diluted to a density of 
5×105 per mL in normal growth medium and seeded in culture plates so that 1.6×103 cells 
were present per mm2 of available culture area. Seeded cells were incubated under 
normal growth conditions for 20 hours. Aliquots of pNHS were thawed placed in sterile 
tubes and incubated with or without Ornithodoros moubata C inhibitor (OmCI) added at 10 
µg/mL at RT for 20 minutes. Serum aliquots were then diluted to a final concentration of 
5% (v/v) in serum free medium. Cells were removed from the incubator and washed twice 
in serum free medium then serum dilutions decanted into relevant wells. The plate was 
then incubated in normal growth conditions for required time. 
2.5 RNA extraction from cultured cells 
2.5.1 RNA Handling 
All procedures involving RNA handling were conducted in an ethanol cleaned tissue 
culture hood with surfaces treated with a solution of 100 mM NaOH + 0.1% SDS to 
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destroy RNases. Pipette tips were RNase/DNase free. Extracted RNA was placed on ice 
immediately and stored long term at -80°C. During experiments RNA was thawed and 
kept on ice at all times. 
2.5.2 Extraction 
RNA extraction was performed using the Genelute Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich, Dorset, UK). Lysis solution was prepared by adding 10 µL β-
mercaptoethanol (βME) per mL of supplied lysis reagent containing guanidine 
thiocyanate. Cell monolayers were washed in saline and 250 µL lysis solution added and 
incubated at RT for 2 minutes followed by repeat pipetting to homogenize the sample. The 
homogenate was then transferred to the blue filtration column and centrifuged at 9,500×g 
for 1 minute (RT) to remove cell debris and shear chromosomal DNA. An equal volume of 
70% ethanol was added to the filtrate then mixed using a vortexer. RNA was bound to the 
silica membrane of the nucleic acid binding column by centrifugation for 15 seconds and 
the flow through discarded. Bound RNA was washed by centrifugation (9,500×g, RT, 15 
seconds) using 500 µL guanidine thiocyanate wash buffer and the column transferred to a 
fresh tube. Bound RNA was washed twice by centrifugation, 15 seconds then 2 minutes, 
in ethanol containing wash buffer. To avoid ethanol contamination the nucleic acid binding 
column was centrifuged dry for one minute before being transferred to a fresh tube. RNA 
was eluted by the addition of 50 µL of elution buffer which was incubated at RT for 1 
minute followed by centrifugation at 9,500×g, RT for 1 minute. 
2.5.3 Quantitation of RNA 
In order to measure concentration, RNA was diluted 1/20 in ultrapure H2O. The 
absorbances at 260nm and 280nm of this dilution were measured by spectrophotometry 
using a nanodrop (Thermo Scientific, DE, USA) spectrophotometer. The machine was 
initialized and blanked with ultrapure H2O. RNA dilutions (2 µL each) were placed on the 
pedestal and measured. Absorbances were noted and the ratio calculated between 
absorbance at 260 and 280 nm. Values calculated as 2.0 ±0.2 were deemed pure and of 
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high quality. Concentration was then calculated from the absorbance reading at 260 nm 
using Beers law given that RNA has an extinction co-efficient of 38 (μg/mL)-1 cm-1: 
                                                            
2.5.4 Reverse Transcription 
Reverse transcription of RNA to generate first strand cDNA was carried out using the 
TaqMan Reverse Transcription Reagents (Applied Biosystems/Life Technologies Ltd, 
Paisley, UK). Master-mixes were prepared for the number of RNA samples with 10% 
excess to allow for pipetting errors then mixed using a vortexer  (Figure 2.5.4.1A). Aliquots 
of 6.15 µL were shared to fresh tubes, 1 µg of RNA added and the volume made up to 10 
µL with ultrapure H2O. Reaction mixes were placed in a DNA Engine Dyad PCR thermo-
cycler machine (MJ Research, MA, USA) and the programme shown in Figure 2.5.4.1B 
used for the reverse transcription reaction. Reaction mixes containing cDNA were either 
diluted directly in ultra-pure (up) H2O for qPCR or placed directly at -80°C for storage. 
 
Figure 2.5.4.1 Reverse transcription protocol. A. reaction mix using the TaqMan kit reagents (Applied 
Biosystems), volume was made up to 10 µL with 1 µg RNA plus upH2O. B. Thermocycler program set 
on Dyad DNA Engine machine (MJ Research). 
  
1x
Rtbuffer 1
Oliogo d(t) 0.5
MgCL2 2.2
DNTPs 2
RNAse Inh 0.2
Rtase 0.25
Total 6.15
Step Temperature Time
2 37°C 1hour
3 95°C 5min
4 4°C ∞
A. B.
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2.6 Quantitative polymerase chain reaction (qPCR) 
2.6.1 Primer design 
QPCR primers were either sourced from PrimerBank,  taken from published research or 
designed using PrimerBLAST. PrimerBank is a comprehensive database of human and 
mouse qPCR primer pairs designed using NCBI transcript sequences, a primer designing 
algorithm, plus a number of specifically designed filters (Spandidos et al, 2010). The 
algorithm used is based upon the oligopicker algorithm proposed for microarray probe 
design which takes a non-redundant protein coding sequence and by sorting all 
sequences satisfying a pre-defined Tm by rejection using  criteria designed to ensure 
specificity to target, good sequence complexity and accessibility (Wang & Seed, 2003b). 
The algorithm was refined for qPCR by testing for specificity to the target transcript using 
BLAST and chances of secondary structure formation minimized by testing for primer self-
complementarity (Wang & Seed, 2003a). The algorithm creates primers with Tm values of 
~60°C and GC content between 35% and 65% preferring oligonucleotide lengths of 
between 19-23 nucleotides. The PrimerBank database has at least one primer pair for 
each known coding transcript in mice and in many cases primer pairs have been 
experimentally validated for efficacy.  
Primers which had been validated were selected preferentially. Those which had not were 
selected based upon product length, between 90-200 nucleotides, and inclusion of 
exon/exon boundaries within product sequence to target transcript over non-transcript 
RNA/cDNA or contaminating genomic material. 
PrimerBLAST is an online primer design tool which combines the pre-existing design tool 
primer3 and the BLAST global sequence alignment tool to assess the possibility of 
unintended amplification. Primer 3 is a popular primer designing tool provided by the NCBI 
which suggests possible primer sequences for the amplification of a desired sequence 
which satisfy a number of user defined constraints including Tm, primer length and product 
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length (Rozen & Skaletsky, 2000). BLAST or basic local alignment search tool uses an 
algorithm which compares a user defined amino acid or nucleotide sequence to database 
sequences by calculating an MSP score to describe the similarity and therefore the 
alignment (Altschul et al, 1990). Combining these two modules creates a powerful primer 
design tool with enormous flexibility. For the designing of validation primers of which there 
were two, the refseq accession codes for target transcripts were inserted as template and 
the following restrictions applied- 
1. 90-200 nucleotide product size 
2. 57 min, 60 opt, 63 max Tm range 
3. Primer must span an exon/exon junction 
4. Enable search for primer pairs specific to the intended PCR template ticked- Mus 
musculus. 
PrimerBLAST generated a list of suitable primer pairs along with possible unintended 
annealing sites within the mouse refseq database. 
2.6.2 QPCR expression analysis 
To analyse the relative expression of genes of interest, real-time qPCR was used. 
Reverse transcription reaction mixes containing first strand cDNA representative of RNA 
material was diluted 1/10 in upH2O. QPCR was performed using 1× SYBR Green Jump 
Start Readymix (Sigma-Aldrich, Dorset, UK) and master-mixes sufficient for triplicates 
were prepared for each primer pair (Figure 2.6.2.1A). For experiments with several 
samples, master-mixes were prepared without cDNA addition until shared into fresh 
tubes. Reaction mixes were aliquoted into white 48-well PCR plates, then the plates 
sealed with optical flat 8-cap strips (Bio-Rad, Hertfordshire, UK). Plates were mixed using 
a vortexer, briefly spun down by centrifugation and placed on the plate of a MiniOpticon 
Real-Time PCR Detection System (Bio-Rad) controlled by PC using the Opticon Monitor 
3.1 software (Bio-Rad). Themocycling protocol shown in Figure 2.6.2.1B was used as 
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standard. The calculation used for relative expression was the ΔΔCt method Figure 
2.6.2.1C+D). Ct values were the cycle number at which fluorescence crossed a threshold 
level chosen as the point at which the PCR expansion was linear in all samples (Figure 
2.6.2.1C). The mean Ct values for β-actin and Polr2A as the housekeeping genes were 
calculated and referred to as the Ct[HKG] and the value for target gene was referred to as 
Ct[sample]; ΔCt was calculated by subtracting HKG from sample (Figure 2.6.2.1Di). ΔΔCt 
was calculated from the ΔCt using the formula in (Figure 2.6.2.1Dii). Control sample was 
included as baseline and so a % relative expression value was calculated (Figure 
2.6.2.1Diii). 
 
Figure 2.6.2.1 qPCR gene expression analysis protocol. A. Reaction mix for qPCR using SYBR Green 
reagent (Sigma) showing for reaction volumes of 20 µL and in triplicate with excess (×3.2). B. 
Thermocycler program set on MiniOpticon machine (Bio-Rad) for qPCR including PCR amplification 
(steps 1-5) and melt curve (step 6). C. Calculation of Ct values through the setting of a threshold; 
threshold is set as the earliest point where amplification is linear and Ct values taken as cycle number 
at which the threshold is reached. D. Equations for the calculation of i=ΔCt, ii=ΔΔCt, iii=% (RE) relative 
expression from Ct values from sample (Ct[sample]) and the mean Ct of  housekeeping genes 
(Ct[HKG]). 
10 20 30 40
1.5
1
0.5
0
Cycle Number
Fl
u
o
re
se
ce
n
ce
β-actin Polr2aTarget
Threshold
C.
1× 3.2×
SyBR Green 10 32
upH2O 7.6 24.32
For 0.2 0.64
Rev 0.2 0.64
RM Total 18 57.6
1/10 cDNA 2 6.4
Total 20 64
Transferred total - 20
Step Temperature Time
1 95°C 15 min
2 95°C 15 sec
3 65°C 1 min 10 sec
4 Plate Read -
5 Cycle 2 ×40 -
6
70-90°C
15 sec every 
0.3C read
end
A. B.
D.
i.
ii.
iii.
41 
 
2.7 Protein separation SDS-PAGE 
Name Contents 
Sodium Dodecyl Sulphate (SDS) 
Stacking gel buffer 
0.5 M Tris, 0.4% (w/v) SDS, pH6.8  
SDS resolving gel buffer 1.5 M Tris, 0.4% (w/v) SDS, pH8.8 
Non-reducing loading buffer 
0.1 M Tris, 10% (v/v) glycerol, 2% (w/v) 
SDS  0.01% bromophenol blue, pH 6.8 
Running buffer 25 mM Tris, 191 mM glycine 1% (w/v) SDS 
Coomassie Blue Stain 
0.2% (w/v) coomassie blue R250 in 45% 
(v/v) methanol, 8% (v/v) acetic acid in dH2O 
De-staining buffer 
20% (v/v) methanol, 8% (v/v) acetic acid in 
dH2O 
 
2.7.1 Gel Casting 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
using the Mini-PROTEAN Tetra Cell system (Bio-Rad). 
 
Stacking (mL) Resolving (mL) 
Gel Percentage 5% 15% 10% 
Upper buffer mL 1.2 3.75 3.75 
40% Acrylamide/Bis mL 0.625 5.625 3.75 
dH2O mL 3.12 5.46 7.335 
10% Ammonium persulphate mL 0.05 0.15 0.15 
TEMED mL 0.005 0.015 0.015 
Total 5 mL 15 mL 15 mL 
 
Gel casts were assembled according to the manufacturers instructions. Stacking and 
lower gel mixes were prepared according to the above recipes, ammonium persulphate 
was added immediately prior to pouring into casts to initiate polymerisation. Lower gels 
were poured first filling three quarters of the volume and butanol used to level and protect 
the top from air which inhibits the polymerisation process. Once polymerised, the butanol 
was removed and the upper compartment washed with dH2O. Ammonium persulphate 
was added to the stacking gel mix and this was poured on top of the set lower gel. The 
comb was then quickly inserted taking care to avoid introducing air bubbles. Once set the 
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cast containing the gel was clamped into the running tank, running buffer was filled to the 
appropriate levels to cover the anode and cathode. 
2.7.2 Sample preparation 
Protein samples were prepared by diluting the required quantity in 6× loading buffer. This 
was mixed using a vortexer and placed on heat block at 90°C for 10 minutes to thoroughly 
de-nature the sample with the exception of serum samples which were incubated at RT 
for 30 minutes. Samples were mixed using a vortexer and loaded into the wells of 
prepared  polyacrylamide gels. The molecular weight marker well was loaded with 8 µL 
Seeblue Plus2 Protein Standards (Invitrogen/Life Technologies Ltd, Paisley UK). The tank 
was connected to the power pack and gels electrophoresed at 100 V for 1h (or until dye 
front reached 0.5 cm from edge of the gel). 
2.7.3 Coomassie  stain 
Polyacrylamide gels were stained with coomassie blue stain for the detection and 
visualisation of separated proteins. Gels were rinsed in dH2O to remove surface running 
buffer and bathed in coomassie stain for 3 hours on a rocker. Coomassie blue stain was 
removed, the gel rinsed then bathed in destain buffer and incubated for an hour on a 
rocker. The destain solution was removed and replaced with fresh destain and the 
process repeated until bands appeared blue against a clear background. Coomassie 
stained gels were then scanned. 
2.8 Western Blot 
Name Contents 
Transfer buffer 
25 mM Tris, 191 mM glycine, 20% (v/v) 
methanol 
Phosphate buffered saline (PBS) 
8.2 mM Na2HPO4, 1.5 mM KH2PO4, 137mM 
NaCl, pH7.4, 0.22 µm filtered 
Blocking buffer 5% (w/v) dried milk in PBS 
Wash buffer 0.1% (v/v) Tween 20 in PBS 
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2.8.1 Transfer by wet electroblotting 
Transfer of protein from SDS-PAGE gels to nitrocellulose membrane for western blotting, 
was carried out using the Mini Trans-Blot Electrophoretic Transfer Cell system (Bio-Rad). 
Polyacrylamide gels containing separated proteins were removed from their glass 
sandwich and equilibrated in transfer buffer for 5 minutes on a rocker. A transfer cassette 
was prepared in the following order; pad, blotting paper, nitrocellulose membrane. All 
components had been thoroughly soaked in transfer buffer prior to cassette assembly. 
The gel was placed on top of the membrane and the sandwich completed with a second 
sheet of blotting paper and pad, the sandwich was placed in the cassette and air bubbles 
expelled using a roller. The complete cassette and transfer sandwich was clamped shut 
and placed in the electrode housing in the transfer tank along with an ice block for cooling 
and a magnetic stirrer. The tank was filled with transfer buffer and connected to power 
pack. Transfer was carried out over 1 hour at 100V. 
2.8.2 Probing of membrane 
Membranes with transferred protein were placed in a 50mL falcon tube and  blocked in 
blocking buffer (as above) either overnight at 4°C or for 1 hour at RT on a roller. Proteins 
of interest were detected with a primary antibody added to 5 mL of blocking buffer at 
dilutions optimized for the individual antibody (normally between 1/500 -1/2000). Primary 
antibodies were incubated with the membranes at 4°C overnight or 0.5-2 hour at RT. 
Membranes were washed 3 × 5 minutes in wash buffer (as above). The HRP conjugated 
secondary antibody was added in 5 mL of blocking buffer at dilutions appropriate to the 
individual secondary antibody (normally between 1/1000 and 1/2000) and the membranes 
incubated for between 30 minutes and 1 hour at RT. The probed membrane was washed 
as above, followed by a final wash with PBS. 
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2.8.3 Membrane development 
Membranes were developed using the ECL Prime western blotting detection reagent (GE 
Healthcare Life Sciences, Buckinghamshire, UK) as per the manufacturers instructions. 
Briefly, reagents A and B were mixed 1:1 allowing 750 µL per membrane and incubated 
on the membrane for 3 minutes. Excess solution was shaken off and luminescence 
detected by  exposing X-ray film (GE Healthcare Life Sciences, Buckinghamshire, UK) to 
the membrane in a dark room for between 30 seconds to 3 hours. Films were developed 
in a SRX-101A autodeveloper machine  (Konica Minolta, NJ, USA) and the results noted. 
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3 Optimization of sublytic C conditions  
3.1 Introduction 
3.1.1 Sublytic C 
Sublytic C attack is defined as C activation in the absence of lysis. In practice this means 
that activation occurs on nucleated cells leading to MAC assembly on the membrane but 
at a level that cells can survive. Surviving cells are activated in a number of ways which 
results in downstream effects on gene expression and protein synthesis. The term sublytic 
is often defined experimentally as levels resulting in lysis below 10%, but throughout the 
literature there is some variation; ranging from below 5% up to 15% lysis (Qiu et al, 2012; 
Reiter et al, 1992). 
3.1.2 CT26 cells 
CT26 cells are a chemically induced transplantable colon carcinoma cell line derived form 
BALB/c mice (Corbett et al, 1975). They  were developed to study colorectal cancers and 
selected as highly proliferative and metastatic (Brattain et al, 1980). Using CT26 as a 
model cell line in vitro will enable the overall findings of these investigations to be 
confirmed in vivo in the BALB/c mouse. 
3.1.3 C fixation 
Activation of C on allogeneic nucleated cells in vitro is often reliant on a trigger for fixation. 
For this cells are coated in antibody often raised against the cells or an abundantly 
expressed antigen. For example the Thy-1.1 antibody is used to coat GMCs binding Thy1 
antigen, this model is derived from the mesangioproliferative glomerulonephritis model in 
rats termed Thy1N (nephritis) (Lu et al, 2012). In the case of the erythroleukaemic cell line 
K562 a heat inactivated antiserum is used for C fixation (Jurianz et al, 2001). In these 
protocols normal human serum (NHS) is used for the C source and heat inactivation of 
this serum used to control for lytic activation and MAC formation. In a heterologous 
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system where serum C source and cell target are derived from differing mammalian 
species, the need for a  targeting antibody is dependant on the efficiency of C activation. 
This is determined by a number of factors including most obviously the expression of 
regulators on the surface of the target cell membrane and robustness of the serum C 
source. Other factors include charge and features of the target surface which will dictate 
the pathway initiated (for example, natural antibodies in serum can initiate the classical 
pathway), stability of the convertase formed, and efficiency of MAC assembly (Morgan et 
al, 2005). 
3.1.4 Strategies for isolating MAC mediated effects 
3.1.4.1 Heat inactivation of serum 
Heating serum at 56°C for ~30 minutes, removes C activity by inactivating its heat labile 
components C2 and factor B as well as C1q and others to a lesser degree (Joisel et al, 
1983; Lozada et al, 1995; Lynen et al, 1973). Heat treatment also destroys the activity of a 
multitude of heat labile non-C factors such as growth factors, vitamins, amino acids, and 
hormones. This non-specific destruction of serum growth factor and hormone content 
make it a poor control for the cell activating sublytic effects of C. 
3.1.4.2 Depletion of C6 
Inhibition of the terminal pathway is also possible by depletion of individual components 
needed to generate the MAC complex. This can be achieved by depletion of any one of 
the terminal components, C6 (Gao et al, 2007), C7, C8 and in some cases C9 (Fosbrink 
et al, 2006). Depleted serum can be used to allow generation of C5b and incomplete 
terminal complexes, C5b-6, C5b-7, C5b-8; the latter two are capable of depositing  on cell 
surfaces and causing disruption in membrane integrity (Podack et al, 1980). Depletion is 
usually achieved by passage of sera over columns containing antibodies against the 
specific components. Reconstitution of depleted components restores the serum lytic 
capacity. 
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C6 occupies a crucial point linking activation to the terminal pathway and thus represents 
an ideal target for removal. Removal of C6 allows activation to progress up to and 
including cleavage of C5 but prevents continuation of terminal pathway because C5b is 
prevented from binding C6, a key step in the pathway towards formation of the MAC . C6 
depleted serum is therefore an ideal reagent for controlling MAC mediated sublytic effects. 
3.1.4.3 OmCI 
Inhibition of terminal pathway selectively can also be achieved using inhibitors such as the 
OmCI which is a saliva protein derived from the Ornithodoros moubata tick. OmCI is a 17 
kDa non-glycosylated protein expressed as a single polypeptide chain, a member of the 
lipocalin family of barrel-forming proteins. OmCI has been shown to act at the C5 stage of 
activation blocking the activity of both the alternative and classical C5 convertase 
enzymes and thus preventing C5 cleavage to C5a and C5b. Excess of C5 but not C3 
removed this inhibitory activity suggesting a direct action on C5 and not the convertase 
enzyme (Nunn et al, 2005). Biochemical analyses has shown that OmCI binds directly to 
C5. Upon binding to C5 away from the cleavage site, OmCI stabilized the global protein 
structure, preventing it’s cleavage into C5b and C5a (Fredslund et al, 2008). Binding of C5 
by OmCI effectively acts as a terminal pathway/MAC inhibitor by blocking progression of 
C activation beyond C5. This makes it an ideal tool as a control for MAC induced effects. 
3.1.5 CD59 
CD59 is the only membrane bound regulator of MAC expressed by human cells. Over-
expression of CD59 by tumour cells is purported to be one of the evasion mechanisms 
tumour cells use to avoid C mediated damage (Fishelson et al, 2003). The presence of 
CD59 at the site of MAC deposition makes it a molecule at the frontier of sublytic attack 
and therefore its role is of great interest. CD59 is linked to the outer leaflet of the 
membrane by a GPI lipid anchor. Cross-linking of CD59 via antibodies on haematopoietic 
cells triggers signalling events such as calcium flux and tyrosine kinase activation leading 
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to ROS release (Morgan et al, 1993; Vandenberg et al, 1995). These events bear 
resemblance to that activated by sublytic MAC. This resemblance was given credence by 
work showing Src family protein tyrosine kinases activation through CD59 cross-linking 
could be induced by C8 (Murray & Robbins, 1998). These observations raise the 
possibility that CD59 may act as a receptor for MAC and mediate some of its sublytic 
effects.  
3.1.6 Putative sublytic C response genes 
3.1.6.1 Osteopontin (OPN) 
Work published by Wai et al in 2005 presented an association between OPN and other 
markers with metastatic and proliferative phenotype in CT26 cells. Si-RNA knockdown of 
OPN decreased the metastatic potential of the cells when injected into syngeneic BALB/C 
mice. In vitro analysis of the cells showed that OPN suppression resulted in significant 
reduction in MMP-2 expression combining to lower their migration and invasion index 
compared to wild type and mismatch controls. This was reflected by in vivo work where 
knock down of OPN resulted in dramatic reduction of hepatic nodules in an injected 
tumour metastasis model (Wai et al, 2005).  
The metastatic potential of OPN is driven through the PI3K pathway. Analysis of a highly 
active 38bp segment of the OPN promoter sequence revealed potential binding sites for 
several transcription factors including the AP-1 consensus binding sequence. Further 
investigations demonstrated that this site was utilised by the c-jun homo-dimer of AP-1. 
Inhibition of PI3K resulted in lowered levels of c-jun together with phosphorylated forms of 
JNK-1 and 2 and these changes correlated with a reduction in OPN expression. Both 
pharmacological inhibition and knock down of JNK suppressed adhesion migration and 
invasiveness to a level similar to that of cells with low OPN expression (Mi et al, 2004).  
The impact of PI3K on the metastatic potential of cancer cells has been shown to involve, 
through Akt, cell proliferation and OPN expression. HepG2 cells treated with EGF showed 
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increased expression in OPN at both mRNA and protein levels, an effect which was 
abrogated on inhibition of PI3K with wortmannin treatment (Zhang et al, 2004).  
The proposed link between sublytic C, OPN expression and an influence on metastasis is 
based on the common initiation of the PI3K pathway and involvement of Akt and c-jun, 
implicated in both protective mechanisms of the cell during sublytic C attack and over-
expression of OPN and the resulting increase in metastatic potential. A link between OPN 
expression and sublethal MAC has not been described. 
In the work defining a role for OPN in metastases using the CT26 cell line, other 
characterising markers were used to assess metastatic and proliferative potential - uPA, 
PCNA and Ki67 (Wai et al, 2005).  
3.1.6.2 Urokinase-type plasminogen activator (uPA)  
Urokinase-type plasminogen activator (uPA) expressed by cancer cells has been linked to 
metastasis both in animal models and in patients where it serves as a predictor of survival 
(Andreasen et al, 1997). The MAPK pathway has been implicated in uPA expression 
involving activation of ERK1 and promoter binding of fos and junD to an AP-1 site on uPA 
promoter (Lengyel et al, 1996). 
3.1.6.3 Ki67 antigen 
Ki67 antigen is present in all active phases of the cell cycle but completely absent in 
resting phases. Its function is not understood but it is clear that without Ki67, proliferation 
is not possible, indeed upon proliferation it is synthesised and degraded in a tightly 
controlled manner (Scholzen & Gerdes, 2000). Ki67 expression was demonstrated to be 
regulated through the binding of Sp-1 to its promoter (Tian et al, 2010). The signalling 
pathways regulating its expression are unknown. Because Ki67 is exclusively expressed 
by proliferative cells it has become a common marker for cells undergoing this process 
and thus is used as a diagnostic tool for neoplasms (Scholzen & Gerdes, 2000). 
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3.1.6.4 proliferating cell nuclear antigen (PCNA) 
PCNA antigen is also found to be expressed in proliferating cells and is an accessory 
protein to DNA polymerase δ and DNA polymerase ε. This means it has functions in DNA 
synthesis, recombination, repair and metabolism. It has also been associated with cell 
cycle regulation and check-point controls (Kelman, 1997). 
Ki67 and PCNA, are often used as proliferative markers and the presence of these 
markers is strongly linked with the aggressiveness of cancer and correlate with patient 
survival (Ben-Izhak et al, 2002).  
3.1.7 Chapter aims 
The aim of the work described in this chapter is to optimize the reagents, conditions and 
controls for sublytic C experiments on tumour cells. Furthermore, preliminary experiments 
are detailed which were carried out  to ascertain detectable effects of sublytic C and 
inform time points used for the microarray experiment. To achieve these aims the practical 
goals were: 
1. Clone Cd59a plasmid and transfect into CT26 cell line. 
2. Assess sensitivity of CT26 to C lysis to ascertain their sublytic threshold and 
confirm the functionality of the transfected Cd59a protein product. 
3. Explore terminal pathway control systems for use in sublytic C experiments. 
4. Explore possible candidates for gene expression changes in response to sublytic 
attack using qPCR.  
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3.2 Methods 
3.2.1 Molecular Biology  
Name Contents 
Lauria-Bertani (LB amp.) broth 1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 
1% (w/v) NaCl, 269 µM sodium ampicillin, in H2O 
 LB amp. Agar LB amp. broth plus 0.7% (w/v) agar 
SOC medium 2% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 
0.05% (w/v) NaCl, 2.5 mM KCl, 10 mM MgCl2, and 20 
mM glucose 
80% Glycerol 80% (v/v) glycerol in H2O 
TAE 40 mM Tris, 40 mM acetic acid, 1 mM EDTA, pH7.2 
Loading buffer (agarose gel 
electrophoresis) 
20% glycerol (w/v) in 10×TAE with 0.2% (w/v) 
bromophenol blue. 
3.2.1.1 LB agar plate preparation 
LB amp agar was prepared using the recipe in reagent list. Mixture excluding ampicillin 
was autoclaved. Molten LB agar was allowed to cool (56°C), mixed with ampicillin then 
poured into petri dishes to give a 5 mm deep layer (~5 mL). These plates were allowed to 
set in an air flow hood and covered and sealed in plastic packaging for storage at 4°C. 
3.2.1.2 Bacterial transformation 
Electro-competent E.coli NEB5α cells (New England Biolabs, Hertfordshire, UK) were 
transformed as per manufacturer’s instructions. Briefly, an aliquot was thawed and 50 µL 
of the cell suspension placed in a sterile tube on ice. Plasmid DNA, ~100 ng in 5 µL was 
added directly and gently mixed then incubated on ice for 2 minutes. The mixture was 
then heat shocked by placing in a water bath set to 42°C for exactly 30 seconds, followed 
by removal to ice for 2 minutes. SOC medium (950 µL, warmed to 37°C) was added 
directly to the cell suspension which was then incubated at 37°C for 1 hour before 100 µL 
aliquots were spread on LB amp agar plates. Plates were incubated overnight at 37°C. 
3.2.1.3 Bacterial culture for glycerol stocks and plasmid isolation 
Single colonies from LB amp agar plates were picked and placed in individual sterile 50 
mL falcon tubes each containing 5 mL of LB amp broth. Inoculated cultures were placed in 
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an orbital incubator (Gallenkamp, Leicestershire UK) and set to mix at 180 rpm overnight 
at 37°C.  
3.2.1.4 Glycerol stock preparation 
Glycerol stocks were used to store positive transformants for long periods. Positive 
plasmid colonies were picked and expanded overnight at 37°C as above. Cell culture 
volumes were mixed 1:1 with 80% glycerol to give a 40% final concentration and 1 mL 
aliquots prepared. Aliquots were labelled and stored at -80°C. 
3.2.1.5 Plasmid purification 
Bacterial cultures created as above were harvested by centrifugation at 4600×g for 10 
minutes, supernatant was discarded and cell pellet processed. Plasmid DNA was purified 
using the QIAprep Miniprep kit (QIAGEN, West Sussex,  UK) as per the manufacturer’s 
instructions. Briefly, cell pellets were resuspended in 250 µL of alkaline lysis buffer. 
Lysates were neutralised with a high salt buffer for adsorption of DNA onto a silica solid 
phase membrane by centrifugation. Adsorbed DNA was washed with 80% ethanol in 
wash buffer and eluted in tris buffer (10 mM TrisHCl, pH 8.5). Concentration of purified 
plasmid DNA was determined by absorbance at 260 nm using a Nanodrop 
Spectrophotometer, then stored at -20°C in aliquots. 
3.2.1.6 Gel extraction PCR product recovery 
PCR products separated by electrophoresis on agarose gels were extracted using the 
QIAquick Gel Extraction Kit (QIAGEN)  as per manufacturer’s instructions. Briefly, bands 
of interest were excised, weighed and melted at 50°C in 300 µL guanidine thiocyanate 
buffer per 100 mg of gel. To this, 100 µL isopropanol per 100 mg of gel was added and 
the mixture applied to a solid phase silica membrane spin column by centrifugation. 
Bound DNA was washed in guanidine thiocyanate buffer followed by 80% ethanol wash 
buffer then eluted in tris buffer (10 mM TrisHCl, pH 8.5). 
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3.2.1.7 DNA agarose gel electrophoresis 
DNA was separated on agarose gels of between 1-2% (w/v). Larger DNA fragments or 
plasmids were separated on lower (1%) percentage gels and smaller fragments on higher 
(1.5-2%) percentage gels. Agarose powder (Life Technologies Ltd, Paisley, UK) was 
weighed out in a conical flask and diluted in 1×TAE buffer then heated in a microwave 
until dissolved. Molten agarose was cooled and ethidium bromide added to a final 
concentration of 0.5 µg/mL. The agarose was poured into a casting tray containing a 
comb to create loading wells. The gel was allowed to set then placed in an electrophoresis 
tank containing 1×TAE running buffer. DNA samples were mixed 1 in 6 with glycerol 
loading buffer and 20 µL loaded into wells alongside a base pair marker of appropriate 
size, i.e. 100 bp for smaller fragments or 1000 bp for larger fragments. DNA was 
electrophoresed at 100V for between 15 minutes to an hour. DNA bands were visualised 
under a UV lamp. 
3.2.1.8 Polymerase chain reaction (PCR) for cloning and screening 
PCR reactions were carried out in a DNA Engine Dyad PCR thermo-cycler machine ( MJ 
Research, MA, USA) using Platinum Blue super mix 1.1 × (Invitrogen, Paisley, UK); 
forward and reverse primers were added to a final concentration of 1 µM and template 
added along with upH2O to create a final volume of 25 µL. 
3.2.1.9 Restriction digest 
Restriction digestion of plasmid or fragment DNA was conducted using XbaI (NEB) in 
buffer 3 (NEB supplied restriction digest buffers) for 1 hour at 37°C.  
3.2.1.10 Dephosphorylation  
Dephosphorylation was achieved using Antarctic phosphatase (NEB). To target DNA 
(linearized plasmid DNA), 10× Antarctic phosphatase reaction buffer (NEB) was added to 
a final concentration of 1×. Antarctic phosphatase (10 units) was then added to the  
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volume and the reaction mixture incubated at 37°C for 30 minutes. The phosphatase was 
inactivated by incubation at 65°C for 10 minutes. 
3.2.2 Cloning of mouse Cd59a into the pDR2 expression vector  
3.2.2.1 pDR2ΔEF1α expression vector 
The pDR2ΔEF1α plasmid referred to as pDR2 hereafter, is a mammalian expression 
vector (Figure 3.2.2.1). The construct carries an ampicillin resistance gene for selection in 
prokaryotic organisms and a hygromycin resistance gene for selection in eukaryotic, 
mammalian cells. Inserted genes are expressed under the control of the human 
elongation factor 1a promoter (EF1α), a constitutive promoter taken from elongation factor 
1A gene.  The presence of the SV40 polyA sequence for polyadenylation improves  
expression levels in mammalian cells (Gimmi et al, 1988). pDR2 contains a large 
polylinker sequence containing amongst others an XbaI restriction enzyme site: TCTAGA. 
3.2.2.2 Cloning of the Cd59a gene 
Cloning of the Cd59a gene required the designing of specific primers directed to the 
sequence with the addition of the recognition site for the endonuclease restriction enzyme 
XbaI at both the 3 and 5 prime ends (Figure 3.2.2.2A).  The forward primer was designed 
to accommodate the XbaI site, plus the consensus Kozak GCCACC sequence and the 
first 14 nucleotides of the target sequence (Figure 3.2.2.2A+B). Kozak proposed that a 
consensus sequence flanking the initiator codon was required for eukaryotic ribosomal 
recognition of the correct initiator codon, the sequence had GCC repeating units with -3 
sequence A or G then CC in relation to initiating AUG (Kozak, 1987). The reverse primer 
also contained an XbaI site plus the last 20 nucleotides of the target sequence (Figure 
3.2.2.2A+B). 
Total RNA was extracted from 20 mg of fresh mouse liver as described in section 2.5.2.  
This was quantified (section 2.5.3) and 1 µg added to a pre-prepared reverse transcription  
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Figure 3.2.2.1 pDR2 plasmid vector and cloning strategy. A. Schematic representation of the pDR2 
plasmid showing positions for EF1α promoter, SV40 polyA, polylinker and resistance genes for hyg. 
and amp. B. Cloning strategy for insertion of Cd59a gene into polylinker region by a non-directional 
cloning strategy. cDNA reverse transcribed form liver total RNA was used to PCR amplify the Cd59a 
gene. pDR2 and Cd59a PCR product were restriction digested using XbaI and plasmid 
dephosphorylated and the two ligated. 
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Figure 3.2.2.2 PCR amplification of mouse Cd59a gene. A. Forward and reverse primers specific for 
the 5 and 3 prime sequence of Cd59a transcript (RefSeq NM_001111060.1). Primers contain XbaI 
recognition site (green), Kozak sequence (underlined), overlap Cd59a transcript sequence (yellow) and 
start/stop codons (red). Fragment sequence is labelled in the same way and primers highlighted in 
brown. B. PCR thermocycling programme for expansion of Cd59a gene. C. PCR product was 
separated on 1% TAE agarose gel for 30 minutes at 100V, band at 397bp represents the amplified 
Cd59a gene, lower band comprises primer dimers. 
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(RT) reaction mix then placed on a thermocycler plate and program set as described in 
section 2.5.4. Once completed, resulting first strand cDNA was placed on ice. 
PCR amplification of mouse Cd59a coding sequence from cDNA was done using specific 
primers shown in Figure 3.2.2.2A. A stepped PCR program was utilised with an initial low 
annealing temperature of 38°C for the first 7 cycles followed by annealing at 54˚C for the 
remaining 30 cycles (Figure 3.2.2.2B). Each PCR reaction contained 1.5 µL of cDNA from 
first strand RT reaction mixture.  
The PCR products were electrophoresed in TAE agarose (section 3.2.1.7) and a band of 
396bp corresponding to the expected size for the Cd59a coding region was excised while 
viewing on a UV transilluminator (Figure 3.2.2.2 C). The PCR fragment was then purified 
from the gel using a QIAquick kit as described in section 3.2.1.6 and eluted DNA 
quantified by Nanodrop measurement of absorbance  at 260 nm. 
3.2.2.3 Recombination of Cd59a into pDR2 expression plasmid 
pDR2 plasmid DNA was purified from  5 mL cultures using the QIAprep Spin Miniprep Kit 
as described in section 3.2.1.5. The purified pDR2 plasmid and Cd59a fragment were 
both separately digested with XbaI to generate complementary ends for ligation. Figure 
3.2.2.3 shows an example of linearized pDR2 plasmid by XbaI digestion compared to 
uncut and restriction digestion with enzyme for which no recognition site exists on the 
plasmid. Plasmid DNA linearized by a single restriction digest is liable to re-circularize or 
become ligated with itself during ligation reaction. To reduce the possibility of plasmid re-
circularization, linearized plasmid DNA was dephosphorylated by treatment with Antarctic 
phosphatase (NEB) added directly to restriction digest reaction mix.  
The digested Cd59a fragment was cleaned with the QIAquick PCR Purification Kit 
(QIAGEN) and ligated with the linearized plasmid using 6:1 and 10:1 insert : vector ratios. 
Ligation mixes were transformed into NEB5α competent cells and colonies selected after 
overnight incubation on ampicillin selective agar plates. 
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Figure 3.2.2.3 Single restriction digest of pDR2 vector. Plasmid DNA was incubated for 1 hour at 37°C 
in NEB buffer 3 containing no enzyme (-ve), SalI, and XbaI. Uncut and SalI ‘digest’ control plasmid 
DNA ran with two distinct bandings roughly 12 and 8 Kb in size representing uncoiled/relaxed plasmid 
and supercoiled plasmid respectively. XbaI cut the plasmid at a single site resulting in linear plasmid 
as shown by the band running to roughly 6Kb, SalI digestion did not linearize the plasmid,  confirming 
the absence of a recognition site. 
Insertion of the gene into the vector digested with XbaI alone allowed the possibility of 
insertion in two orientations. To select colonies containing the Cd59a gene ligated in the 
correct orientation, a direction specific primer pair was used for PCR based screening 
(Figure 3.2.2.4A). The forward primer used was specific for the plasmid sequence up-
stream from the polylinker site and the reverse primer was specific for Cd59a terminal 
sequence (Figure 3.2.2.4A). Colonies formed on agar amp. plates after transformation 
from ligation  were picked at random (6 and 7 for 6:1 and 10:1 ligation ratios respectively) 
and diluted directly in the pre-prepared PCR mix and placed on thermocycler for 
screening. PCR program was set as shown in Figure 3.2.2.4 B then products separated 
on 1% TAE agarose gel by electrophoresis. As shown in Figure 3.2.2.4C, 4 colonies for 
each of the ligation ratios were shown to contain plasmid containing correctly oriented 
Cd59a gene. Corresponding colonies were used to inoculate LB broth for expansion and 
plasmid purified using the QIAprep Spin Miniprep Kit (QIAGEN).  
Purified plasmid DNA was sequenced by Cardiff University Central Biotechnology 
Services via the dye-terminator method and capillary electrophoresis using Genetic  
BP 
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Figure 3.2.2.4 Screening PCR of colonies transformed with ligation reaction mixes. A. Forward primer 
specific for a  region upstream of pDR2 polylinker and reverse primer specific for 3 prime region of the 
Cd59a gene, fragment length is 506bp. B. PCR program for screening of colonies. C. PCR products 
were separated on a 1% TAE agarose gel for 30 minutes at 100V. 4 colonies were positive in 6:1 ratio 
and 4 in 10:1. 
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Figure 3.2.2.5 Sequencing data and gene alignment for positive plasmid. Plasmid DNA expanded from 
colony 2 of 6:1 ligation was sequenced using the pDR2 5 and 3 prime primers specific for either side 
of the polylinker site. A. Chromatogram showing 5 prime sequencing with 100% coverage of the 
ligated Cd59a gene. B. BLAST alignment of sequence demonstrated the Cd59a gene had been cloned 
with high fidelity, without introduction of base changes or mutations. 
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Analyzer 3130xl (Applied Biosystems, Warrington, UK). Sequencing was carried out using 
forward and reverse primers specific for pDR2 polylinker region: 
For:  CAAGCCTCAGACAGTGGTTC 
Rev:  ATGTCTGGATCGGTGCGGGC 
The sequencing data provided 100% coverage of the Cd59a plasmid insert and use of the 
NCBI basic alignment search tool (BLAST) confirmed that the inserted fragment was 
100% identical to the sequence published for mus musculus Cd59a antigen (Cd59a), 
transcript variant 1, mRNA (RefSeq NM_001111060.1) Figure 3.2.2.5. Positive colonies 
were cultured in 5 mL aliquots of LB broth and cells used to  generate sufficient plasmid 
DNA for further work, purified using the QIAprep Spin Miniprep Kit (QIAGEN), and for 
glycerol stock preparation, which were stored at -80°C. 
3.2.2.4 Transfection of CT26 cells with pDR2 and pDR2/Cd59a 
Transfection of CT26 cells with the prepared  plasmids was achieved with either Effectene 
(QIAGEN) or Nanofectin (PAA, Somerset, UK) transfection reagents. For each 
transfection cells were seeded at 2×105 cells per well of a six well plate and incubated 
overnight in normal growth conditions. 
For complex formation when using the  effectene reagent 2 μg of pDR2/Cd59a plasmid 
DNA were diluted in DNA-condensation buffer (EC) to a volume of 100 μL. A volume of 16 
μL of enhancer was then added and mixed using vortexer. This was incubated at room 
temperature for 5 minutes then spun down and 40 μL effectene reagent added (1:20, 
DNA:effectene). The final volume was mixed using a vortexer and incubated at room 
temperature for 7 minutes. 
For complex formation, when using the  nanofectin reagent, 3 μg pDR2 plasmid DNA and 
9.6 µL nanofectin reagent (1:3.2, DNA:nanofectin) were both placed in 100 μL of diluent in 
separate tubes and mixed using a vortexer. The nanofectin containing solution was added 
62 
 
to the DNA containing solution and mixed using a vortexer. The resulting mixture was 
incubated for 20 minutes at room temperature. 
To add the complex to seeded cells, spent medium was aspirated from the 6 well-plate, 
the cells washed and 1600 μL fresh full growth medium added. The transfection complex 
containing mixtures were diluted in 600 μL full growth medium and added dropwise to 
cells. 
To allow for complex settling and cell uptake, the plates were incubated in normal growth 
conditions for 24 hours before selection antibiotic was added. For effective selection fresh 
medium with selection antibiotic Hygromycin (hyg.), at a concentration of 250 μg/mL, was 
added daily until colony formation was observed. Selection took 13 and 20 days for pDR2 
and pDR2/Cd59a respectively for colony formation at which point cell numbers were 
adequate for expansion. 
3.2.2.5 PCR for confirmation of transfection 
In order to demonstrate and optimize a method for transfection screening, a PCR was 
developed using primers specific for the polylinker region of pDR2 (Figure 3.2.2.6). 
Fragment sizes depended on presence of the Cd59a gene in transfected plasmid and are 
shown in Figure 3.2.2.6A. PCR reaction mixes were prepared as in section 3.2.1.8 and 50 
and 100 ng pDR2 and pDR2/Cd59a plasmid added. Reaction mixes were placed on 
thermocycler plate and program shown in Figure 3.2.2.6 run. PCR products were 
separated by electrophoresis on 1% agarose TAE gel (Figure 3.2.2.6C) showing product 
size for pDR2 as 143bp and pDR2/Cd59a as 527 bp. 
This system is therefore useful in distinguishing the two plasmids and can be used to 
identify the presence of plasmid in transfected cells. 
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Figure 3.2.2.6 Development of transfection screening PCR. A. 5 and 3 prime pDR2 primers (brown) 
flanking the polylinker site expand PCR products of 143bp and 527bp for pDR2 and pDR2/Cd59a 
plasmids respectively. B. PCR thermocycler programme with 60°C annealing temperature and 40 
cycles. C. 50 and 100 ng of purified plasmid was used for PCR reaction and the volumes separated by 
agarose gel electrophoresis (1% in TAE at 100V for 30 minutes), fragments predicted are clearly visible 
for pDR2/Cd59a and pDR2 plasmids, the negative control was clean. 
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3.2.3 Flow cytometry  
For detection of surface antigens expressed by cells flow cytometry of antibody stained 
cells was used. Cells were detached in PBS+EDTA (5 mM) to protect protein from tryptic 
digestion and washed in FACS buffer - PBS+1% bovine serum albumin  (BSA). Cell were 
incubated with a primary antibody for 1 h at 4°C. The cells were washed three times, and 
incubated with a FITC labelled secondary antibody for 30 min at 4°C in the dark. The 
stained cells were washed three times then analysed on a FACSCalibur (Becton 
Dickinson, Heidelberg, Germany) and the data analysed with Summit 4.3.1 software and 
plotted as a fluorescence intensity histogram. 
3.2.4 Haemolysis C activity assay 
3.2.4.1 Preparation of activated sheep erythrocytes (ShEA) 
Haemolysis assays were conducted using aged sheep erythrocytes (ShE) which were 
required to be activated by coating in antibody for C activation. C fixation diluent (CFD) 
was freshly prepared from CFD tablets (Oxoid, Basingstoke, England) and kept on ice 
throughout. ShE were washed by placing 1 mL of sheep blood in Alsever’s (TCS 
Biosciences, Buckingham, UK) in 20 mL CFD and centrifugation at 860×g (low braking) 
for 5 minutes. Supernatant was discarded and cells re-suspended in 20 mL CFD and 
centrifuged again. This was repeated until supernatant was clear, then 400 µL of the 
pelleted ShE were transferred to 10 mL warmed at 37°C CFD, this was mixed with 10 mL 
of warmed CFD containing 1/2000 amboceptor anti-ShE (Siemens Healthcare 
Diagnostics, Forchheim, Germany). The mixture was incubated for 30 minutes at 37°C on 
a rotator/roller. Cells were then washed by centrifugation as before until the supernatant 
was clear, the final pellet resuspended in 20 mL CFD creating a 2% activated ShE (ShEA) 
suspension that was stored on ice. 
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3.2.4.2 Haemolytic assay 
ShEA prepared as described above were utilised to determine the haemolytic activity of 
various batches of human sera. Controls representing non-specific haemolysis (min) and 
100% haemolysis (max) were prepared with 100 µL CFD or 0.2% triton-X-100 
respectively. Serum samples were serial diluted ½ in CFD and placed in rows of a 96 well-
plate, including a row for serum only to control for absorbance caused by serum. To 
experimental and min/max control volumes, 50 µL of the 2% ShEA suspension was added 
and to serum only controls CFD was added, then all wells made up to 150 µL and plates 
incubated for 1 hour at 37°C. To measure haemolysis, release of haemoglobin was 
measured in the supernatant. Plates were spun at 350×g for 3 minutes at 4°C, 80 μL of 
the supernatant was transferred to a flat bottomed 96 well-plate and absorbance 
measured at 410 nm using a FLUOstar OPTIMA plate reader (BMG Labtech, Aylesbury, 
UK). Percentage haemolysis was calculated using the following equation: 
         
                                         
                                       
      
3.2.5 Calcein release C dependent cytotoxicity (CDC) assays 
CDC assays were developed using the fluorescent labelling reagent calceinacetoxymethyl 
(AM). Calcein AM is a cell-permeant dye molecule, non-fluorescent in its precursor form, 
with its lipophilic blocking AM groups. Upon entry into a live cell the blocking groups are 
removed through acetoxymethyl ester hydrolysis by non-specific intracellular esterases. 
Hydrolysis converts the molecule into a less lipophilic moiety preventing its exit from the 
cell. The calcein molecule also becomes strongly fluorescent making it an excellent cell 
dye for use in lysis assays. For CDC assays all buffers and reagents, with the exception of 
serum dilutions, were pre-warmed to 37°C. 
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3.2.5.1 CDC assay 
To measure the sensitivity of CT26 cells to CDC lysis the following protocol was followed. 
Cells grown to 80% confluency were washed in saline and detached using 10mM EDTA 
PBS. Cells were washed in serum free RPMI and live cell density measured by trypan 
blue exclusion assay as described in section 2.2.5. Cells were diluted to a density of 
5×105 cells per mL, 100 µL placed in a flat-bottomed 96 well-plate, and the plate 
incubated for 16 hours at 37°C, 5% CO2. Adherent cells were washed in serum free 
medium and 100 µL complete growth medium + 2 µg/mL calcein AM was dispensed into 
each well. The plate was then incubated for 1 hour at 37°C, 5% CO2. Loaded cells were 
then washed twice in RPMI no additives and serum dilutions dispensed directly into wells 
and incubated for 1 hour at 37°C, 5% CO2. For testing of C fixation, cells were incubated 
with or without 1/100 αMCF-7 antiserum in serum free RPMI for 1 hour at 4°C then 
washed twice. Serum dilutions were prepared by mixing human serum in serum free 
RPMI and 100 µL added per well of cells then incubated for 1 hour at 37°C, 5% CO2. 
3.2.5.2 Calcein release measurement 
After exposure to serum, supernatant was transferred from plates either after 
centrifugation in detached cell experiments or directly from plates in monolayer 
experiments, to flat-bottomed 96-well plates and the fluorescence measured at excitation 
485nm and emission 520nm using a  FLUOstar OPTIMA plate reader (BMG Labtech, 
Aylesbury, UK). Remaining cells were lysed by addition of 100 µL 0.2 % Triton-X-100 
RPMI solution per well and incubated for 15 minutes then, the plate was then spun and 
the supernatant transferred to a fresh flat-bottomed 96-well plate and fluorescence 
measured as above to quantify the total releasable calcein for each sample. Percentage 
lysis was calculated with the formula below. Values were then plotted using Graphpad 
Prism. 
                                                                            ) 
67 
 
3.2.6 Affinity purification of Human C6 from serum 
3.2.6.1 Anti-C6 column preparation 
Name Contents 
Phosphate buffered saline (PBS) 
8.2 mM Na2HPO4, 1.5 mM KH2PO4, 137mM NaCl, 
pH7.4, 0.22µm filtered 
Phosphate buffered saline (PBS) 
Azide 
As above + 0.01% (w/v) NaN3 
Coupling buffer 
0.2 M NaHCO3, 0.5 M NaCl, 
pH 8.3, 0.22µm filtered 
Wash buffer A 
0.5 M ethanolamine, 0.5 M NaCl pH 8.3, 0.22µm 
filtered 
Wash buffer B 
0.1 M sodium acetate, 0.5 M NaCl, pH 4.0, 0.22µm 
filtered 
 
An in-house generated mouse IgG anti-human C6 antibody, 27d1 was dialyzed overnight 
at 4°C in coupling buffer. Dialysed antibody was filtered through a 0.22 µm syringe filter 
and the concentration determined by absorbance at 280nm. 43.5 mg of antibody was 
coupled to a 5 mL Hi Trap column (GE Healthcare, Little Chalfont, UK), pre-washed with 1 
mM HCl, by repeated (3×) passage at 1 mL/min. Free active binding sites on the column 
were blocked by application of buffer A (3×10 mL); followed by buffer B (3×10 mL). The 
column was then incubated in buffer A for 30 min at RT followed by a repetition of the first 
wash sequence. The finished column with bound antibody was washed into PBS azide 
and stored at 4°C. 
To assess the coupling efficiency the antibody concentration in the retained flow-through 
coupling buffer was determined by absorbance at 280nm. Coupling efficiency was 
calculated as ~70%, equivalent to 33 mg of IgG coupled to the column. 
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3.2.6.2 Fast Protein Liquid Chromatography (FPLC) Purification of Human C6 
Name Contents 
Glycine Elution buffer 
100 mM Glycine in H2O,  pH 2.5, 0.22 µm 
filtered 
Tris Neutralising buffer 1 M Tris, pH 10.5 
H2O 0.22 µm filtered 
 
Purification of human C6 by affinity chromatography from plasma was carried out on an 
Akta Prime FPLC machine controlled with UNICORN 2.11 software (GE Healthcare, Little 
Chalfont, UK). The machine fluidics, normally stored in 20% ethanol, were washed with 
H2O before washing into running buffer. The affinity column was attached, avoiding 
introduction of air bubbles. For first use the column was washed in elution buffer (0.3 
mL/min) to remove any unbound or weakly attached antibody and re-equilibrated in 
running buffer (2 mL/min). Pooled, 0.22 µm filtered normal human serum (pNHS) was 
injected using a 50 mL Akta ‘superloop’ (GE Healthcare) installed on the injection valve. 
The column was washed in 4 column volumes (CV) running buffer and bound protein 
eluted in 2 CV of elution buffer. Eluted protein was collected in 1 mL fractions using a frac-
950 (GE Healthcare) into 12 mm tubes containing 100 µL tris neutralising buffer to adjust 
the pH of the elution buffer to neutral and thus protect the integrity of the eluted protein. 
The column was  re-equilibrated in 4 CV of running buffer. 
3.2.6.3 Generation of  C6 depleted Pooled Human Serum 
Name Contents 
CFD run buffer (made from tablets, 1 per 
100 mL) 
4 mM Na barbitone, 145 mM NaCl, 0.83 
mM MgCl2, 0.25 mM CaCl2, pH 7.2, 0.22 
µm filtered 
Diethylamine Elution buffer 
50 mM Diethylamine, 10 mM Tris, 150 mM 
NaCl, pH11, 0.22 µm filtered 
Tris Neutralising buffer 1 M Tris, pH 7 
 
Serum, freshly prepared as described (section 2.3) was filtered through a 0.22 µm syringe 
filter and kept on ice. The 5 mL HiTrap column prepared as described in section 3.2.6.1 
was attached to a FPLC, as described (section 0). Running buffer used for serum 
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preparations was CFD so that serum dilution would not interfere with C activity as is the 
case for PBS. Serum was injected by superloop as described in (section 0) and flow-
through collected in 5 mL fractions. Flow-through was immediately placed on ice, pooled 
and filtered. C6 was eluted from the column and fractions neutralised with 1 M tris (pH 7), 
the column was then washed and re-equilibrated in running buffer. Where repeat 
injections were required the flow-through serum was injected by superloop and the 
method repeated. At every opportunity the serum was kept on ice. Depleted sera was 
tested to confirm lack of C lytic activity by haemolysis assay (section 3.2.4), aliquoted 
appropriately and stored at -80°C. 
3.3 Results 
3.3.1 Confirmation of transfection 
The CT26 mouse colon carcinoma cell line does not express the CD59a antigen, the 
primary regulator of the MAC in mice (Baalasubramanian et al, 2004). In order to 
understand the role CD59a plays in sublytic MAC responses, CT26 cells were transfected 
with pDR2/Cd59a and pDR2 as an empty plasmid control. Transfection was conducted as 
described in 3.2.2.4 and cells tested for uptake of plasmid by PCR using the protocol 
described in section 3.2.2.5. PCR reactions confirmed the presence of pDR2 and 
pDR2/Cd59a in respective transfected cells corresponding in fragment sizes to purified 
pDR2 and pDR2/Cd59a positive controls (Figure 3.3.1.1A). To establish that the plasmid 
present was functional and driving constitutive expression of the CD59a antigen the cells 
were stained for CD59a, and analysed by flow cytometry (Figure 3.3.1.1B). CT26 cells 
confirmed by PCR as containing pDR2 and pDR2/Cd59a constructs were compared with 
untransfected cells. Untransfected and pDR2 transfected cells gave no signal above the 
background represented by secondary only control confirming that CT26 cells do not 
express the CD59a; however pDR2/Cd59a transfected cells had a much higher signal, a 
broad distribution of expression with >90% positive of total population.  
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Figure 3.3.1.1 A. Screening of transfected CT26 cells using PCR. 50 ng of plasmid DNA isolated from 
cells designated CT26/pDR2 and CT26/pDR2/Cd59a (expanded colonies formed following hygromycin 
selection), was screened using the developed PCR. Fragments at 143 bp and 527 bp confirmed 
presence of pDR2 and pDR2/Cd59a plasmids in respectively. B. FACS staining for CD59a protein 
expression on transfected cells. CT26/pDR2 and CT26/pDR2/Cd59a were expanded and detached 
using EDTA then stained with mCD59a7 and an anti-mouse IgG FITC conjugated secondary antibody. 
FACS plot lines: Green; CT26/pDR2 secondary (2’) control, Blue; CT26/pDR2 1’ and 2’, Red; 
CT26/pDR2/Cd59a 2’ control and Pink; CT26/pDR2/Cd59a 1’ and 2’. 
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3.3.2 C susceptibility of CT26 cells 
3.3.2.1 C fixation using antiserum 
To assess whether CT26 cells required antibody binding for C fixation, an antiserum 
raised against MCF-7 breast cancer cell line was used. The antiserum was shown by  
FACS analysis to bind CT26 cells (Figure 3.3.2.1A). CT26 cells were treated with anti 
serum and CDC lysis during incubation with 0-10% serum concentrations measured as 
described in section 3.2.5.2 
Lysis profiles for cells incubated with and without antiserum were roughly similar, 
demonstrating an increase from 0 to 40% lysis with serum increasing 0 to 10% (Figure 
3.3.2.1B). Addition of the αMCF-7 antiserum resulted in no significant increase in lysis 
compared to without its addition suggesting CT26 cells were capable of activating the C 
cascade spontaneously or through serum-natural antibody against expressed surface 
antigens. Note that the target cells are of mouse origin and serum from human. Binding of 
antibodies present in the antisera as shown by FACS did not contribute to increased C 
activation.  
3.3.2.2 Sensitivity of CT26 cells to C 
To assess the sensitivity of CT26 cells to C lysis, determine sublytic conditions and 
demonstrate that transfected CD59a was functionally capable of MAC regulation in these 
cells a CDC lysis assay was performed Figure 3.3.2.1C. CT26, CT26/pDR2 and 
CT26/pDR2/Cd59a cultured in a monolayer were loaded with calcein-AM and exposed to 
0-40% pNHS concentrations for 1 hour, then lysis was calculated as described in section 
3.2.5.2. Sensitivity of cells to C lysis was dependent on serum concentration, a clear effect 
of serum titration showed 40% pNHS resulted in the highest levels of lysis of  around 
50%. Lysis rose rapidly between 0 and 10% but increased less rapidly between 10 and 
40% though not reaching a plateau. CT26 and CT26/pDR2 cells were roughly similar in 
CDC susceptibility with CT26 being marginally more susceptible.  
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Figure 3.3.2.1 C dependent cytotoxicity (CDC) of CT26 cells using calcein release assays. A. FACS 
analysis of cells incubated with αMCF-7 anti-sera to assess binding of antibody to cell antigens. B. 
Comparison of detached CT26 cell susceptibility to C mediated lysis with and without αMCF-7 anti-
sera pre-treatment. C. Susceptibility of CT26, CT26/pDR2 and CT26/pDR2/Cd59a cells in a monolayer 
to C lysis. In each CDC assay cells were loaded with calcein AM then exposed to serum for  1h at 37°C. 
Fluorescence was measured in the supernatant together with the residual released from the cells by 
0.2% triton-X-100 treatment. % lysis was calculated as described in section 3.2.5.2. Results are mean 
n=3 +/- SEM (ns= not significant, *p<0.05, **p<0.01, ***p<0.001). 
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In contrast, CT26/pDR2/Cd59a cells were protected from C lysis with cell killing reaching 
a maximum of 20% when exposed to 40% serum. Indeed, the lytic profile showed a less 
rapid increase in lysis between 0 and 10% compared to CT26 and CT26/pDR2. CD59a 
expressing cells were significantly protected from lysis compared to CT26  and 
CT26/pDR2 at all serum doses between 10 and 40%. 
At the lower serum concentrations (1.25, 2.5 and 5%) lysis was similar in each of the cells 
types irrespective of the presence of transfected CD59a, resulting in 10% lysis and below. 
C activation which achieves 10% lysis or less can be considered sublytic. The serum 
concentration which achieved this sublytic level in all cells was 5%. 
3.3.3 C6 depletion of serum 
To generate a control reagent for MAC induced sub lytic effects it was initially decided to 
prepare serum depleted of C6 since C6 is an essential component of the terminal pathway 
and the MAC. All purifications and depletions of C6 from plasma or serum were performed 
using the anti-C6 Hi TRAP column (section 3.2.6.1). 
3.3.3.1 C6 purification: C6 activity 
 To test the column performance, capacity and also to ensure that purified C6 was active 
for use in future add-back experiments, C6 was purified from frozen plasma stocks. 
Plasma was thawed and filtered with a 0.2 µm syringe filter and 50 mL injected onto the 
column  (FPLC setup and column attached as described in section 0). Protein was eluted 
in glycine buffer pH 2 and fractions corresponding to the elution peak (Figure 3.3.3.1A) 
were pooled and dialysed overnight against PBS at 4°C. Purified C6 was analyzed by 
SDS-PAGE on 10% polyacrylamide gels under reducing and non-reducing conditions and 
the gels coomassie stained (section 2.7.3) (Figure 3.3.3.1B). C6 ran faster on the gel 
under non-reducing conditions compared to reduced, bands appearing ~100 kDa 
according to molecular weight markers. C6 contains 32 internal disulphide bonds making 
it a highly stable protein and thus insensitive to SDS linearization (Discipio & Hugli, 1989). 
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However, under reducing conditions the covalent linkages are broken and the protein 
unravels to its fully linearized length.  
Activity of purified C6 was confirmed using serum from C6-/- rats (Figure 3.3.3.1C+D). 
Haemolysis was conducted as in section 3.2.4. Deficient serum was titrated with or 
without addition of 50 µg/mL of C6 and ShEA added to each well. A serum only titration 
was used to control for signal caused by serum. The plate was incubated at 37°C for 1 
hour and percentage haemolysis calculated from maximum and minimum controls. C6 
deficient serum from knockout rats was haemolytically inactive until the addition of human 
C6 protein restored haemolytic activity to the serum (Figure 3.3.3.1C). Further 
experiments showed that as little as 10 µg/mL of human C6 was capable of restoring full 
haemolytic activity to the serum (Figure 3.3.3.1D). 
3.3.3.2 C6 purification: column capacity 
To test the capacity of the column to deplete plasma of C6, 50 mL plasma was run 
through the column  and the flow-through collected then C6 eluted from the column (run 
1). The diluted 60 mL flow-through was passed back over the column, eluted (run 2) and 
the 100 mL flow-through collected. This was passed over a third time and the remaining 
C6 protein eluted (run 3). Fractions were collected and pooled so that a C6 sample was 
retained after each run, elution peaks are shown in Figure 3.3.3.2 A. The C6 protein was 
analyzed on 7.5% polyacrylamide gels which were coomassie stained and western blotted 
(Figure 3.3.3.2B+C). Coomassie gels and western blots showed that the first pass 
extracted the greatest quantity of C6 with a little in the second run. None could be 
detected in the elution from the final pass by either coomassie or western blot. The data 
suggested that complete depletion of C6 from 50 mL plasma required at least 2 passes 
through the column. 
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3.3.3.3 C6 depletion from serum: single injections 
The next step was to investigate the capability of the column to deplete serum with a 
single pass of the column since it is desirable to reduce the negative impact of passing 
serum through an antibody coupled column on C activity. Separate injections of 5 and 10 
mLs serum (runs 1 and 2 respectively) were made and depleted serum collected (Figure 
3.3.3.3A). Coomassie stain and western blot of eluted fractions demonstrated C6 recovery 
(Figure 3.3.3.3B+C). However, when haemolytic activity of the depleted serum from runs 1 
and 2 was compared to that of pNHS (Figure 3.3.3.3D) the seras retained significant lytic 
activity showing less than a log decrease in activity. Depletion of 5 mL serum was 
marginally more effective than 10 mL injection. Thus, trace amounts of residual C6 were 
sufficient for significant haemolytic activity suggesting that MAC formation remains 
possible because of incomplete depletion. 
3.3.3.4 C6 depletion: triple injection 
Having demonstrated that single injections even of low volumes of sera were not able to 
achieve complete depletion of C6, repeated injections were performed starting with 20 mL 
volumes of pNHS. Collected flow-through was passed over the column twice more after 
original inject so that in total the serum had been thrice through the column (runs 1-3) 
(Figure 3.3.3.4A). To reduce any dilution of serum flow-through, only the most 
concentrated fractions were pooled as judged by UV trace post-injection. Depleted serum 
was then tested for its haemolytic activity compared to pNHS and showed a log reduction 
in activity which could be restored to that of pNHS with the addition of C6 to a final 
concentration of 50 µg/mL (Figure 3.3.3.4B). Apart from demonstrating a reduction of 
haemolytic activity by the near-total removal of C6, this also demonstrates that there is no 
loss of haemolytic potential subsequent to the passing of serum three times through a 
HiTrap column. 
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3.3.3.5 C6 depletion: quad injection 
Although a log reduction in haemolytic activity was achieved after three passes of the 
serum, it was thought that a further reduction in activity could be achieved with a fourth 
pass. Western blot of serum after each run shows that C6 is undetectable after first run 
(Figure 3.3.3.5A). However, haemolytic activity remained in the final depleted serum, 
albeit reduced by more than a log compared to that of pNHS, and was fully restored upon 
the addition of C6 at a final concentration of 50 µg/mL (Figure 3.3.3.5B). Reduction of 
haemolytic activity of this depleted serum represented the closest to depletion thus far. 
CDC lysis assays conducted as in section 3.2.5, show that the depleted sera had 
significantly reduced lytic activity against CT26 cells compared to pNHS (Figure 3.3.3.5C). 
Addition of C6 to a final concentration of 50 µg/mL increased CDC activity but could not 
restore lytic activity of C6 depleted sera to that of pNHS. At this point, although C6D 
showed reduced haemolytic activity and very low CDC activity the failure to achieve 
complete inhibition of MAC formation capacity and restore CDC activity by C6 add-back, it 
was concluded that total C6 depletion as a sublytic C reagent presented a significant 
challenge that could not be overcome with the available tools and methods. 
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Figure 3.3.3.1 C6 purification from plasma using Hi-trap column coupled with 27d1 anti-human C6 
antibody. A. UV absorbance at 280 nm profile of eluted protein. B. coomassie stain of pooled eluted 
fractions (1; non-reduced, 2; reduced). C. Haemolysis of C6
-/-
 rat serum plus eluted fraction at 50 
µg/mL of serum reconstituted lytic activity. D. Reconstitution of haemolytic activity in rat serum over 
protein concentrations from 100 µg/mL down to 0. 
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Figure 3.3.3.2 C6 depletion from 50 mL plasma. A. UV absorbance profile of eluted protein from 
sequential elutions (1-3, left to right). B coomassie stain and C. western blot; of pooled eluted 
fractions: 1+4; first, 2+5; second, 3+6; third run(1-3 non-reduced, 4-6 reduced). 
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Figure 3.3.3.3 C6 depletion of 5 and 10 mL single injections of serum. A. UV absorbance at 280 nm 
profile of eluted protein from run 1 and run 2 (left to right). B. coomassie stain and C. western blot of 
eluted fractions 1+3; Run 1, 2+4; Run 2 (1-2; non-reduced, 3-4 ;reduced, 5; 2’ control WB). D. 
Haemolytic activity of depleted sera from runs 1 and 2 compared to pNHS. 
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Figure 3.3.3.4 Serum depletion of C6, triple injections. A. UV absorbance at 280 nm profile of eluted 
protein from 3 sequential injections (left to right). B. Haemolytic activity of depleted sera with and 
without supplementation of C6 at 50 µg/mL serum compared to pNHS. 
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Figure 3.3.3.5 Serum depletion of C6, four injections with high pH elution conditions. A. Western blot 
of depleted sera probed with 27d1 (1’) and HRP conjugated α-mouse IgG (2’) (1;C6 protein, 2; pNHS, 3-
6; depleted sera 1-4 injections, 7;C6 2’ control, 8; pNHS 2’ only control). B. Haemolytic activity of 
depleted sera with and without supplementation with C6 at 50 µg/mL serum compared to pNHS. C. 
CDC lytic activity (against CT26 cells) of C6D serum with and without supplementation with C6 at 50 
µg/mL compared to pNHS. Results are mean n=3 +/- SEM (*p<0.05, **p<0.01, ***p<0.001). 
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3.3.4 OmCI 
The failure of C6 depletion to provide a haemolytically inactive serum necessitated the 
use of a new strategy. I thus next explored the possibility of using inhibiting reagents to 
remove/block haemolytic activity. One such available reagent was OmCI, a C5 inhibiting 
protein isolated from the Ornithodoros moubata tick (Nunn et al, 2005). 
3.3.4.1 OmCI Haemolysis 
The concentration of OmCI required for complete inhibition of C activity was determined 
by haemolysis assay. A dilution series of OmCI concentrations ranging from 20 to 0.02 
µg/mL in 50 µL was prepared in CFD. To each well 50 µL of a 50% serum solution was 
added and the plate incubated for 15 minutes at room temperature. Fifty microlitres of a 
pre-prepared 4% ShEA cell suspension was then added to each well. Maximum and 
minimum release wells were prepared as described (section 3.2.4.2) and the plate 
incubated for an hour at 37°C. Haemoglobin release was measured by absorbance and 
percentage haemolysis calculated using maximum and minimum release controls as in 
section 3.2.4. The concentration of OmCI required to achieve complete inhibition of C 
activity was found to be 10 µg/mL (0.6 µM) of serum (Figure 3.3.4.1A). Inhibition of serum 
using this dose was further confirmed by haemolysis comparing pNHS with pNHS treated 
with OmCI in serial titration (Figure 3.3.4.1B). Inhibition of CT26 CDC using OmCI was 
tested by calcein release as described in section 3.2.5 (Figure 3.3.4.1C). CDC was 
significantly inhibited by OmCI at both 5 and 10% pNHS (p<0.01 and 0.05 respectively) 
with OmCI treated serum diluted to 10% (v/v) achieving little over 5% lysis. The sublytic 
threshold level of 5% pNHS achieved just under 7% lysis and OmCI treated serum about 
1% confirming it as a suitable control for assessing sublytic C. 
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Figure 3.3.4.1 OmCI inhibition of the lytic potential of human serum. A. Haemolytic assay of serum 
treated with different doses of OmCI. B. Haemolytic activity of serum treated with or without 10+20 
µg/mL OmCI, serum was titrated from 16% down to 0. C. OmCI inhibition of pNHS mediated CDC of  
CT26 cells. CDC assay showing lysis of cells exposed to 0-10% pNHS with or without 10 µg/mL OmCI 
treatment, results are mean n=3 +/- SEM (*p<0.05, **p<0.01) .   
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3.3.5 Sublytic attack 
Section 3.3.2 described  the sensitivity of CT26 mouse colon carcinoma cells to C lysis as 
defined in CDC calcein release assays. CT26 cells seeded to generate a monolayer of 
1.6×103 per mm2 of available culture surface area, exposed to 5% pNHS for 1 hour, 
resulted in less than 10% lysis and can be considered sublytic. Section  3.3.4 described 
the use of the terminal pathway inhibitor, OmCI as a control in sublytic experiments. 
Complete terminal pathway inhibition of serum was achieved by pre-treatment with 10 
µg/mL OmCI for 15 minutes at room temperature shown both in haemolysis and CDC 
lysis assays (Figure 3.3.4.1). Looking carefully at the data, the conditions chosen for 
sublytic experiments were as follows: Cell monolayers 1.6×103 per mm2 exposed to 5% 
pNHS, treated with or without 10 µg/mL OmCI and incubated in normal culture conditions 
(37°C, 5% CO2) for 1 hour. 
With conditions optimized, preliminary experiments could be performed to ascertain the 
best possible design for analysis of sublytic C effects and the role of the MAC. To do this 
measurable outputs were required to show that CT26 cells were indeed responding to 
sublytic C. 
The first possible markers representing a response by tumour cells to sublytic C to be 
examined were informed by literature associations. Particular focus was placed on genes 
which had been shown to influence metastasis and proliferation acting as markers for 
tumour aggression. Proliferative markers chosen were Ki67 and PCNA. Metastatic 
markers chosen were OPN and uPA (Wai et al, 2005). 
3.3.5.1 qPCR analysis 
To determine whether expression of these marker genes was responsive to sublytic C, 
real time qPCR analysis was used to give gene expression relative to β-actin as a 
housekeeping control. Briefly, CT26, CT26/pDR2 and CT26/pDR2/Cd59a cells were 
cultured in the absence of hygromycin for 24 hours prior to seeding overnight at the stated 
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density (section 3.2.5.2) in normal growth conditions. Serum was treated with or without 
OmCI for 15 minutes at room temperature then diluted to 5% in serum free medium. The 
monolayers were then washed in serum free medium and 5% serum dilutions added. 
Cells were exposed for 1 hour and total RNA extracted directly from the monolayers using 
the Genelute extraction kit (Sigma). Concentration of extracted total RNA was measured 
and 1 µg reverse transcribed (section 2.5.4). PCNA, Ki67, uPA and OPN expression was 
measured relative to β-actin by qPCR analysis as described in section 2.6.2. 
Expression data from the qPCR analyses of the proliferative markers PCNA and Ki67 
revealed contradictory changes in gene expression with PCNA increasing strongly while 
Ki67 was decreased in un-transfected cells (Figure 3.3.5.1A and B). PCNA expression 
was significantly upregulated  in response to pNHS compared to pNHS+OmCI in 
untransfected (p<0.01) and to a lesser extent  in CD59a expressing cells (p<0.05) but not 
in empty vector controls which could indicate a proliferative response by CT26 cells to 
sublytic C; however, the effect was diminished in transfected cells suggesting perhaps 
that the presence of a transfected plasmid and hygromycin selection pressure interfered 
with this response (Figure 3.3.5.1A).  
Relative expression of Ki67 in CT26 cells was significantly decreased in response to 
sublytic C (p<0.05), however in empty vector transfection controls gene expression 
increased significantly (p<0.05), whilst CD59a transfected cells showed no response to 
sublytic attack but had higher basal expression levels. Overall expression values for Ki67 
calculated relative to β-actin were very low suggesting very low abundance compared to 
the housekeeping gene. This may make it difficult to interpret expression values.  
The metastasis associated markers uPA and OPN  were both increased in response to 
sublytic C when compared to the OmCI control (Figure 3.3.5.2A+B respectively). 
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Figure 3.3.5.1 qPCR expression analysis of PCNA and Ki67 in response to sublytic C. Total RNA was 
extracted from CT26, CT26/pDR2 and CT26/pDR2/Cd59a cells exposed to 5% serum with or without 
OmCI treatment, reverse transcribed and subjected to qPCR analysis using primers specific for PCNA 
(A.) and Ki67 (B.) relative to β-actin calculated using the ΔΔCt calculation outlined in section 2.6.2. 
Results are mean n=3 +/- SEM (ns= not significant, *p<0.05, **p<0.01). 
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Figure 3.3.5.2 Expression analysis of uPA and OPN in response to sublytic C. Total RNA was extracted 
form CT26, CT26/pDR2 and CT26/pDR2/Cd59a cells exposed to 5% serum with or without OmCI 
treatment, reverse transcribed and subjected to qPCR analysis using primers specific for uPA (A.) and 
OPN (B.) relative to β-actin calculated using the ΔΔCt calculation outlined in section 2.6.2. Results are 
mean n=3 +/- SEM (ns= not significant, *p<0.05, **p<0.01). 
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Figure 3.3.5.3 Expression analysis of OPN in response to exposure to sublytic C over a 12 hour time 
course. CT26 cells were exposed for 6 and 12 hours to 5% serum treated with or without OmCI then 
total RNA extracted and reverse transcribed. OPN gene expression was  analysed by qPCR and 
calculated as relative to β-actin using the ΔΔCt calculation outlined in section 2.6.2 then presented as 
a % of untreated control . Results are mean n=3 +/- SEM (***p<0.001). 
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The effect was mirrored in all three cell lines suggesting expression of CD59a had little 
impact on the expression levels although basal expression for both genes was higher in 
transfected cells and upregulation somewhat less in CD59a expressing cells compared to 
transfection controls. Upregulation of uPA was significant in all three cell lines (CT26 and 
CT26/pDR2 p<0.01, CT26/pDR2/Cd59a p<0.05) but OPN upregulation was only 
significant in pDR2 (p<0.01) cells although relative expression values were greater in OPN 
compared to uPA which suggests, as was the case for Ki67, that uPA was in deficit 
compared to the housekeeping gene. For this reason OPN was used as an indicative 
gene for gene expression changes in response to sublytic C and was investigated further. 
To understand the time frame during which the upregulation of OPN occurred the 
experiment was repeated with only untransfected CT26 cells looking at expression levels 
at 6 and 12 hours post exposure.  Cell monolayers were exposed to serum dilutions for 6 
and 12 hours along with an untreated control. Total RNA was extracted and  reverse 
transcribed for qPCR analysis of OPN. Expression levels were analysed relative to β-actin 
and calculated as a % of the untreated control as described in section 2.6.2.  
Significant upregulation of OPN occurred at 6h (p<0.001) and 12h (p<0.001) hours 
showing a steady increase over the time course (Figure 3.3.5.3). Expression in OmCI 
control cells remained roughly the same as untreated cells at both time points. This data 
demonstrated a sustained gene expression change in response to sublytic C over a 12 
hour period.  
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3.4 Discussion 
The aims of the work described in this chapter were to develop and optimize the reagents 
and conditions for sublytic C experiments. Specifically, I sought to determine the 
concentration  of pNHS required to achieve a sublytic threshold when used as a source of 
C on CT26 cells and investigate systems which could be used as controls for comparison 
against C terminal pathway activation as well as assess the influence of CD59a in any 
observed effects. 
3.4.1 Cd59a transfection 
For investigations into the role of CD59 in sublytic C effects on CT26 murine colon 
carcinoma cells a plasmid construct containing the murine homologue Cd59a was 
engineered. Cells were transfected with this construct (or its empty vector control) and 
transfection confirmed by PCR and expression of Cd59a protein product by flow 
cytometry. A feature of the expression profile revealed by flow cytometry was a broad 
spread of expression levels ranging from 1 log up to 3. To remove this spread CD59a 
expression could be sorted by serial dilutions to single cells and cloned out then screened 
to isolate high, middle and low expressors which could be used to further characterise the 
influence of MAC on cellular responses. 
3.4.2 Susceptibility of CT26 cells to CDC 
Calcein release CDC assays were used to demonstrate the functionality of expressed 
CD59a and define conditions for subsequent investigations into the cellular consequences 
of sublytic C attack.  
CT26 cells were capable of triggering C activation in the absence of a fixing antibody. The 
mechanism for this activation is likely to be classical pathway activation via natural 
antibodies present in human sera. In a heterologous system such as this where a murine 
cell line is exposed to human serum, one possible explanation is that activation is 
91 
 
mediated by the natural presence in human serum of antibodies reactive to HMAg, a 
foetal bovine antigen incorporated in cell surfaces during culture with FBS (Richter et al, 
1977). 
Assays were initially developed using cells in suspension, as in antibody C fixation tests, 
but these were adapted for adherent cells which was the preferred format for sublytic 
experiments. CD59a expressing cells demonstrated significant protection from lysis 
compared to both the transfection control and untransfected cells. Overexpressed CD59a 
was therefore functionally active and capable of influencing susceptibility to lysis. In all 
cases the lytic profiles showed the cells had roughly similar  sublytic thresholds revealing 
that the serum concentration which resulted in below 10% lysis was 5% for all three cell 
lines. It is from these assays that the cell density and sublytic threshold were derived for 
subsequent sublytic C experiments.  
3.4.3 C6 depletion of serum 
Detection of a cellular response to sublytic C is dependent on a comparison with a control, 
the choice of control is key in it’s interpretation. Sublytic experiments which use serum as 
a C source require careful consideration because of the many growth factors and 
hormones present. These will inevitably activate cells and induce signalling events which 
must be controlled for. In addition to this, the use of serum as a C source to study the non-
lethal effects of the MAC is further complicated by the  release of the anaphylatoxins 
(C3a, C5a) prior to activation of the terminal pathway and formation of MAC.  
It is therefore not sufficient to simply inactivate C completely as is the case in heat 
treatment of serum. A better strategy aimed at focussing on MAC formation is to remove 
the ability of serum to form MAC by depleting sera of factors required for its sequential 
formation.  Terminal pathway progression and MAC formation can be restored by addition 
of the removed component. C6 depletion of serum was achieved by affinity 
chromatography using a Hi-trap column to which had been coupled a monoclonal 
92 
 
antibody reactive against human C6. The column had a dual purpose in that it allowed C6 
to be purified for reconstitution of the haemolytic activity of C6 depleted serum.  
C6 purification from 50 mL plasma by repeated passages suggested the column capacity 
was sufficient to deplete this volume with 3 passes (with elution of bound C6 between 
runs). However, it was desirable to keep the number of passes down to reduce the risks of 
on-column activation and dilution of the sera. Single runs of 5 or 10 mLs  of serum 
suggested that complete depletion was achievable according to coomassie and western 
blot. However, the “depleted” sera retained significant haemolytic activity despite 
increasing the number of repeat passages of serum over the column from 1 to 4 and an 
alteration of elution conditions from low to high pH, it became clear that complete removal 
of haemolytic activity, despite the apparent removal of C6 as tested by western blot. 
 Haemolytic activity in serum “depleted” of C6 can be explained by trace amounts of 
residual C6. It is apparent that serum with extremely low quantities of C6 retains the ability 
to form MAC. This feature is perhaps not unexpected because subtotal C6 deficient 
individuals have been described with serum C6 concentrations as low as 0.74 µg/mL 
(compared to the normal ~45 µg/mL) but with relatively normal terminal pathway activation 
capacity (Wurzner et al, 1991). C6 is abundant in serum and it is clear that inhibition of 
terminal pathway activation and lysis requires it to be completely depleted. Formed C5b 
remains associated with the C5 convertase enzyme and is only released when it binds 
C6, this might explain why C6 does not limit activation because the C5b essentially ‘waits’, 
although briefly, for binding. With the excess C7 in C6 depleted serum any C5b6 that does 
form can readily bind C7 and the pathway continues. A more effective method might have 
been depleting of C7 because of its known rate limiting properties during terminal pathway 
activation (Silversmith & Nelsestuen, 1986). If C7 levels are restricted C5b6 accumulates 
in the fluid phase but is less likely to encounter C7. Binding of C7 allows it to associate 
with membrane and recruit C8 and C9. Depletion of C8 or C9 was not used because of 
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the reported cell activating properties of C5b-7 and C5b-8, though this activity is 
significantly less compared C5b-9 (MAC) (Niculescu et al, 1999). 
 A less likely explanation for the retention of haemolytic activity by C6 depleted sera is that 
the 27d1 antibody did not recognise a polymorphic variant of C6 such as that reported 
previously by Orren at al (1992). In that case a C6 protein, of 86% the molecular weight of 
the wild type, was isolated in patients with subtotal C6 deficiency. Serum containing this 
C6 subtotal deficiency (C6SD) protein retains haemolytic activity (Orren et al, 1992).  
3.4.4 OmCI treatment of serum 
In the search for a suitable control for MAC formation the C5 binding tick protein OmCI 
was tested. OmCI inhibited haemolytic activity of serum at 10 µg/mL of neat serum. C5 is 
present in serum at roughly 75 µg/mL equivalent to 0.39 µM, with OmCI inhibiting at 10 
µg/mL or 0.6 µM the C5:OmCI molar ratio equates to 1:1.5. This is close to the 
hypothetical 1:1 ratio required for complete inhibition (Hepburn et al, 2007). OmCI 
concentrations above 10 µg/mL did not achieve improved inhibition indicating that 
saturation of available C5 had been reached. This is in agreement with concentrations 
determined by Hepburn et. al. (2007). Assays with human serum showed OmCI inhibited 
haemolysis completely  at 14 µg/mL and to 92% at 9.4 µg/mL (Hepburn et al, 2007). 
The use of a single reagent to inhibit the terminal pathway as a control has many 
advantages compared to depleted serum approaches. OmCI can be used to treat serum 
at the optimised concentrations determined in previous experiments; whereas depleted 
sera would likely require further optimization because of reduction in activity and a 
requirement for C6 supplementation for sublytic C activation. It has further advantages 
because it allows the use of pooled normal human serum (pNHS) which can be readily 
prepared in large quantities compared to C6 depleted sera which would require multiple  
depletion protocols to be undertaken. 
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3.4.5 Sublytic C influence on putative marker genes 
With sublytic conditions optimized the next key objective was to develop the protocol on 
which a microarray experiment could be conducted. From the literature several genes 
were chosen representing key processes in tumour development and metastases in which 
a role for sublytic C attack could be hypothesised. The metastatic associated genes OPN 
and uPA, and the proliferation associated PCNA and Ki67 were found to be expressed by 
CT26. OPN expression by CT26 is directly linked to metastatic potential in both in vitro 
and in vivo studies (Wai et al, 2005). The remaining genes serve as surrogate markers of 
proliferative potential. 
The metastatic markers OPN and uPA proved to be the most reliable markers. Both were 
upregulated in response to sublytic C and to similar degrees. Upregulation was reflected 
in each transfected cell line apart from an increase in basal expression. CD59a 
expression slightly suppressed the effect of upregulation probably by reducing functional 
MAC deposition and abrogating to some extent any sublytic effect. A C mediated 
upregulation of either of these genes has not been described previously. OPN  was 
upregulated over a 12 hour time course in which the response was tested in CT26 cells. 
The effect was mirrored in all three cell lines suggesting expression of CD59a had little 
impact on the expression levels although basal expression for both genes was higher in 
transfected cells and upregulation somewhat less in CD59a expressing cells compared to 
transfection controls. 
3.4.6 Murine cells , human serum 
The system optimized for the investigation of sublytic C effects makes use of human 
serum but the model cell line is of murine origin. This has some advantages  but some 
important implications which should be considered. 
The system has several practical advantages compared to the alternatives. The lack of a 
requirement for a complement fixing antibody means that there is no need to develop a 
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cell/antibody model where the recognised antigen is suitable, lacking signalling capacity. 
Also, human serum is plentiful making it easy to prepare large homogeneous batches for 
freezing compared to murine which is difficult to source in any great quantity. Finally, as 
discussed in section 1.1.6 murine serum is less haemolytically active than human and 
notoriously difficult to work with. 
Though the system has these benefits it is clearly not advantageous to use a mixed 
species model. Cells bathed in non-homologous serum may respond differently to the 
stimulus intended and therefore may present a challenge when extrapolating results. 
3.4.7 Summary and conclusion 
Conditions for sublytic C attack were optimized in this chapter including cell density, 
format and serum concentration. Attempts to generate a non-lytic C6 depleted serum to 
control for MAC were unsuccessful and so the C5 inhibiting tick protein, OmCI, was used 
in its stead. Out of the four genes analysed by qPCR OPN and possibly uPA were 
upregulated in serum conditions compared to the OmCI treated control, demonstrating 
that sublytic C, and specifically the terminal pathway, could induce expression of genes 
associated with metastasis. OPN was shown to significantly increase over a 12 hour 
period in response to sublytic C attack from serum. These results allowed the construction 
of a 12h based sublytic attack experiment wherein RNA obtained from attacked CT26 
cells would be subject to whole genome microarray analysis. 
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4 Global gene expression microarray 
4.1 Introduction 
4.1.1 Microarray gene expression analysis 
4.1.1.1 Microarray principles 
Microarray analysis allows the expression levels of many genes to be determined 
simultaneously.  In recent years it has become commonplace to use microarray 
technology for various applications due to the democratisation of the available platforms 
through proliferation of information, access and reduction in cost. All microarray 
technologies are based on the hybridisation of DNA or RNA, a unique phenomenon first 
predicted by Watson and Crick, where sequences with high levels of complementarity are 
able to bind with high levels of specificity and affinity (Marmur & Doty, 1961; Watson & 
Crick, 1974). Microarray, as its name suggests, is a miniaturised version of the 
hybridisation technique allowing the number of queried entities to be increased by many 
thousands of times. Thus, the technology can be described as thousands of parallel dot 
blot experiments (Kafatos et al, 1979; Saiki et al, 1989; Southern, 2001). 
4.1.1.2 Microarray technology 
Principally, the technologies are based upon immobilization of specific nucleotide 
sequence onto a platform; these sequences are referred to as probes. Spots containing 
many identical immobilized probes are arranged so that their specific location is defined. 
An RNA or DNA sample, referred to as the target, is labelled, usually with a fluorescent 
moiety and incubated with the immobilized probes to allow for hybridisation of 
complementary sequence. After washing, each probe location is scanned for fluorescent 
signal. Fluorescent signal from each spot corresponds to the quantity of a DNA or RNA 
sequence hybridised with its specific probe, revealing the comparative quantity of a 
specific sequence in the starting material (Miller & Tang, 2009). 
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The technological underpinnings for the many platforms vary in three key aspects; the 
probe size, the method of manufacture and number of samples that can be 
accommodated (Tarca et al, 2006). A major advancement in the development of 
microarray technology was the move to rigid impermeable support materials from the 
flexible porous membrane (such as nitrocellulose) used in the dot blot technique; glass 
and in some cases silicon have been used, the impermeable quality of the material allows 
probes to be directly immobilized or synthesised in situ on the surface of the support with 
a high degree of accuracy. An impermeable support also promotes hybridisation by 
allowing improved access of probe to target (Southern, 2001). Printing of probes onto a 
glass support using inkjet technology or a contact printing method accurately places spots 
on the surface to create 10,000-30,000 separate and probe enriched 100-150 µm sized 
spots.  
Early arrays used probes or complementary DNAs (cDNA) which were synthesised as 
dsDNA by PCR. Larger probes up to 1 KB in length have the advantage of specificity 
(Tarca et al, 2006). Immobilization of large dsDNA probes is achieved either through 
electrostatic forces or by UV cross-linking (Cheung et al, 1999; Ehrenreich, 2006). 
Covalent linkages can  also be achieved with 5 prime amino group modification which is 
then linked to an available aldehyde or epoxy group present on a coated surface. The 
method of ‘printing’ dsDNA probes onto a glass support was the first microarray to be 
successfully used in a lab setting (Schena et al, 1995). Technology now more often use 
shorter oligonucleotide probes of between 25-70 nucleotides in length which give greater 
sensitivity and are more often chemically synthesised (Tarca et al, 2006). 
4.1.1.3 In situ synthesis 
The relative simplicity of placing a pre-synthesised probe on to a support then 
immobilizing it has given way to the much more specific and complex process of in situ 
synthesis where probes are ‘built’ base by base directly on to the support. In situ synthesis 
for modern microarrays is achieved by one of three strategies, photolithographic, digital 
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mask or inkjet methods. Photolithography is a system which uses bases coupled with a 
photo labile protecting group which will only allow chemical attachment of bases when the 
group is removed by exposure to UV. Bases are made available sequentially and a 
lithographic mask used to selectively expose spots for attachment. Over several cycles of 
A, T, G and C each probe is synthesised to a pre-programmed sequence. This is the 
method used by Affymetrix to create its quartz based GeneChips. Digital mask utilises a 
similar strategy replacing the lithographic mask with a virtual mask or digital micro mirror 
device (DMD). This technology is used by Roche to produce its NimbleGen chips which 
are also based upon quartz platforms. In contrast to these mask utilising approaches, 
Agilent uses inkjet technology to place nucleotides one by one in sequence specific to 
each probe onto a glass support (Hughes et al, 2001). 
4.1.2 Bead array 
4.1.2.1 Introduction 
A novel system, known as bead array, substitutes the chip based substrate onto which the 
probes are attached, with 3µm silica beads which are allowed to self-assemble randomly 
onto a platform etched with micro-wells as shown in Figure 4.1.2.1 (Michael et al, 1998). 
Bead arrays allow for a greater density of features compared to conventional spotted 
arrays but necessitate a method of identifying the probes on randomly arranged beads. 
An ingenious method was devised to decode the location of beads using hybridisation 
with fluorescently labelled decoder sequences. In addition to the gene specific sequence 
of each probe a unique 29-mer identifier sequence or address is also included (Figure 
4.1.2.1). Defined pools of oligonucleotide decoders labelled with one of four ‘colours’ are 
hybridised and scanned and then the Beadchip washed. Repetition of this sequence with 
several decoder pools builds a unique code for each bead based on the colour status after 
each hybridisation (Gunderson et al, 2004). This method also has the advantage of 
validating hybridisation and providing quality control for every bead on the array. 
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4.1.2.2 BeadChip 
In its current form, Illumina BeadChips are manufactured by immobilizing 10s of 
thousands of unique synthesised oligonucleotides of 50 nucleotide bases in length onto 
beads in separate reactions to create a bead type for each probe. For every unique probe 
there are roughly 30 separate beads on any given chip which arrange randomly resulting 
in a Poisson distribution of beads per type and chip, a fact which is compensated for by 
the abundance of beads per probe. This abundance also adds an extra level of data 
quality due its inherent redundancy, controlling for outliers and read problems which in 
conventional single probe features can confound results (Kuhn et al, 2004). 
For murine expression studies the MouseRef-8 v2.0 Expression BeadChip is suitable. It 
includes expression probes for 25600 refseq transcripts of which 19100 are unique genes. 
Probe content is informed by the National Centre for Biotechnology Information Reference 
Sequence (NCBI refseq) database, build 36 release 22, and is supplemented with content 
derived from the Mouse Exonic Evidence Based Oligonucleotide (MEEBO) and RIKEN 
FANTOM2 databases. Construction of the BeadChip accommodates 8 samples which 
when paired allows interrogation of 16 samples in total. 
4.1.2.3 RNA Sample preparation 
For the detection of gene expression, abundance of hybridised material must be 
measured easily. Historically this has meant the labelling through various means of target 
with fluorescent probe, usually Cy3 or Cy5. Many early microarray methods relied on the 
labelling of cDNA during reverse transcription of mRNA samples, through incorporation of  
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Figure 4.1.2.1 Mouse ref8v2 BeadChip array. Plasma etched wells are populated with 3 µm silica beads 
coated in conjugated nucleotide sequence containing both an address and probe sequence. Address 
sequence is used for localisation of randomly distributed beads. Probe sequence is 50 nucleotide 
bases in length and complementary to target sequence. Each BeadChip contains 8 arrays to 
accommodate 8 separate samples, and chips are shipped in pairs to accommodate 16 samples. 
  
Address Probe sequence
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dye labelled nucleotides. RNA quantity is a key consideration in the success of a 
hybridisation experiment; with some starting materials yielding tiny amounts of RNA it is 
often necessary to amplify the signal. A now common method to achieve amplification of 
RNA uses T7 polymerase to achieve a linear amplification (Figure 4.1.2.2) . Firstly, mRNA 
is specifically reverse transcribed using oligo(dT) primers with an incorporated T7 
promoter sequence, then second-strand DNA synthesis is performed using DNA 
polymerase creating double stranded cDNA strands. Double stranded cDNA is then used 
as a template for in vitro transcription by T7 polymerase which recognises the promoter 
sequence and generates many cRNA strands from the template (Vangelder et al, 1990). 
T7 amplified RNA was shown to give reliable expression data when compared with 
unamplified RNA prepared using standard techniques, giving similar differential 
expression ratio values (Pabon et al, 2001). T7 amplified cRNA can also be produced with 
incorporated labelling such as biotin labelled nucleotides. Inclusion of a biotinylated 
uridine (16-UTP) in the mixture allows the incorporation of biotin in all new cRNA strands. 
Cyanine 3 conjugated to streptavidin is used for detection through binding to biotin 
labelled cRNA post hybridisation. 
4.1.2.4 Hybridisation procedure and data collection 
Direct hybridisation of biotinylated cRNA with BeadChip probes is achieved by incubation 
overnight in HYB buffer. Fluorescence is detected by the iScan system which uses a laser 
confocal system to scan the BeadChip and generate an image from which spot locations 
can be defined and signal assigned. Signal intensity represents relative abundance of 
complementary cRNA sample which directly correlates with mRNA transcript and thus 
gene expression. 
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Figure 4.1.2.2 T7 polymerase amplification method for RNA sample amplification and labelling. A. 
Starting material is reverse transcribed with poly d(T) primers containing the T7 promoter sequence 
then a second DNA strand is synthesised using a DNA polymerase leaving dsDNA. T7 polymerase 
then creates cRNA from biotin labelled 16-UTP to produce amplified and biotin labelled cRNA strands. 
B. Hybridisation of labelled cRNA sample to probe sequence conjugated beads. 
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4.1.3 Chapter aims 
The aim of this chapter is to explore the use of global gene expression analysis to 
determine the effects of sublytic C attack on CT26 cells under the experimental conditions 
optimized in chapter 3. To best understand the impacts of sublytic C on tumour cells the 
expression analysis will seek to determine changes in genes which would confer an 
advantage to developing tumours. To achieve these aims the practical objectives are: 
1. Conduct a sublytic C experiment and interrogate gene expression using 
microarray technology. 
2. Conduct quality control analysis of acquired data using principal components 
analysis and other exploratory techniques. 
3. Ascertain differentially expressed genes by statistical analysis to create gene lists 
and heatmaps. 
4. Use pathway and network analysis tools to mine for possible implicated pathways 
or processes and define a set of genes of interest which can be proceeded by 
further experimental investigation. 
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4.2 Results 
4.2.1 Microarray experiment 
4.2.1.1 Sublytic C attack 
In order to understand the influence of sublytic C on tumour cells a microarray experiment 
was proposed as a means to identify the gene expression signature of cells exposed to 
sublytic C. Microarray allows the interrogation of gene expression for tens of thousands of 
genes and their transcript variants.  
For the generation of good quality data it is vital that the experiment be well designed and 
thus it was carefully planned. Conditions for sublytic C were as set out in chapter 3 and 
performed on CT26 cells seeded from a 5×105 per mL suspension (at 1.6×103 cells per 
mm2) into a 12 well plate and incubated under normal growth conditions for 20 hours and 
exposed to C attack conditions for 1 and 12 hours from initial addition, RNA was then 
extracted directly from the cell monolayers. Cell detachment during sublytic attack was 
controlled for by centrifugation of medium at 800×g then adding lysis buffer to cell pellet. 
Cell pellet and monolayer lysates were pooled before continuing with RNA extraction. 
Each experimental condition was run in quadruplicate and arranged as shown in Figure 
4.2.1.1 giving a total of 20 RNA samples extracted. Eluted RNA was placed immediately 
on ice and stored at -80°C.  
4.2.1.2 RNA quantitation and quality control 
Extracted RNA was analysed using the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Cheshire, UK) by Megan John at Cardiff University’s in-house central biotechnology 
services (CBS). Briefly, 1 µL of sample was applied to an RNA 6000 Labchip which was 
then placed in the 2100 Bioanalyzer and a voltage applied so that the sample was drawn 
through microfluidic channels passing through a sieving polymer and a fluorescent dye. 
Detection of fluorescently labelled RNA during its migration and mass separation was  
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Figure 4.2.1.1 Sublytic C experimental design and protocol.  A. Colour coded sample arrangement on 
3×12 well culture plates outlining the experimental design, green=control, 
blue/purple=pNHS/pNHS+OmCI 1 hour, red/orange=pNHS/pNHS+OmCI 12 hour, grey=samples 
excluded from microarray for later validation. B. Schematic diagram of sublytic C protocol: cells 
seeded overnight at 5×10
5
; pNHS treated with or without 10 µg/mL OmCI for 20 minutes; cells washed 
then serum dilution added and incubated under normal growth conditions for 1 and 12 hours, leaving 
one as untreated control; RNA extracted from cell monolayer. 
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Figure 4.2.1.2 RNA quality and quantification analysis using Agilent 2100 Bioanalyzer. A. RNA mass 
ladder electropherogram and band pattern 5606, 4000, 2000, 1000, 500, 200, 25 nucleotide peaks. B. 
Example electropherogram and band pattern of sample RNA 28s and 18s peaks are labelled. C. 
Sample RNA band patterns of 28s and 18s ribosomal RNA presented alongside RNA size ladders. 
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recorded as an image similar to agarose gel separations and plotted on an 
electropherogram. An RNA 6000 ladder was run alongside the samples for identification 
of mass. RNA integrity was assessed using the ratio of the ribosomal 18s and 28s RNA 
(rRNA), this gives an indication of RNA degradation status. RNA quality was scored using 
the RNA integrity number (RIN) calculated by the proprietary software as a function of the 
electropherogram trace. 
Extracted RNA intended for microarray analysis was of high quality with each sample 
achieving RIN scores of 10. Electropherograms showed minimal degradation and 
ribosomal peaks 18s:28s were between 1.8 and 2.5. Concentrations varied from 210 to 
594 ng/µL (Figure 4.2.1.2). 
4.2.1.3 Microarray 
Having generated high quality RNA it was possible to proceed to the microarray 
experiment. Protocols for RNA labelling hybridisation and BeadChip scanning were 
conducted as per manufacturer’s instructions by Megan John at Cardiff University’s in 
house central biotechnology services (CBS). All equipment, reagents and materials were 
purchased from Illumina (Illumina UK, Essex, UK). 
The mouse ref8v2 BeadChips can accommodate 8 samples per chip and were purchased 
as a pair. 16 of the 20 samples extracted were used excluding 1 sample per test condition 
except the control as highlighted in grey in Figure 4.2.1.1. Biotinylated cRNA was 
produced from RNA samples using the process outlined in section 4.1.2.3. 750 ng of 
Biotin-cRNA were prepared in HYB buffer, pipetted into sample ports of BeadChips and 
groups were distributed equally over the two chips to minimize batch effects. The samples 
were hybridised for 14 hours at 58°C in a rocking Illumina Hybridisation Oven. BeadChips 
were then washed at 55°C for 10 minutes in a high temperature wash buffer, then at room 
temperature in E1BC buffer for 5 minutes with shaking. BeadChips were washed in 100% 
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EtOH for 10 minutes and then for a further 2 minutes in E1BC buffer. BeadChips were 
blocked on a rocker for 10 minutes by incubation in 4 mL block E1 buffer. 
A 1 µg/mL Cy3-Streptavidin solution was prepared by dilution in E1 block buffer and the 
BeadChips incubated on a rocker for 10 mins at room temperature followed by washing 
shaking in E1BC buffer for 5 minutes. BeadChips were dried by centrifugation at 1400 rpm 
for 4 minutes to prevent evaporation which might leave residue and interfere with 
scanning. 
BeadChips were scanned by laser excitation using the iScan Reader controlled by iScan 
Control Software (Illumina). Fluorescence detected by this procedure allowed the 
generation of an image from which signal intensity data was calculated for defined 
positions on the chip. GenomeStudio Expression Module software (lllumina) was used to 
convert the signal intensity data into expression data. 
4.2.1.4 Quality control 
Contained within the HYB buffer are a comprehensive set of control oligonucleotides 
corresponding to probes located on the BeadChip which allow various qualitative aspects 
of the process to be monitored within the experiment. Hybridisation controls are 6 directly 
Cy3 labelled oligonucleotides complementary to 6 probes on the chip in defined 
concentrations of low, medium and high yielding a signal gradient (Figure 4.2.2.1A). 
Stringency controls are 4 probes each with mismatched bases at 2 positions (Figure 
4.2.2.1B). Each mismatched probe has a perfect matched counterpart complementary to 
a hybridisation control oligonucleotide. Occurrence of signal on mismatch probe indicates 
low stringency. To check the quality of streptavidin staining, there are 2 probes 
complementary to biotin labelled oligonucleotides present in the HYB buffer present on 
the BeadChip. Detected signal indicated that Cy3-streptavidin labelling had been 
successful and high stringency conditions could remove the hybridised biotin oligo (Figure 
4.2.2.1C) Negative controls are probes which do not have a complementary target in the 
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sample, thus any signal detected represents the background level from which the 
detection limits can be calculated in conjunction with standard deviation (Figure 
4.2.2.1D.). Housekeeping controls include a set of 14 probes on the chip targeted to 7 
housekeeping gene sequences in the sample which indicate the intactness of transcript 
(Figure 4.2.2.1E). The GenomeStudio software produced a QC report summarizing the 
signal from the various internal controls. 
QC data from the BeadChips averaged across the dataset showed good hybridisation 
demonstrating tight titration in low, medium and high abundance Cy3 oligonucleotides  
and good stringency able to differentiate mismatch and perfect match control probes. In 
the experiment, Cy3-streptavidin labelling was shown to have been successful. Signal 
from negative controls was about 120 AU (arbitrary units) and thus very low with a small 
amount of noise, which was about 10 AU. A good signal was gained from housekeeping 
genes demonstrating the quality of the transcript and confirming its murine origin. 
4.2.2 Data handling and primary analysis 
4.2.2.1 Data normalization 
Once the GenomeStudio software had generated signal intensity data from scan images 
data were normalized using the quantile method. The fundamental aim of normalisation is 
to ensure that the signal from each chip is equivalent overall. Normalization is necessary 
to remove unwanted variability, an inevitable product of a large number of parallel arrays. 
Sources of bias include differences in starting RNA quantity, quality, labelling efficiency, 
and systematic bias (Quackenbush, 2002). Quantile normalization aims to match the 
distribution of probe intensity values across each array. To do this each array’s probe 
intensity values are ranked in order (regardless of probe identity) and then adjusted so 
that if plotted against each other they would produce a straight line. In practice this is done 
through sorting columns (sample) in order then calculating the mean from each row and 
substituting it to each entry in the row, the data is then re-sorted to its original order,  
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Figure 4.2.2.1 Microarray hybridisation quality control output. Oligonucleotides present in HYB buffer 
and probes present on the chip allowed the assessment of A. hybridisation specificity. B. 
hybridisation robustness under low stringency, C. streptavidin labelling success and high stringency 
signal removal D, negative control background and noise levels and E. signal form housekeeping 
gene controls. 
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resulting in normalized values (Bolstad et al, 2003). Normalized data were presented in a 
tab delimited text file for entry into analysis software. 
4.2.2.2 Partek and GeneSpring 
Empirical data processing, which included entity exploration and statistical analysis, was 
performed using GeneSpring 12.0 GX (Agilent Technologies, Cheshire, UK) and 
PartekGenomics Suite version 6.6 (build 6.13.0213, Partek Incorporated, Missouri, USA). 
Data input in both software applications required the data to be presented in a tab 
delimited text file (probes by row, sample by column) with a corresponding annotation file 
(also in tab delimited text to define probe identities, gene codes, chromosomal locations, 
gene ontology information and other pertinent details). The file used was the Illumina-
provided MouseRef-8_V2_0_R2_11278551_A.txt. Normalized data were given a 
threshold of 1 to eliminate missing values and transformed by a logarithm base 2 to scale 
down the raw signal values as is standard practice for microarray data. In the case of 
GeneSpring, in addition to log2 transformation, the baseline was adjusted according to the 
median taken across the dataset. This adjustment allowed simple data representation and 
could be used for downstream analysis as will be described later. 
4.2.2.3 Principal components analysis (PCA) and batch removal 
Initial analysis was aimed primarily at exploratory description of the data. In order to 
ascertain the spread of the data and determine the possible contributors to variation a 
principal components analysis (PCA) was performed using Partek. 
PCA aims to reduce a multivariate dataset containing large numbers of correlated 
variables to a small number of uncorrelated variables whilst retaining much of the original 
information. To arrive at the key components the data are transformed and compressed to 
derive the ‘principal components’ (Jolliffe, 2002). Plotting the data summarized from each 
sample by its top 3 principle components results in a 3D map, on which  the position of 
each sample describes the influence of each component. 
112 
 
The PCA map in Figure 4.2.2.2 A. describes the separation of the dataset as functions of 
principal components 1,2 and 3; assigning contributions of 14.1, 9.37 and 7.99% of overall 
variation respectively. Sample spheres were colour coded by condition, red=control, 
blue=pNHS+OmCI and green=pNHS. Centroids were added, linked and colour coded by 
sample groupings; black=control, light blue/green=1 hour and dark blue/green=12 hours. 
Centroid groupings clearly show that the data are well separated by experimental 
conditions. However, grouping based on batch number, i.e. the chip number on which the 
samples were placed, revealed a clear batch effect.  
Batch effects are due to experimental differences caused by processing of samples on 
separate chips or, in some cases, at different times. Batch effects in this experiment were 
probably due to the spread of 16 samples across 2 chips. Effects exerted by batch in this 
experiment are unlikely to have influenced the biological interpretation of the data due to 
the careful design of the experiment. 
Batch effects were removed from the data via the batch removal tool in the Partek 
software by including chip location information as a variable and selecting remove batch 
effect by factor. Figure 4.2.2.2 B shows the PCA map post batch removal showing tight 
groupings with greatly improved separation. Percentage of variation accounted for by PCs 
#1(14.8%) , 2 (9.78%) and 3 (8.37%) are largely in agreement between plots suggesting 
that the batch effect was small. 
Batch removal was not maintained in further statistical and downstream analysis due to its 
influence on p-values. The analysis of variance (ANOVA) function within Partek is capable 
of adjusting for batch effects so that batch removal was not necessary during further 
analyses.  
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Figure 4.2.2.2 Principal component analysis (PCA) plots. A. 3D PCA plot displaying the top 3 principal 
components before batch removal and B. after batch removal. C. PCA plot key, left box; red=control, 
blue=pNHS+OmCI, green=pNHS, right box centroids; black=control, blue=pNHS+OmCI, green=pNHS, 
light=1 hour, dark=12 hour. 
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4.2.2.4 Gene expression change scatter plots 
 Linear scatter plots were created using GeneSpring comparing the mean gene 
expression values between sample groups. Serum conditions pNHS and pNHS+OmCI 
were compared at each exposure time point, 1 and 12 hours, on two separate plots. 
Normalized and transformed gene expression values taken from pNHS conditions were 
used to colour code the data; red=upregulation (above median baseline), yellow=no 
expression change (on or close to median baseline) and blue=down regulation (below 
median baseline). Plotted data represents the comparative gene expression levels of 
pNHS against the control condition containing OmCI. Because the data is plotted between 
sample groups, genes with no difference in expression levels will fall upon a central line, 
this line represents a fold change of 1. Differences between sample groups will fall either 
side of this line. In addition to this central line, parallel lines are drawn above and below 
which represent a boundary of 1.3 fold change. Genes up or down regulated by more than 
1.3 fold when compared to their control fall beyond these boundaries. 
Cells exposed for 1 hour to pNHS compared to the OmCI treated control had a large 
number of differentially expressed genes changing by more than 1.3 fold and marginally 
more genes appeared to be upregulated in the pNHS condition compared to 
pNHS+OmCI. A great many genes fell between the 1.3 fold change boundaries 
representative of an equal effect across the groups. Exposure for 12 hours resulted in far 
fewer differentially expressed genes and were more tightly distributed. 
115 
 
  
Figure 4.2.2.3 Scatter plot comparisons between samples. Log2 transformed, median baseline 
adjusted data and means calculated for sample groups. Data is plotted comparing pNHS and 
pNHS+OmCI at 1 hour (A.) and 12 hours (B.) post exposure. Correlation of points along a central line 
represent no gene expression change between samples i.e. 1 fold change (FC), parallel lines represent 
1.3 FC. 
  
B.
A.
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4.2.2.5 ANOVA analysis 
To analyse the data properly it is necessary to perform statistics for the detection of 
differentially expressed genes. This was done using Partek by analysis of variance 
analysis (ANOVA). A 2-way ANOVA model was applied using method of moments 
(Eisenhart, 1947).  
Contrasts were prepared by comparing serum condition (pNHS vs. OmCI), exposure time 
(1 vs. 12), serum conditions after 1 hour (pNHS * 1 vs. OmCI * 1) and serum conditions at 
12 hours (pNHS * 12 vs. OmCI * 12) using Fisher's Least Significant Difference (LSD) test 
(Tamhane & Dunlop, 2000). 
ANOVA results output included p-values for significance, ratios and fold-change values of 
expression. The comparisons also allow the calculation of effect sizes for each of the 
defined factors including time, serum condition and both time and serum conditions. 
Figure 4.2.2.4 shows the mean F ratio, which is the signal to noise ratio; noise (error) is 
defined as the remaining variation not explained by the defined factors. Values above the 
error are above background noise and thus important. A hierarchy of effect size is clear, 
time having the largest effect size with a mean F ratio of 6.18. Serum condition 
contributed a much smaller effect size of 1.54 times the background and time tabulated 
with serum condition (i.e. pNHS at 1 or 12 hours compared with pNHS+OmCI at 1 or 12 
hours etc.) slightly greater with 1.7. 
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Figure 4.2.2.4  Sources of variation from experimental factors. Mean F ratio plotted for serum 
condition  (pNHS, pNHS+OmCI) , time (1 hour, 12 hours) , cross tabulation (pNHS 1 h or 12h, 
pNHS+OmCI 1h or 12h) and error.  
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4.2.3 Gene list generation from ANOVA statistics 
4.2.3.1 Gene list criteria 
ANOVA statistics applied to the dataset allowed lists to be created of differentially 
expressed genes following specified patterns. Gene lists were generated on comparisons 
set by the LSD test and further refined by expression status; increase, decrease, any 
change or no change. Once these were selected, lists were sorted by fold change and p-
value, with or without false discovery rate (FDR). Inclusion of the FDR applies a restriction 
on the rejection of the null hypotheses based upon a calculated false discovery rate 
(Benjamini & Hochberg, 1995). FDR increases the stringency by predicting the rate of 
false rejections based on the number of tests then altering the p-value cut-off accordingly 
thus reducing the number of apparently significant differences. 
4.2.3.2 Heatmap generation 
In order to present gene lists as clustered heatmaps, data (log 2 transformed) were 
standardized by shifting to a mean of zero and scaled to a standard deviation of one. 
Clustering of ANOVA gene lists was achieved through the ‘clustering of significant genes’ 
option in Partek. Gene lists created as described above were organised by hierarchical 
clustering of gene expression patterns and heatmaps generated. Hierarchical clustering 
groups genes displaying similar expression patterns together and organises them into a 
hierarchy described by dendrograms. Clustering by this method is unsupervised, taking no 
account of sample and experimental condition information. Heatmaps were organised by 
clustered genes in rows with expression values (standardized and scaled) colour coded 
so that genes decreased were represented by green, no change by black and increased 
by red. 
4.2.3.3 Serum and time point comparison heatmaps 
Heat maps were generated using Partek to summarize the lengthy gene lists created from 
the macro comparisons, i.e. pNHS vs. pNHS+OmCI serum treatment and 1 hour vs. 12 
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hour time points.  The criteria applied to create the time point comparison lists were as 
follows: any change, any fold change, FDR adjusted p-value of  <0.01 generating 1429 
entities, and to the serum condition comparison: any change with an unadjusted p-value 
of <0.01 generating 529 entities. 
Figure 4.2.3.1 shows the heatmap generated from clustering of genes in the time point 
comparison list. A clear separation can be seen between the sample groupings. As was 
shown by mean F ratio plot of variation, time point is responsible for much of the variation 
in the dataset. Two clearly defined groupings of genes are revealed displaying expression 
increase at either 1 hour and not 12 or 12 hours and not 1 hour with marginally more 
genes upregulated in the 1 hour time point. Controls were more similar to both serum 
conditions at 1 hour compared to 12 hours as would be expected. 
Figure 4.2.3.2 is the heatmap generated from clustering of genes in the serum condition 
comparison gene list. Clustering is much less defined. Dendrogram linkage shows that 
controls are most similar to pNHS+OmCI at 1 hour and the next level of hierarchy is 
occupied by pNHS at 1 hour with pNHS at 12 hours. 
4.2.3.4 Direct comparison gene list 
Smaller lists were generated focussing on the differentially expressed genes comparing 
pNHS with pNHS+OmCI at each time point. Genes with any significant change at these 
time points were selected using an FDR adjusted p-value <0.05 and no fold change 
restrictions to create gene lists of 49 and 26 entities for 1 and 12 hour time points 
respectively. These were then used to create hierarchically clustered heatmaps showing 
grouping of genes up and down regulated at 1 and 12 hours.  
Gene lists were also created using the most stringent restrictions to give the most 
statistically significant changes at each comparison. P-value was FDR adjusted (p<0.05) 
and pNHS versus pNHS+OmCI comparison with FC>2 (up) or -2 (down) at 1 and 12 
hours (except up at 12 hours FC>1.5). 
120 
 
At 1 hour there was a clear set of differentially regulated genes both up and 
downregulated (Figure 4.2.3.3 and Figure 4.2.3.4). Genes associated with signal 
transduction such as Rgs16, Dusp2 and Itprip were upregulated. Regulator of G-protein 
signalling 16 (Rgs16) is a GTPase activating protein which limits G-protein activation by 
GPCRs (G-protein coupled receptors), it has also been described as important in 
controlling GPCR induced Ca2+ oscillation in conjunction with IP3 (Berman et al, 1996; 
Luo et al, 2001). Dual specificity phosphatase 2 (Dusp2) is a MAPK phosphatase acting to 
regulate MAPK signalling cascades through dephosphorylation at serine/threonine and 
tyrosine residues (Owens & Keyse, 2007). Dusp2 is a nuclear inducible regulator of MAPK 
activation thus is expressed upon signal activation (Owens & Keyse, 2007). Inositol 1,4,5-
trisphosphate receptor interacting protein (Itprip is also referred to as DANGER) is 
involved in altering the Ca2+ sensitivity of IP3R increasing the potency of Ca2+ mediated 
inhibition of Ca2+ release (van Rossum et al, 2006). Involvement of Ca2+ signalling is 
indicated by these hits as well as Gα-protein mediated signalling and MAPK kinase 
activation. Each hit was upregulated and had regulatory functions suggesting an inducible 
self-regulation. 
Genes with transcription regulatory functions which were upregulated at 1 hour were Egr1, 
Egr2 and Fos (Figure 4.2.3.3). Early growth response 1 and 2 (Egr1/2) gene products are 
both zinc finger containing transcription factors members of the immediate early response 
genes (Joseph et al, 1988; Lau & Nathans, 1987). Egr1 follows similar kinetics to c-fos 
induction responding to mitogen stimulation, cell differentiation and cell de-polarization 
(Sukhatme et al, 1988). Egr1 gene product regulates gene expression of transcription 
regulators, signalling proteins, cell-cycle regulatory proteins, extracellular matrix proteins, 
ion channel proteins, growth factors and cytokines (Fu et al, 2003). FOS is the gene 
product of c-fos gene expression and is like Egr1/2 in its status as an immediate early 
response gene. It can form heterodimers with jun or atf-2 of the AP-1 
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Figure 4.2.3.1 Hierarchical clustering heatmap of time point comparison. 1 hour relative to 12 hour. 
Gene list criteria: any change, 0 FC, FDR adjusted p-value  <0.01 = 1429 entities. Dendrograms 
clustering sample bar: Serum condition; red=control, orange=OmCI, yellow=pNHS Time point; 
black=0, blue=1 hour, purple=12 hour. Gene expression values(log2 transformed, 0 mean shifted, 
scaled to SD=1) for clustered entities: green=downregulated, black=no change, red=upregulated. 
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Figure 4.2.3.2 Hierarchical clustering heatmap of serum condition comparison pNHS relative to 
pNHS+OmCI. Gene list criteria: any change, 0 FC, unadjusted p-value  <0.01 = 529 entities. 
Dendrograms clustering sample bar: Serum condition; red=control, orange=OmCI, yellow=pNHS Time 
point; black=0, blue=1 hour, purple=12 hour. Gene expression values(log2 transformed, 0 mean 
shifted, scaled to SD=1) for clustered entities: green=downregulated, black=no change, 
red=upregulated. 
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Figure 4.2.3.3 Gene list of significantly differential genes 1 hour post exposure; pNHS 1 hour relative 
to pNHS+OmCI 1 hour. List criteria: any change, 0 FC, FDR adjusted p-value <0.05 = 49 entities. 
Entities are sorted by p-value and fold change displayed (pNHS relative to OmCI). 
  
Probeset ID Symbol Transcript
p-value(pNHS * 1  
vs. OmCI * 1)
Fold-Change(pNHS * 1  
vs. OmCI * 1)
4 ILMN_2600744 Rgs16 ILMN_209950 3.03E-09 2.74759
18 ILMN_2662926 Egr1 ILMN_215729 9.47E-08 2.37517
11 ILMN_2995794 Itprip ILMN_242056 6.49E-08 2.16089
1 ILMN_2623983 Egr2 ILMN_212209 4.57E-11 2.08117
19 ILMN_2757634 Fam110c ILMN_222981 1.89E-07 2.07236
29 ILMN_1216764 Ier3 ILMN_223302 2.47E-07 1.86804
47 ILMN_2698449 Hbegf ILMN_218639 3.40E-05 1.84976
13 ILMN_3009243 Dusp2 ILMN_212470 1.14E-06 1.83362
6 ILMN_1242406 Dusp2 ILMN_212470 3.54E-08 1.7654
44 ILMN_1243862 Il11 ILMN_215774 4.13E-07 1.68709
25 ILMN_2790357 Sema7a ILMN_210076 1.36E-05 1.66959
42 ILMN_2617468 Chac1 ILMN_211596 8.14E-05 1.63399
26 ILMN_3105417 Bdnf ILMN_241360 8.49E-07 1.59235
39 ILMN_2714031 Errfi1 ILMN_246139 2.60E-05 1.57705
10 ILMN_2636403 Axud1 ILMN_213373 2.16E-07 1.56266
9 ILMN_2737685 Mmp13 ILMN_210384 4.96E-07 1.52378
34 ILMN_3162407 Zfp36 ILMN_188430 3.28E-05 1.51643
20 ILMN_2742075 Cd14 ILMN_221922 1.50E-05 1.48833
49 ILMN_2763002 Eno2 ILMN_223357 3.66E-07 1.47919
22 ILMN_1216335 Cttnbp2nl ILMN_252976 4.68E-07 1.47526
45 ILMN_2595732 LOC100046232 ILMN_310357 1.59E-06 1.45961
28 ILMN_2776909 Irx3 ILMN_224225 2.34E-05 1.43995
21 ILMN_1238547 Areg ILMN_217903 8.00E-05 1.43899
36 ILMN_2744138 BC003236 ILMN_191936 8.74E-05 1.4349
23 ILMN_2619330 Plk3 ILMN_211765 5.73E-05 1.39709
33 ILMN_2736471 Ccno ILMN_239687 5.61E-05 1.39025
15 ILMN_2750515 Fos ILMN_222500 2.37E-06 1.38727
16 ILMN_3161263 Fzd5 ILMN_260431 4.47E-06 1.37462
43 ILMN_1221429 Mllt11 ILMN_209038 3.46E-05 1.36678
40 ILMN_2825817 Spry4 ILMN_220989 8.02E-05 1.34179
27 ILMN_3162369 Fbxo33 ILMN_234957 8.27E-05 1.32069
30 ILMN_3031099 Coq10b ILMN_235389 1.84E-05 1.31654
24 ILMN_2775307 Lamc2 ILMN_210712 4.16E-05 1.27519
12 ILMN_1249426 Socs4 ILMN_216527 1.72E-05 1.24619
5 ILMN_1240323 Dnajb1 ILMN_222931 1.06E-07 1.23503
32 ILMN_1235006 Slc14a1 ILMN_246276 6.52E-05 1.20163
31 ILMN_1242054 Bard1 ILMN_212214 6.02E-05 1.17755
48 ILMN_2883414 Cenpl ILMN_236103 3.91E-05 -1.14079
41 ILMN_1221886 Zfp3 ILMN_220772 2.44E-05 -1.21309
38 ILMN_1228568 Irf2bp1 ILMN_213448 7.76E-06 -1.259
37 ILMN_3109491 6430527G18Rik ILMN_230817 8.64E-05 -1.37081
46 ILMN_2672190 Id1 ILMN_216536 8.74E-05 -1.52188
7 ILMN_2737713 Edn1 ILMN_221606 2.40E-07 -1.55358
3 ILMN_2599782 Irf1 ILMN_209850 1.50E-08 -1.65858
14 ILMN_2759365 Angptl4 ILMN_259520 2.30E-08 -1.7643
8 ILMN_1239294 Cdc42ep2 ILMN_235254 4.58E-08 -1.77185
17 ILMN_2903945 Gadd45g ILMN_222120 3.26E-08 -1.85834
35 ILMN_2744890 Gadd45g ILMN_222120 3.53E-06 -1.90128
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Figure 4.2.3.4 Hierarchical clustering heatmap of 1 hour serum condition comparison. pNHS 1 hour 
relative to pNHS+OmCI 1 hour. Gene list criteria: any change, 0 FC, FDR adjusted p-value <0.05 = 49 
entities. Dendrograms clustering sample bar: Serum condition; red=control, orange=OmCI, 
yellow=pNHS Time point; black=0, blue=1 hour, purple=12 hour. Gene expression values (log2 
transformed, 0 mean shifted, scaled to SD=1) for clustered entities: green=downregulated, black=no 
change, red=upregulated. 
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Figure 4.2.3.5 Gene list of significantly differential genes 12 hours post exposure; pNHS 12 hours 
relative to pNHS+OmCI 12 hours. List criteria: any change, 0 FC, FDR adjusted p-value <0.05 = 26 
entities. Entities are sorted by p-value and fold change displayed (pNHS relative to OmCI). 
 
Probeset ID Symbol Transcript
p-value(pNHS * 12 
vs. OmCI * 12)
Fold-Change(pNHS * 12 
vs. OmCI * 12)
1 ILMN_1260323 Akr1c18 ILMN_215518 4.16E-07 1.61755
2 ILMN_1225816 Hbb-bh1 ILMN_216390 1.99E-07 1.58676
3 ILMN_3024416 Lca5 ILMN_228057 1.15E-05 -1.21942
4 ILMN_1215755 Grwd1 ILMN_217875 6.54E-06 1.35417
5 ILMN_1233461 Irf9 ILMN_213365 3.30E-05 -1.2958
6 ILMN_1248415 Tgoln1 ILMN_217106 8.19E-06 1.20895
7 ILMN_2834379 Tgfbi ILMN_259309 1.18E-05 1.22264
8 ILMN_2730003 Ccdc86 ILMN_259483 6.87E-06 1.44565
9 ILMN_2726931 Blnk ILMN_220791 4.48E-05 1.23898
10 ILMN_2851735 Ankrd13d ILMN_218809 2.67E-05 -1.14059
11 ILMN_2650915 Jmjd2b ILMN_214701 2.32E-05 -1.19633
12 ILMN_2840082 P2ry12 ILMN_234920 1.76E-05 1.11138
13 ILMN_2980858 Lpcat3 ILMN_210660 2.49E-05 -1.24422
14 ILMN_2862379 Rhod ILMN_213115 4.10E-06 1.30125
15 ILMN_2591632 Gtf2e1 ILMN_209005 1.10E-05 1.226
16 ILMN_2595283 Rrp1b ILMN_231400 1.22E-05 1.39104
17 ILMN_2855315 Hist1h1c ILMN_235246 3.91E-05 1.31188
18 ILMN_2742152 Gadd45a ILMN_221926 1.58E-05 -1.47492
19 ILMN_2689138 2310044G17Rik ILMN_226732 1.06E-05 1.28768
20 ILMN_3104025 Asb13 ILMN_236715 4.87E-06 1.26694
21 ILMN_1252745 Gtf2h2 ILMN_256180 2.49E-05 1.19023
22 ILMN_2664686 Chaf1b ILMN_215876 4.77E-05 1.3061
23 ILMN_1243862 Il11 ILMN_215774 1.29E-05 -1.44406
24 ILMN_2595732 LOC100046232 ILMN_310357 5.16E-05 -1.29817
25 ILMN_2807665 2010003O18Rik ILMN_250737 3.22E-05 1.21124
26 ILMN_2763002 Eno2 ILMN_223357 3.91E-07 -1.47538
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Figure 4.2.3.6 Hierarchical clustering heatmap of 12 hour serum condition comparison pNHS 12 hour 
relative to pNHS+OmCI 12 hour. Gene list criteria: any change, 0 FC, FDR adjusted p-value <0.05 = 26 
entities. Dendrograms clustering sample bar: Serum condition; red=control, orange=OmCI, 
yellow=pNHS Time point; black=0, blue=1 hour, purple=12 hour. Gene expression values (log2 
transformed, 0 mean shifted, scaled to SD=1) for clustered entities: green=downregulated, black=no 
change, red=upregulated. 
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Figure 4.2.3.7 Gene list of top most significant expression changes when comparing pNHS with 
pNHS+OmCI at 1 hour and 12 hours. List criteria: FDR adjusted p-value <0.05 A. pNHS 1 hour relative 
to OmCI 1 hour 1FC> 2 (upregulated) and B. FC< -2 (down regulated), C. pNHS 12 hour relative to 
OmCI 12 hour FC> 1.5. Entities are sorted by p-value and fold change displayed (pNHS relative to 
OmCI) D. Egr2, Rgs16, Itprip, Egr1, Fam110c, Irf1, Akr1c18, Hbb-bh1 genes are identified and function 
summary taken from UniProt database general annotation. 
 
Probeset ID Symbol Transcript
p-value(pNHS * 1 
vs. OmCI * 1)
Fold-Change(pNHS * 1 
vs. OmCI * 1)
1 ILMN_2623983 Egr2 ILMN_212209 4.57E-11 2.08117
2 ILMN_2600744 Rgs16 ILMN_209950 3.03E-09 2.74759
3 ILMN_2995794 Itprip ILMN_242056 6.49E-08 2.16089
4 ILMN_2662926 Egr1 ILMN_215729 9.47E-08 2.37517
5 ILMN_2757634 Fam110c ILMN_222981 1.89E-07 2.07236
Probeset ID Symbol Transcript
p-value(pNHS * 1 
vs. OmCI * 1)
Fold-Change(pNHS * 1 
vs. OmCI * 1)
1 ILMN_2834777 Irf1 ILMN_209850 5.15E-10 -2.19138
Probeset ID Symbol Transcript
p-value(pNHS * 12 
vs. OmCI * 12)
Fold-Change(pNHS * 12 
vs. OmCI * 12)
1 ILMN_1260323 Akr1c18 ILMN_215518 4.16E-07 1.61755
2 ILMN_1225816 Hbb-bh1 ILMN_216390 1.99E-07 1.58676
Gene Symbol Gene Name function
Egr2 Early growth response 2 (Egr2), mRNA.
Sequence-specific DNA-binding transcription factor. Binds to 
two specific DNA siteslocated in the promoter region of 
HOXA4. E3 SUMO-protein ligase helping SUMO1 conjugation 
to its coregulators NAB1 and NAB2, whose sumoylation 
down-regulates EGR2 own transcriptional activity.
Rgs16 Regulator of G-protein signaling 16 (Rgs16), mRNA.
Inhibits signal transduction by increasing the GTPase activity 
of G protein alpha subunits thereby driving them into their 
inactive GDP-bound form. Binds to G(i)-alpha and G(o)-
alpha, but not to G(s)-alpha. May play a role in regulating 
the kinetics of signaling in the phototransduction cascade.
Itprip
Inositol 1,4,5-triphosphate receptor interacting 
protein (Itprip), mRNA.
Enhances Ca(2+)-mediated inhibition of inositol 1,4,5-
triphosphate receptor (ITPR) Ca(2+) release
Egr1 Early growth response 1 (Egr1), mRNA.
Transcriptional regulator. Recognizes and binds to the DNA 
sequence 5'-CGCCCCCGC-3'(EGR-site). Activates the 
transcription of target genes whose products are required 
for mitogenesis and differentiation.
Fam110c
Family with sequence similarity 110, member C 
(Fam110c), mRNA.
May play a role in microtubule organization
Irf1 Interferon regulatory factor 1 (Irf1), mRNA.
Transcriptional regulator which displays a remarkable 
functional diversity in the regulation of cellular responses. 
These include the regulation of IFN and IFN-inducible genes, 
host response to viral and bacterial infections, regulation of 
many genes expressed during hematopoiesis, inflammation, 
immune responses and cell proliferation and differentiation, 
regulation of the cell cycle and induction of growth arrest 
and programmed cell death following DNA damage.
Akr1c18
Aldo-keto reductase family 1, member C18
(Akr1c18), mRNA.
Converts progesterone to its inactive form, 20-alpha-
dihydroxyprogesterone (20-alpha-OHP). In the liver and 
intestine, may have a role in the transport of bile. May have 
a role in monitoring the intrahepatic bile acid concentration. 
Has a low bile-binding ability. May play a role in myelin 
formation
Hbb-bh1
Haemoglobin Z, beta-like embryonic chain (Hbb-
bh1), mRNA.
amma chains make up the fetal hemoglobin F, in 
combination with alpha chains
A.
B.
C.
D.
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Figure 4.2.3.8 Microarray data bar charts for top most significant expression changes when comparing 
pNHS with pNHS+OmCI at 1 hour and 12 hours. Data is displayed as log2 transformed, median 
baseline adjusted and mean calculated for sample groups ± SEM. Baselines therefore represents 
median of values taken across the dataset. A. upregulated after 1 hour; B. Down regulated at 1 hour; 
C. upregulated at 12 hours. 
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transcription factor family (Karin et al, 1997). C-fos is regulated by the MAPK pathway 
ERKs which stimulate its expression and regulate its activation (Monje et al, 2005). 
Genes that have products with growth factor functions which were upregulated by pNHS 
after 1 hour (Figure 4.2.3.3) were Bdnf and Areg. Brain derived neurotrophic factor (Bdnf) 
gene product  is a neuronal growth factor involved in regulation neuronal cell 
differentiation and survival of neuronal cells (Barde et al, 1982). Amphiregulin (Areg) gene 
product codes for an EGF like growth factor which works via the EGFR receptor to either 
stimulate or suppress proliferation depending on cell type, hence the ‘amphi’ prefix 
(Shoyab et al, 1989). 
The suppressor of cytokine signalling 4 (Socs4), upregulated at 1 hour (Figure 4.2.3.3) 
gene product is associated with EGFR signalling through its role as a negative regulator. It 
performs this role via promoting ubiquitination of the receptor, tagging it for degradation 
(Bullock et al, 2007). Interferon regulatory factor 1 (Irf1) was down regulated at 1 hour, 
gene product is a nuclear transcription factor involved in regulation of interferon 
responsive genes (Miyamoto et al, 1988). It can be induced in response to IFNα and β, IL-
1, IL-6 and Ca2+ ionophores (Nguyen et al, 1997). In addition to this Irf9 was also down 
regulated in pNHS at 12 hours. In response to interferon stimulated JAK/STAT signalling a 
heterotrimeric complex of STAT1/STAT2/IRF9 forms and translocates to the nucleus to 
regulate interferon responsive genes (Qureshi et al, 1995). Irf1 is thought to be a tumour 
suppressor gene through its role in apoptosis induction and regulation of cell growth (Kim 
et al, 2004). Irf1 gene expression has been shown to mediate influence on apoptosis via 
transcription induction of caspase-8 (De Ambrosis et al, 2007). 
Genes upregulated at 12 hours (Figure 4.2.3.5 and Figure 4.2.3.6) included Hbb-bh1, 
Tgbi, Akr1c18. Haemoglobin Z, beta-like embryonic chain (Hbb-bh1) gene product is 
involved in oxygen transport and is expressed by yolk sac-derived erythroid cells during 
early embryonic development (Farace et al, 1984). This haemoglobin has been shown to 
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be upregulated in gemcitabine resistant colon tumour tissue which was likely due to high-
level amplification rather than gene function through amplification of the 7E1 chromosomal 
location. This may also explain olfactor gene (olf prefixed) upregulation in the microarray 
which also clusters to this region (van de Wiel et al, 2005). Transforming growth factor β-
induced (Tgfbi), upregulated at 12 hours, gene product is an extracellular matrix protein 
induced by TGFβ1 involved in cell adhesion, migration and integrin signalling in 
keratinocytes (Jeong & Kim, 2004; Skonier et al, 1992). It also interacts with fibronectin 
and collagen I and is tightly co expressed with the fibronectin gene involved in microtubule 
stabilization (Ahmed et al, 2007; Billings et al, 2002). Aldo-ketoreductase family 1, 
member C18 (Akr1c18) gene product is a hydroxysteroid dehydrogenases (HSD) and 
NADP(H)-dependent oxidoreductase which belongs to the AKR super family, it functions 
as an enzyme in progesterone inactivation (Ishida et al, 1999).  
The top most statistically significant genes are summarized in figures Figure 4.2.3.7 and 
Figure 4.2.3.8. 
4.2.4 Gene enrichment analysis 
4.2.4.1 Introduction 
Having gained an insight into the genes most responsive to the various experimental 
conditions through ANOVA statistics and gene list creation it was necessary to apply more 
complex methods to gain more biologically relevant interpretations of these data. There 
are many strategies that allow the gene expression patterns to be mined to assign 
interpretations based upon information regarding each gene’s expression, regulation and 
interactions. These are further supplemented by gene product information regarding 
function and protein interactions i.e. enzyme activation or inhibition. Generically this type 
of analysis is termed pathway analysis.  
Pathway analysis relies on annotation information for the probes used by the technology. 
There are a plethora of systems which categorise gene information to facilitate pathway 
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analysis, including Gene Ontology (GO), Kyoto Encyclopaedia of Genes and Genomes 
(KEGG) and GenMAPP (Curtis et al, 2005).  
The Gene Ontology (GO) project was created by a collaboration of gene databases in 
1998 aiming to standardize a set of controlled and structured vocabulary which describes 
key molecular biology characteristics of a gene, including sequence and product function. 
GO annotations include stable identifiers which are organised into 4 over-arching 
categories; molecular function (MF), biological process (BP), cellular component (CC) and 
sequence ontology (SO) (Harris et al, 2004).  
By labelling of genes with a standardized vocabulary, gene lists created from expression 
information can reveal mechanistic information by enrichment of gene ontology terms 
allowing greater insights into the biology of the gene expression changes than would be 
possible with manual investigations of large gene lists. This is the basic premise upon 
which all pathway analysis sits, different methods and software rely on various statistical 
techniques and ontology information databases to determine likelihood of involvement of a 
process or pathway (Curtis et al, 2005). 
The KEGG pathway database intends from the outset to create literature informed 
pathways integrating information regarding the role played by each gene. Pathways are 
represented by genes and molecules linked by wiring diagrams linking them by interaction 
to create a network (Kanehisa et al, 2004). 
Pathway analysis is now, after 2 decades of development, becoming an invaluable tool in 
modern day biological research allowing far greater inferences  from data than could ever 
have been achieved before. Responsibility for this lies with the expansion of knowledge in 
various fields of biology allowing a platform of collated databases containing large 
amounts of literature confirmed information on gene linkages, interactions and much 
more. This explosion makes possible a greater degree of integration between the various 
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information including genetic, proteomic, transcriptomic and metabolomic interactions. 
This integrative approach is known as systems biology (Cavalieri & De Filippo, 2005).  
MetaCore (GeneGo, Encinitas, CA) is a comprehensive online systems biology database 
with a proprietary collection of metabolic and cell signalling pathway based upon primary 
literature sources created by a dedicated team. MetaCore software relies on the mapping 
of data upon prebuilt pathway maps and networks to calculate a p-value based upon the 
alignment between the two (Bugrim et al, 2004). The online environment offers several 
analysis tools for mining of datasets using these comprehensive databases including 
enrichment analysis of pathway maps, process networks, diseases (by biomarkers), 
metabolic pathways and  GO processes. 
4.2.4.2 Enrichment analysis using MetaCore  
Gene enrichment analysis was conducted, aligning the database held within MetaCore 
pathway maps, process networks and disease by biomarkers with gene expression data 
from the sublytic C microarray experiment. The dataset was uploaded via the general 
parser upload wizard as 5 sample means of log2 transformed median baseline altered 
data. Experiments were activated in the software window and enrichment analysis 
selected. Enrichment analysis using the extensive pathway maps ontology databases of 
MetaCore provided a revealed a spectrum of pathways which sublytic C influenced and 
activated. For this analysis, data was presented as mean gene expression changes about 
the median so that up or down regulation could be detected using a threshold of -/+ 0.1 
and a p-value filter of 0.1. Samples were colour coded as shown in Figure 4.2.4.1. 
Presented p-values represent the probabilities of a particular enrichment being by chance 
and are displayed as –log histograms. 
Charts displaying greatest enrichments of gene expression changes in pNHS conditions 
compared to OmCI inhibited (red=1 hour and brown=12 hours) are of greatest interest. 
These include the following implicated pathway maps: Reproduction GnRH signalling,  
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Figure 4.2.4.1 Pathway map enrichment score histograms. The 10 most enriched pathway maps 
detected by the number of differentially expressed entities within the uploaded dataset. Each bar 
represents a sample group and coloured as in key, giving the –log p-value score for enrichment of 
pathway maps. 
0
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1
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12
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12 
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Figure 4.2.4.2 Pathway map- Immune response: Oncostatin M signalling via MAPK in mouse cells.  
Map displays the collated linkages of the oncostatin M signalling pathway describing the cell 
signalling and transcriptional changes in response to receptor ligation.  Linkages are shown by 
slender lines with description of linkage displayed in hexagonal symbols, B=binding, +P= 
phosphorylation, T=transformation IE=influence on expression, TR=transcription regulation. 
Expression data is presented as thermometer like symbols, red=above median expression, 
blue=below median expression. 
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TGFβ induction of EMT via MAPK, IL-1 signalling, CD137 signalling in immune cells, 
oncostatin M signalling via MAPK (Figure 4.2.4.1).  
Enrichment analysis data show influences exerted by serum as discussed in previous 
sections; hence the influence exerted by sublytic C could be viewed. Interpretation of 
maps required focussing on genes dysregulated upon pNHS treatment at 1 and 12 hours, 
either up or down, ignoring those that are similarly dysregulated in both pNHS and 
pNHS+OmCI conditions which would indicate a serum response independent of C. TGFβ, 
IL-1, CD137 and oncostatin M signalling pathways were implicated. Epithelial to 
mesenchymal transition and apoptosis-endoplasmic stress response processes were also 
implicated. Common within these pathways were expression changes in components of 
MAPK signalling pathways including suggestion of MKK7 and MEK1 phosphorylation of 
JNK, c-Raf1 phosphorylation of MEK2 and p38α phosphorylation and activation of ATF-2 
or STAT1 transcription factors. TRAF6 binding or modification of TAB1/2 or SITPEC is 
implicated as involved in signal transduction through MEK4/JNK exerting transcription 
influence through the AP-1 monomer c-fos. TRAF2 may be involved in MEK3/p38 or 
MEK4/JNK influencing transcription through ATF-2 or AP-1 respectively. Many of the 
implicated gene expression changes are upregulated at 1 and downregulated at 12 hours 
suggesting feedback mechanisms. 
The oncostatin M signalling pathway map contains implicated objects outside of the 
signalling and transcription regulating components (Figure 4.2.4.2). The extracellular 
matrix regulating genes Mmp3 and Mmp13 were each upregulated by pNHS at both time 
points giving a clear indication that p38, JNK and MEK/ERK MAPK pathways may be 
activated by exposure to sublytic C regulating gene expression via AP-1 transcription 
factor. 
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4.2.5 Network analysis 
The work described in this chapter has identified the gene expression signatures given by 
sublytic C attack under the conditions used. Enrichment analysis has indicated the 
involvement of various processes including the immune response and apoptosis 
modulation in cell responses to sublytic C. However the aim to identify specific genes 
which may confer an advantage to a forming tumour has been confounded by the lack of 
convincing pathway related genes on which to focus. The strong influence that the chosen 
time point has on the data variation can potentially mask the effects of sublytic C attack 
the experiment is designed to explore. Using the power and flexibility of Partek statistics 
and gene list generation a more focussed strategy can be employed to determine the 
specific influence of sublytic C. 
4.2.5.1 Overlap gene list generation 
Partek statistics provide the opportunity to focus in on gene sets which present a very 
specific pattern of expression within the dataset. A gene list was collated to better 
represent the influence of sublytic C on CT26 cells. Genes responsive to sublytic C were 
selected as upregulated at both 1 hour and 12 hours post exposure to the conditions. This 
was reasoned to highlight those genes which were consistently upregulated over the 
period of the experiment. Firstly two lists were created from ANOVA statistics with the 
following filters applied: Increase in pNHS * 1 relative to OmCI * 1 with p value < 0.05 and 
increase in pNHS * 12 relative to OmCI * 12 with p value < 0.05. It was necessary to 
generate large gene lists initially in order to create a sufficiently large (but not too large) 
overlap list and so a lower level of stringency was applied; no FDR adjustment and no fold 
change restriction. Created lists were populated with 781 and 1148 entities respectively. 
From these lists an overlap was taken as the intersecting region of a Venn diagram 
comparison, this contained 66 entities (Figure 4.2.5.1). Clustering of the genelist as shown 
in Figure 4.2.5.2 demonstrates the list contains genes upregulated in response to pNHS  
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Figure 4.2.5.1 List of genes significantly upregulated at both 1 and 12 hours; pNHS 1 and 12 hour 
relative to pNHS+OmCI 1 and 12 hours. List criteria: unadjusted p-value <0.05; pNHS 1 hour relative to 
OmCI 1 hour UP, 0 FC; pNHS 12 hour relative to OmCI 12 hour, UP, 0 FC. Entities are sorted by p-value 
(1 hour) and fold change displayed (pNHS relative to OmCI).  
Probeset ID Symbol Transcript
p-value(pNHS * 1 
vs. OmCI * 1)
Fold-Change(pNHS * 1 
vs. OmCI * 1)
p-value(pNHS * 12 
vs. OmCI * 12)
Fold-Change(pNHS * 12 
vs. OmCI * 12)
1 ILMN_1240323 Dnajb1 ILMN_222931 1.06E-07 1.23503 0.00185733 1.07348
2 ILMN_2737685 Mmp13 ILMN_210384 4.96E-07 1.52378 0.00650418 1.14512
3 ILMN_1249426 Socs4 ILMN_216527 1.72E-05 1.24619 0.00157409 1.13555
4 ILMN_1238547 Areg ILMN_217903 8.00E-05 1.43899 0.0180413 1.18086
5 ILMN_2860804 Tfrc ILMN_211824 0.000125388 1.40674 0.00247263 1.25972
6 ILMN_2753809 Mmp3 ILMN_219123 0.000159494 1.23906 0.0462792 1.08968
7 ILMN_1260323 Akr1c18 ILMN_215518 0.000200139 1.281 4.16E-07 1.61755
8 ILMN_2762380 Enpp4 ILMN_223315 0.000207995 1.16497 0.000395452 1.15143
9 ILMN_2631994 Hexim1 ILMN_212955 0.000249227 1.16175 0.000532145 1.14598
10 ILMN_3033753 Fndc5 ILMN_244553 0.000438051 1.10563 0.0426112 1.04763
11 ILMN_2600646 Mia3 ILMN_209942 0.000524624 1.16672 0.0249163 1.08631
12 ILMN_2757617 Il1rl1 ILMN_215312 0.000608952 1.19425 0.000550805 1.19704
13 ILMN_2798753 Gnl2 ILMN_250623 0.000681798 1.20127 0.00371376 1.15482
14 ILMN_1237058 Cnga3 ILMN_221213 0.000714416 1.06946 0.0117395 1.0446
15 ILMN_2705604 Ppp1r15b ILMN_186016 0.000855383 1.19491 0.00154355 1.17839
16 ILMN_2619848 Tfrc ILMN_211824 0.0015468 1.28305 0.00240607 1.26335
17 ILMN_2759415 Cenpe ILMN_227180 0.00219871 1.05983 0.0103522 1.04622
18 ILMN_1225816 Hbb-bh1 ILMN_216390 0.00329093 1.16353 1.99E-07 1.58676
19 ILMN_2666018 Mgp ILMN_215984 0.0034199 1.26867 6.50E-05 1.48997
20 ILMN_1241657 Cnot2 ILMN_219105 0.00532856 1.07852 0.00877129 1.07192
21 ILMN_2797928 Mustn1 ILMN_215350 0.00610923 1.15646 0.00182066 1.19161
22 ILMN_2875251 Ang ILMN_244375 0.00619403 1.1171 0.0457869 1.07665
23 ILMN_2923285 Rnf32 ILMN_213506 0.0063251 1.09164 0.0418454 1.06186
24 ILMN_2502596 Nmnat1 ILMN_232308 0.00654942 1.07596 0.0237638 1.05908
25 ILMN_2907499 Tatdn2 ILMN_244008 0.00667741 1.17943 0.0071941 1.17698
26 ILMN_3143227 Tmem183a ILMN_249013 0.00730189 1.12779 0.000514444 1.19426
27 ILMN_2720786 Scmh1 ILMN_247166 0.00732057 1.07901 0.0263702 1.0612
28 ILMN_2763245 Cxcl1 ILMN_223377 0.00831195 1.55636 0.0206054 1.45109
29 ILMN_2720763 BC025546 ILMN_220336 0.00841115 1.17742 0.00525206 1.19349
30 ILMN_2751090 Cep68 ILMN_222538 0.00965334 1.08604 0.00840214 1.08827
31 ILMN_2671344 Adamts12 ILMN_242188 0.0106427 1.05428 0.0215408 1.04715
32 ILMN_3097726 Gnl3 ILMN_250637 0.0117709 1.11868 0.000137441 1.23639
33 ILMN_2716558 LOC669251 ILMN_235418 0.0125271 1.05613 0.0190704 1.05159
34 ILMN_2724942 Ptgis ILMN_220660 0.0131669 1.11756 0.0109388 1.12193
35 ILMN_2791578 Gspt1 ILMN_216927 0.0146217 1.10004 0.0229139 1.09097
36 ILMN_1231287 Msi1 ILMN_217693 0.0156498 1.05121 0.00793649 1.05822
37 ILMN_1224651 2810405J04Rik ILMN_217867 0.0156769 1.11424 0.00414044 1.14635
38 ILMN_2703748 Luc7l ILMN_219060 0.0186717 1.11708 0.0366221 1.10023
39 ILMN_2634768 Olfr78 ILMN_213211 0.0199231 1.082 0.0265471 1.07697
40 ILMN_2605096 Rsl1d1 ILMN_210385 0.0207247 1.14149 0.0437253 1.11818
41 ILMN_2659644 Map2k3 ILMN_215446 0.0209027 1.07477 0.00842064 1.08952
42 ILMN_2650439 Galnt1 ILMN_212372 0.0212788 1.10417 0.00272697 1.15253
43 ILMN_2935998 Tmeff2 ILMN_194817 0.0213607 1.07636 0.0018916 1.11779
44 ILMN_2598050 1700049K14Rik ILMN_256176 0.0221217 1.06819 0.0293862 1.06398
45 ILMN_2872058 Ctsh ILMN_241653 0.0223128 1.10535 0.0273958 1.10056
46 ILMN_1236889 Selp ILMN_216201 0.0253795 1.12538 0.0328451 1.11795
47 ILMN_1216854 Zfp787 ILMN_242380 0.0289459 1.05575 0.000742605 1.10493
48 ILMN_3161571 Olfr104 ILMN_249555 0.0294168 1.05714 0.0280145 1.05779
49 ILMN_2600627 Noc4l ILMN_209940 0.0305599 1.09742 0.00628803 1.13449
50 ILMN_1228590 Ogfod2 ILMN_221240 0.0308091 1.08774 0.00901813 1.11346
51 ILMN_2593774 1190002H23Rik ILMN_209224 0.0311035 1.07557 0.000476638 1.15525
52 ILMN_1239947 Hnf4g ILMN_221613 0.0319447 1.04848 0.0234694 1.05199
53 ILMN_2829129 Dcpp1 ILMN_240826 0.0335684 1.05797 0.027549 1.0607
54 ILMN_1239345 Asf1a ILMN_214517 0.034306 1.04164 0.0388347 1.04041
55 ILMN_1240933 Ambn ILMN_217978 0.0367144 1.04166 0.0118774 1.05304
56 ILMN_1258977 Tmem33 ILMN_225515 0.0384204 1.08152 0.0391759 1.08112
57 ILMN_2653081 Prkab1 ILMN_214884 0.0391979 1.07229 0.0409149 1.07151
58 ILMN_2836664 Polr1a ILMN_260912 0.0394424 1.05206 0.00427644 1.081
59 ILMN_3151503 C130032J12Rik ILMN_222501 0.0408503 1.10148 0.000261866 1.24628
60 ILMN_2792809 Arpc5 ILMN_218989 0.0425289 1.06436 0.0470318 1.0627
61 ILMN_2679037 LOC100046883 ILMN_310789 0.0448332 1.11185 0.00110273 1.22763
62 ILMN_2856457 Krtap16-3 ILMN_208768 0.0449878 1.05583 0.00357391 1.09265
63 ILMN_2737479 Slc12a9 ILMN_215442 0.0450887 1.06685 0.0217535 1.07948
64 ILMN_1245139 Scamp3 ILMN_218241 0.0455026 1.07573 0.038499 1.07905
65 ILMN_1227235 Timm10 ILMN_216641 0.046028 1.15605 0.0173915 1.19764
66 ILMN_2698361 Ars2 ILMN_217819 0.0474577 1.0767 0.00713001 1.11537
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Figure 4.2.5.2 Hierarchical clustering heatmap of overlap gene list. PNHS 12 hour relative to 
pNHS+OmCI 12 hour. Gene list criteria: unadjusted p-value <0.05; pNHS 1 hour relative to OmCI 1 hour 
UP, 0 FC; pNHS 12 hour relative to OmCI 12 hour, UP, 0 FC. Overlap list=66 entities. Dendrograms 
clustering sample bar: Serum condition; red=control, orange=OmCI, yellow=pNHS Time point; 
black=0, blue=1 hour, purple=12 hours. Gene expression values (log2 transformed, 0 mean shifted, 
scaled to SD=1) for clustered entities: green=downregulated, black=no change, red=upregulated. 
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compared to pNHS+OmCI at either 1 hour only, 12 hour only and crucially at both time 
points. 
4.2.5.2 Network building form overlap gene list 
The gene list generated in section 4.2.5.1 was uploaded into GeneGo as a custom entity 
list. It was then used to explore the possible linkages by building a network from the 
custom entities. The network was built using the list as seed ‘nodes’ and the algorithm for 
linkage based upon standard Dijkstra’s shortest path. This algorithm plots the shortest 
pathway between nodes by the addition of up to 2 steps based upon ‘from’ - ‘to’ pathways 
between seed nodes. Additional nodes are therefore added as linkages. Canonical 
pathways are considered as 1 linkage and so multiple nodes are added in this case. It is 
important to note that generated networks are created using the curated ontologies 
contained within MetaCore. This means that each connection between nodes derive from 
confirmed biological interactions taken from literature citations. 
Once generated the network was explored at length. For clarity, nodes were manually 
moved to determine the key seed nodes and their overlapping connections. Nodes 
unconnected to the main network were removed. Node groups displaying little connectivity 
to the main network were pruned to reveal the most interrelated nodes. With the network 
reduced to its most connected nodes it was organised by cellular location from left to right: 
the extracellular space representing gene products which are secreted, cytoplasmic where 
much of the signalling is transduced, and nuclear from which gene expression is 
regulated. 
Out of the network seed nodes derived from the gene list, generated as described in 
section 4.2.5.1, four key downstream genes; matrix metalloproteinases (Mmp) 3 and 13, 
C-X-C motif ligand 1 (Cxcl1) and amphiregulin (Areg) were highlighted. These genes were 
co-regulated by a network of putative signalling events and cascades including Ca2+ 
release, PI3K, various MAPK pathways, PKC and JAK/STAT pathways via a number of  
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Figure 4.2.5.3 Gene linkage analysis of overlap gene list. Networks describing the interconnected 
regulation of four key downstream effector genes, generated: shortest path, max 2 steps, either 
inclusion of (A) or exclusion of canonical linkages (B). Network is organised to cellular localization of 
gene product. Seed nodes are circled in navy blue. Thick light blue lines describe canonical pathways 
of signal transduction and transcription regulation. Thin lines are non-canonical interactions either 
transcriptional regulation or protein association e.g. enzymatic regulation/cleavage. Hexagonal labels 
represent mechanism of interaction, c=cleavage, green=positive activation, grey=unspecified. 
 
A.
B.
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Figure 4.2.5.4. Network derived hits. A. Microarray data bar charts for network analysis derived hits, 
data is displayed as log2 transformed, median baseline adjusted and calculated mean for sample 
groups. Baselines therefore represents median across the expression values taken for each probe. B. 
Gene list entities are sorted by p-value (1 hour) and fold change displayed (pNHS relative to OmCI). C. 
Areg, Cxcl1, Mmp3, Mmp13 genes are identified and function summary taken from UniProt database 
general annotation. 
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Probeset ID Symbol Transcript
p-value(pNHS * 1 
vs. OmCI * 1)
Fold-Change(pNHS *1 
vs. OmCI * 1)
p-value(pNHS * 12 
vs. OmCI * 12)
Fold-Change(pNHS * 12 
vs. OmCI * 12)
1 ILMN_1238547 Areg ILMN_217903 2.31E-06 1.43899 0.00185142 1.18086
2 ILMN_2737685 Mmp13 ILMN_210384 1.06E-06 1.52378 0.0100312 1.14512
3 ILMN_2753809 Mmp3 ILMN_219123 9.89E-05 1.23906 0.00367792 1.08968
4 ILMN_2763245 Cxcl1 ILMN_223377 8.74E-03 1.55636 0.0215031 1.45109
Gene Symbol Gene Name function
Areg amphiregulin (Areg), mRNA.
Ligand of the EGF receptor/EGFR. Autocrine growth factor as well as a 
mitogen for a broad range of target cells including astrocytes, Schwann 
cells and fibroblasts.
Cxcl1
chemokine (C-X-C motif) ligand 1 
(Cxcl1), mRNA.
Has chemotactic activity for neutrophils. Contributes to neutrophil
activation during inflammation. Hematoregulatory chemokine, which, in 
vitro, suppresses hematopoietic progenitor cell proliferation. KC(5-72) 
shows a highly enhanced hematopoietic activity
Mmp3
matrix metallopeptidase 3 (Mmp3), 
mRNA.
Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens 
III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase.
Mmp13
matrix metallopeptidase 13 (Mmp13), 
mRNA.
Degrades collagen type I.
A.
B.
C.
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Figure 4.2.5.5 Gene linkage analysis of collated gene list. A. Network describing the interconnected 
regulation of the four key downstream effector genes as well as the 8 statistically significant genes 
from Figure 4.2.3.8. generated: shortest path, max 2 steps, excluding of canonical linkages Network is 
organised to cellular. B. Direct interaction informed by network in A showing the interactions of 
transcriptional regulators with the four key effector genes. Seed nodes are circled in navy blue. Thin 
lines are non-canonical interactions either transcriptional regulation or protein-protein association. 
Lines represent interaction: red=inhibition and green=activation. 
  
B.
A.
143 
 
transcription factors including AP-1 and NFκB. The generation of this network was 
significant because it was the first indication of a set of linked sublytic C responsive genes 
on which attention could be focussed.  
To better display this network the highlighted downstream effectors were uploaded as a 
fresh entity list and network generation carried out as described above. The generated 
network is displayed in Figure 4.2.5.3.A. 
Figure 4.2.5.4 A. shows the microarray gene expression data transformed and baseline 
adjusted to median as described in 4.2.2.2. Each of the genes highlighted by the network 
were upregulated at both 1 and 12 hours post exposure to pNHS compared to 
pNHS+OmCI. Both Mmp3 and Mmp13 were increased. They display similar expression 
patterns rising to ~0.2 above median levels but Mmp13 expression in controls at 0 and 1 
hour were greatly below baseline. This is due to an increase in expression compared to 
the non-treated control in pNHS+OmCI  at the 12 hour time point. Areg and Cxcl1 were 
also increased in response to pNHS in comparison to pNHS+OmCI by 0.5 above median 
at the 1 hour time points. The increase of Cxcl1 was reduced after 12 hours. At the 12 
hour time point Areg is below baseline, -0.5 in control conditions but above baseline by 
~0.2 in response to the treatment suggesting an overall drop in expression after 12 hours. 
With these genes identified as important responsive genes to sublytic C it was of interest 
to correlate these with previous gene expression changes highlighted as the most 
statistically significant shown in Figure 4.2.3.7 and Figure 4.2.3.8. To understand the 
possible interconnectivity of these genes with those highlighted through network 
generation, they were combined to form a new gene list which was uploaded as seed 
nodes in a network selecting for shortest path with a maximum of 2 steps and canonical 
pathways excluded  (Figure 4.2.5.5A). This analysis demonstrated the striking connectivity 
of the 4 downstream genes to  AP-1 suggesting its crucial role in the observed response. 
In addition the association of EGFR with Rgs16 is evidence of Gαi-protein mediated trans-
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activation of EGFR by phosphorylation (Derrien & Druey, 2001). Analysis was also 
repeated using the central interacting seed nodes plus NFκB to find direct interactions 
(Figure 4.2.5.5B). The interplay between EGR1, EGR2, IRF1, AP-1 and NFκB with the 
four previously described hits may go some way in informing a mechanism to explain the 
sequence of events leading to the observed response. Figure 4.2.5.5B makes clear that c-
fos (AP-1) may be downstream of Egr1 and 2 and that Mmp3 and 13 may be controlled 
via this pathway. NFκB may be responsible for Cxcl1 induction  but other interactions 
suggested are not backed up by the data, i.e. Irf1 was downregulated in the data. Areg is 
shown to be outside this network suggesting an independent mechanism. Taking the 
network data together a possible mechanism might be EGFR activation possibly via Gαi 
leading to transcription regulation primarily via AP-1 and NFκB. 
4.3 Discussion 
The aim of this chapter was to identify the gene expression profile induced by exposure of 
CT26 tumour cells to sublytic C using the conditions optimized in chapter 1. Specifically, 
the chapter aimed to identify gene expression changes which might be tumour promoting 
in nature. A microarray experiment was performed and bioinformatic analysis of 
expression data revealed a number of genes responsive to sublytic C attack which were 
sustained over 12 hours. Of these, 4 genes with roles in the extracellular space were 
identified as being co-regulated via network analysis. These had roles in extracellular 
matrix regulation, inflammation and proliferation acting to influence the interaction 
between a tumour cell and its environment. This is indirect evidence of a tumour 
promoting role for sublytic C. 
4.3.1 Data handling 
Data normalization was achieved using quantile method. Normalization methods were 
studied comparing complete methods which normalize based upon the signal data in its 
entirety with methods which make use of a baseline array (Bolstad et al, 2003). Within the 
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comparison the quantile method performed well in all the measures used. Quantile gave 
the smallest distance between arrays which was maintained across intensity data, scored 
well on bias and was the fastest to calculate. Quantile normalization is now considered the 
most robust method, performing well in reducing masking variation without affecting the 
biologically significant variation. 
PCA analysis showed how the experimental groupings separated from each other initially 
revealing a batch effect, groupings were clearly seen once this was removed. Separation 
revealed influence of time and serum but crucially a difference between OmCI treated and 
untreated pNHS conditions. This gave a clear  indication that a specific effect of terminal 
pathway competency could be detected in the gene expression response. 
4.3.2 ANOVA gene lists 
ANOVA statistics demonstrated that the main sources of variation as a factor of the error 
was serum exposure time contributing the majority of the variation. By comparison with 
this, the serum condition i.e. pNHS and pNHS+OmCI contributed much less variation. 
This was supported by the number of significant differentially expressed genes in the 
comparison between the 1 and 12 hour timepoints. Hierarchical clustering showed the 
main clustering effect to be time point dependent regardless of terminal complement 
competency further supporting the dominance of serum in this system.  
Sublytic C attack experiments were designed in a way that focussed upon the terminal 
pathway of C. Serum isolated from human blood was used as a source of C and the 
terminal pathway controlled using OmCI, a specific inhibitor of C5 added to the same 
serum. Serum, with its complex mixture of growth factors, hormones and cytokines, can 
therefore be considered a dominant influence on gene expression changes. Cells respond 
to serum exposure by upregulating a number immediate early response genes which will 
have been detected by the hybridisation experiment as well as changes to genes 
downstream of these altered response genes. With such a high throughput technique it is 
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advisable to carefully formulate the experimental design. Complex and unpredictable 
effects such as those given by serum are not ideal. Eliminating such an effect could be 
achieved with a cleaner system such as reactive lysis (Abe et al, 2004). To do this C7 
depleted serum could be treated with purified zymosan and the formed C5b6 complex 
then purified (Discipio et al, 1983).The C5b6 complex and C7 would be deposited on the 
membrane by co-incubation then the final components added separately (Wiedmer et al, 
1987). 
PCA analysis provided evidence that despite the substantial serum influence there was a 
sublytic complement effect that could be focused on using the ANOVA statistics. 
ANOVA statistics facilitated the comparisons that yielded changes exclusive to terminal 
pathway activation. Among the responsive genes there were clues to the events induced 
by this activation. Genes involved in signal transduction (Itprip, Rgs16, Dusp2), 
transcription factors (Fos, Egr1, Egr2), proliferation (Areg, Bdnf) and inflammatory 
responses (Irf1, Socs4) were significantly altered. 
Signalling involving G-protein, Ca2+ and MAPK activation were therefore implicated in 
agreement with reported signalling events associated with MAC deposition (Cole & 
Morgan, 2003). C-fos is well established to be upregulated rapidly in response to MAC 
deposition and may also uphold the possibility of Ca2+ and MAPK (particularly ERK) 
involvement (Badea et al, 2003). 
A comparison of hits found in this study can be made to a microarray experiment where 
MAC deposition was shown to induce apoptosis in a Thy1N model (Liu et al, 2012). This 
was found to be through upregulation of Irf1 and induction of caspase 8 transcription and 
activation. Within the study by Liu et al (2012), microarray analysis of MAC deposition 
demonstrated upregulation of Irf1, Atf3, Egr1, C/EBPβ, Gadd45, connective tissue growth 
factor, IL-6, IL-1β, HO-1, schlafen 3, and cyclin L1. Of these, Egr1 upregulation was in 
agreement with data presented here but Irf1 and Gadd45ɣ were contrasting. Explanation 
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for this discrepancy may lie in the time scale used; RNA extraction of samples by the 
group was taken 40 minutes and 3 hours post-exposure and genes down regulated in the 
presented analysis  may indicate the drop in expression of a gene which had previously 
been greatly upregulated, falling below basal levels. This is difficult to prove and it may be 
that the cell types respond to sublytic C differently. The observed down regulation of Irf1 
and Gadd45ɣ at 1 hour may demonstrate a novel anti-apoptotic influence of sublytic C in 
CT26 cells. 
4.3.3 Enrichment analysis 
Gene list creation from ANOVA statistics allowed the comparison between conditions and 
provided indications of the systems and mechanisms that might be in play during 
exposure to sublytic C. These indications are significant but characterised by an 
assumption that a single or collectively significant gene expression change is indicative of 
a definite response. A more global and holistic view was therefore needed to take the 
entirety of the data and make informed correlations between groups of responsive genes 
and the systems they are involved with. This was achieved by enrichment analysis. 
The implication of TGFβ, IL-1, CD137, and OSM pathway map enrichment by sublytic C 
are important leads to which some attention must be paid but interpretation requires 
consideration and caution. Their suggestion by enrichment analysis is likely due to 
common signalling pathway components and transcription regulation as set out in section 
4.2.4.2.  
Thrombospondin1 (TSP-1) and TGFβ was shown to be expressed in response to sublytic 
MAC deposition by GMCs via PI3K/Akt pathway activation, TSP-1 protein could then 
activate latent TGFβ1 (Gao et al, 2007). TGFβ (but not TSP-1) genes were upregulated 
after 12 hours as a serum response rather than as a consequence of sublytic C according 
to the microarray presented here. However it is conceivable that latent TGFβ secreted by 
the cells may have been cleaved by other factors expressed or activated by sublytic C.  
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IL-1β is reported to be released in response to sublytic MAC by several cell types and is 
associated with prostaglandin secretion (Schonermark et al, 1991). An IL-1β expression 
response is not shown in the microarray data but may still be involved in its pro form 
which can be cleaved to release the active cytokine (Black et al, 1988). 
CD137 is a member of the TNF receptor super family, expressed primarily by T-cells as a 
co-stimulatory molecule and binds its ligand CD137L on target cells as a mechanism to 
regulate T-cell proliferation (Kwon et al, 2000). There is some evidence of expression 
change in the microarray data for both the CD137 and CD137L though it is most likely a 
serum response and the relevance of such a change is not clear. 
As mentioned previously, it is the presence of common signalling component expression 
changes within each of the mentioned pathway maps which explains their significant 
enrichment scores. There is strong suggestion of mitogen activated protein kinase  
(MAPK) signalling cascade activation upon exposure to pNHS compared to pNHS+OmCI. 
MAPK signalling cascades are organised by a hierarchy of kinases starting from the 
triggering MAPK kinase kinase, which as its designation suggests phosphorylates the next 
component in the sequence, MAPK kinase which in turn phosphorylates MAPK. There are 
a number of MAPK modules in mammalian cells; they are the extracellular signal-
regulated kinase 1 and 2 (ERK1/2) cascade, the c-Jun N-terminal kinase (JNK) and p38 
MAPK pathways designated to refer to the main MAPK of the pathway. Each have their 
own specific kinase components that fit the described hierarchy and each component has 
close specificity to its substrate along the chain (Schaeffer & Weber, 1999). JNK cascade 
signalling is activated by cytokine and cell stress regulating transcription via 
phosphorylation of the AP-1 monomer c-jun (Davis, 2000). P38, like JNK, is responsive to 
stress stimuli such as LPS and osmolarity changes acting via c-jun and ATF-2 
transcription factors (Han et al, 1994). ERK1/2 cascade is generally responsible for signal 
transduction from growth factor receptor triggers leading to cell activation and proliferation 
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as well as inhibition of  apoptosis. Activated ERK1/2 regulates transcription via fos or Elk-
1 (Mebratu & Tesfaigzi, 2009). 
Within pathway maps there were common pathways which suggest activation of each of 
the three described MAPK cascades. A MEKK1/MEK3 or MEK4/JNK or p38 pathway 
implicates TRAF6/SITPEC activity.  
TNF receptor associated factor 6 (TRAF6) is an adaptor protein involved in IL-1R, TLR 
and TNFR signalling pathways and is therefore a key component of innate immune 
signalling (Chung et al, 2002). In general TRAF mediated signalling involves the 
trimerization and recruitment of TRAF to receptor upon its activation (Ye & Wu, 2000). 
Association between receptor and TRAF6 is either direct, as with TNFR, or via IRAK 
adaptor proteins as with IL-1 and TLRs  (Wu & Arron, 2003). TRAF6 can induce both 
MAPK (JNK, ERK, p38) and IKK pathways leading to activation of AP-1 and NFκB 
transcription factors. This requires TAK1 activation via adaptor proteins TAB1 and 2 a 
process which is now known to be regulated by k63 polyubiquitination (Ninomiya-Tsuji et 
al, 1999; Wang et al, 2001). TRAF6 is also capable of activating the PI3K/Akt signalling 
cascade (Wong et al, 1999; Yang et al, 2009). TRAF6 regulates signalling by way of its E3 
ubiquitin ligase activity (Deng et al, 2000). It is through this activity that TRAF6 was shown 
to mediate PI3K/Akt activation in response to sublytic deposition of the MAC in Thy-1 
GMCs (Qiu et al, 2012). It is therefore possible that activation induced by insertion of MAC 
into a cell membrane causes activation of pathways via TRAF6, indeed Qiu et. al. (2012) 
demonstrated direct binding between the MAC and TRAF6 through the  immunoblotting of 
an anti-C5b-9 antibody immunoprecipitate, with anti-TRAF6. 
Enrichment analysis of microarray data showed Oncostatin M (OSM) signalling via MAPK 
was strikingly enriched following pNHS treatment at both 1 and 12 hours. Two matrix 
metalloproteinases; 3 and 13 (Mmp13 and stromelysin-1 AKA Mmp3), were responsive to 
sublytic C. OSM is a multifunctional cytokine and a member of the interleukin 6 super-
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family, signalling via the GP130 IL-6 signal transducer (Rose et al, 1994; Zhang et al, 
1994). According to the microarray data OSM did not alter in response to pNHS treatment 
compared to pNHS+OmCI and so an association with OSM signalling shown in 
enrichment is likely indicative of the involvement of MAPK pathway signalling. 
4.3.4 Network analysis of genes upregulated at both time points 
Network analysis using a custom list of genes upregulated at both time points revealed 
possible co-regulated genes expressed into the extra-cellular compartment; Mmp3, 
Mmp13, Cxcl1 and Areg. Co-regulation is via canonical pathways including p38, JNK and 
ERK MAPK cascades controlling via AP-1 and NFκB,  largely backing up the assertions 
made through enrichment analysis. However, in addition, the network points to EGFR 
involvement as well as possibly PI3K and PKC signalling cascades.  
Epidermal growth factor receptor (EGFR) is a member of the erbB receptor tyrosine 
kinase family. erbB members are activated by ligand binding at the cell surface which 
leads to the phosphorylation of the intracellular tyrosine kinase domain. Phosphorylation 
causes homo/heterodimerization and auto/transphosphorylation of erbB RTKs which via 
adaptor molecules activate downstream signalling cascades (Lemmon & Schlessinger, 
1994; Olayioye et al, 2000). Signalling cascades triggered are various including ERK1/2, 
PI3K/Akt and STAT pathways (Ono & Kuwano, 2006). Activation of the EGFR system has 
been described in response to UV,  osmotic and oxidative stress via autophosphorylation 
of the receptor leading to the expression of EGFR ligands (Carpenter, 1999). UV and 
osmotic stress induction of EGFR responses was primarily mediated by a JNK pathway 
activation which also activated IL-1 and TNF receptors (Rosette & Karin, 1996). 
Additionally Oxidative stress can induce auto-phosphorylation of the EGFR tyrosine 
kinase domain (Gamou & Shimizu, 1995).  
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ErbB2 may link to the GP130 receptor in a constitutive association acting to regulate its 
phosphorylation and signalling indicating a possible link to OSM signalling (Grant et al, 
2002) 
MAC deposition is reported to be capable of activating of Gαi protein independent of 
receptor (Niculescu et al, 1994). Rgs16 expression suggests that EGFR activation is 
probably triggered by receptor coupled Gαi activation since Rgs16 has been shown to co-
immunoprecipitate (Derrien & Druey, 2001) and gene expression is thought to be induced 
as a feedback mechanism for G-protein signalling (Beadling et al, 1999). This provides an 
indication that EGFR transactivation by tyrosine phosphorylation through activation of Gαi 
is part of the response by CT26 cells to sublytic C (Daub et al, 1997) Indeed such an 
effect has been observed in which MAC deposition activated EGFR signalling without 
ligand binding (Cybulsky et al, 1999). MAC is capable of transactivating several other 
RTKs such as fibroblast growth factor receptor-2 (FGFR2), and hepatocyte growth factor 
receptor (HGFR) which signal via ERK-2 tyrosine phosphorylation (Cybulsky et al, 1999). 
Expression of both Mmp3 and 13 mRNAs can be induced by the EGF system and further 
regulated at the post-transcriptional level in fibroblasts (Delany & Brinckerhoff, 1992). 
Transactivation of the EGFR has been described by the MMP3 cleavage of pro-HB-EGF 
into the active HB-EGF which then ligates and activates the receptor providing a possible 
feedback mechanism (Suzuki et al, 1997). A similar mechanism has been reported for 
MMP13 induced EGFR transactivation but the cleavage substrate which mediated this 
effect was not discovered (possibly epiregulin) (Mukhin et al, 2006). Cxcl1 can also be 
expressed in response to EGFR activation through PI3K, through it can also be 
responsive to prostaglandin E2 release additionally involving MAPK signalling (Moscova 
et al, 2006; Wang et al, 2006). G-protein coupled receptor activation leads to the 
production of second messengers DAG and IP3 (Raghuwanshi et al, 2012). Activation of 
CXCR2 by CXCL1 triggers MEK and ERK MAPK pathways leading to an increase in c-fos 
expression (Shyamala & Khoja, 1998). Receptor activation can also transactivate EGFR 
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via MMP mediated cleavage of HB-EGF (Bolitho et al, 2010). Since a similar phenomenon 
involving EGFR transactivation by C5b-9 has been demonstrated previously (Cybulsky et 
al, 1999), it is possible that this is a central activator of signal transduction in response to 
MAC deposition thus mediating many of the reported sublytic C effects.  
In addition to the EGFR, other systems responsive to stress stimuli might be considered. 
Mmp13 and mmp3 can be upregulated in response to oxidative stress via ERK1/2 and 
p38 pathways in RPE cells (Alge-Priglinger et al, 2009) and in response to osmotic stress 
via JNK (Li et al, 2004). IL-1β and TNFα are also shown to be inducers of Mmp3,  Mmp13 
and Cxcl1 gene expression through NFκB (Li et al, 2003; Liacini et al, 2002; Ribaux et al, 
2007; Spiekstra et al, 2007) . This provides a possible link between stress induced 
EGFR/IL-1βR/TNFαR activation and expression of Mmp3, Mmp13, Cxcl1 and Areg and 
may provide a possible mechanism. 
Mmp3 and Mmp13 upregulation has previously been associated with terminal C activation 
on chondrocytes in human disease and an experimental model of osteoarthritis (Wang et 
al, 2011). Deposition of MAC on cultured human chondrocytes induced expression of both 
Mmp3 and Mmp13 mRNA over the course of 72 hours in a reactive lysis system. Higher 
expression was also seen when comparing chondrocytes taken from C5+/+ with C5-/- mice 
subjected to the destabilization of the medial meniscus (DMM) osteoarthritis model. The 
response by the Mmps was found to be mediated by ERK signalling. In addition to Mmp3 
and Mmp13 the work also described the MAC mediated upregulation of  c-jun. Though 
CT26 are epithelial in origin the data on their response to MAC presented in this section 
show some interesting similarities to the data published by Wang et. al. (2011) on 
chondrocytes, suggesting common response mechanisms.  
4.3.5 Summary and conclusion 
This chapter aimed to understand the gene expression effects of sublytic C membrane 
attack on tumour cells. Microarray data were generated from a carefully designed sublytic 
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C attack experiment and primary analysis of microarray data showed a dominant serum 
effect but that upon more careful and stringent analysis, including ANOVA statistics and 
gene list generation, the sublytic C effect and MAC dependence could be seen. 
Enrichment analysis revealed regulation pathways hidden within the data pointing to some 
key processes including ERK1/2, JNK and p38 MAPK signalling, IL-1, TNF and OSM 
signalling pathways and transcription regulation through AP-1, ATF-1 and NFκB. Network 
analysis revealed a small group of co-regulated genes upregulated at both time points 
with functions at the cell surface and ECM. With the benefit of enrichment analysis and 
network tools it was possible to propose mechanistic hypotheses regarding these 
expression changes which correlate with current knowledge of sublytic C and MAC 
effects. This revealed a number of possible feedback mechanisms, transcriptional and 
post-transcriptional regulatory connections and signalling activations which give an 
unprecedented perspective of the mechanisms involved in sublytic C induced cell 
activation. 
Genes implicated here, including Areg, Cxcl1, Mmp3 and Mmp13, are strongly associated 
with carcinogenesis, tumour development and metastasis and so are candidate genes as 
mediators of a pro-tumour role for sublytic C attack.  
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5 Validation of microarray and interrogation 
of sublytic effects  
5.1 Introduction 
5.1.1 Validation 
The validation of a microarray experiment is a crucial part of integrating this large dataset 
with an overall experimental approach. Chapter 4 set out the bioinformatic analyses and 
mining of microarray data which defined an influence on tumour cell gene expression after 
exposure to sublytic C. Several hits were in agreement with previously reported effects 
mediated by MAC deposition on nucleated cells, constituting an in silico validation and 
giving a degree of confidence in the results (Chuaqui et al, 2002).  
The process of experimental validation is fundamental in dealing with concerns about 
false negatives and false positives and is required to confirm both the results of the 
microarray and the universality of those results, i.e. do the data reflect a biologically 
significant response to the treatment (Chuaqui et al, 2002; Rockett & Hellmann, 2004). 
The data can be confirmed using a corroborating method to assess transcript quantity 
such as quantitative PCR (qPCR)  which has become a common validating technique for 
microarray studies. Microarray and qPCR data were shown to significantly correlate under 
certain criteria regarding statistical significance and fold change of chosen target genes 
(Morey et al, 2006).  
Gene expression changes, defined as transcript level alterations may or may not translate 
into changes in level of expressed protein products and so in order to gauge the biological 
relevance of microarray hits, a protein level validation must also be sought. 
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5.1.2 Candidate gene products 
5.1.2.1 Amphiregulin (AR) 
The product of the Areg gene is the amphiregulin protein (AR) which has a 38% homology 
with EGF and, in a similar manner to EGF can trigger the erbB2 transmembrane receptor 
(Johnson et al, 1993). AR is expressed as a membrane anchored precursor which is 
cleaved at the cell surface to a soluble form by MMPs (Dong et al, 1999). Soluble AR is 
then able to act upon cognate receptors in autocrine or paracrine loops (Johnson et al, 
1992). A disintegrin and metalloprotease (ADAM) 17 is the primary enzyme responsible 
for ectodomain cleavage and release of the AR at the membrane surface (Sahin et al, 
2004). Oxidative and osmotic stress has been shown to stimulate activation of ADAM17 
leading to shedding of EGFR ligands such as HB-EGF and AR (Fischer et al, 2004).  
5.1.2.2 C-X-C motif  ligand 1 (CXCL1) 
CXCL1 is a potent chemoattractant of neutrophils in the event of infection and signals via 
the CXCR2; a G-protein coupled receptor (Chintakuntlawar & Chodosh, 2009). 
5.1.2.3 Matrix metalloproteinases (MMPs) 3 and 13  
MMPs have functions in extracellular matrix regulation, playing major roles in 
development, wounding, proliferation, inflammation and several disease processes 
including carcinogenesis and metastasis (Nagase et al, 2006). As the metallo designation 
suggests the proteins require a zinc ion bound to a HEXXHXXGXXH consensus 
sequence for catalytic activity (Stocker et al, 1995). MMP3 is a stromelysin enzyme and 
has ability to degrade several substrates, including  collagens III, IV, V, IX, X, and XI, 
laminins, elastin, entactin, fibronectin, fibrin, fibrillins, fibulin, link protein, osteonectin, 
tenascin, vitronectin, ECM proteoglycans and latent IL-1. MMP13 is a collagenase enzyme 
which cleaves type II collagen preferentially to types I and III. All MMP enzymes are 
expressed in pro-forms and require cleavage by proteases or chemical activation to 
become enzymatically active (Visse & Nagase, 2003). MMP3 is capable of cleaving the 
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pro-form of itself and of MMP13, which in-turn is able to cleave its own pro-form (Lochter 
et al, 1997). 
5.1.3 Chapter Aims 
This chapter aims to provide validation of microarray data using qPCR and western 
blotting procedures. The chapter will also investigate the contributions made by the 
signalling cascades shown to inter-connect the downstream effectors revealed by network 
analysis. Finally, the chapter will investigate the roles of the terminal pathway products 
C5a and MAC in mediating the effects witnessed.    
5.2 Methods 
5.2.1 Set up of qPCR for validation 
5.2.1.1 Housekeeping controls 
Choosing genes which are expressed stably is key in the calculation of relative expression 
from qPCR data. The chosen gene must also be robust; unaffected by the experimental 
treatment. There are a number of genes suggested by the literature to be suitable for this 
purpose but the choice is context driven. Common housekeeping control genes include β-
actin, GAPDH and 18s ribosomal RNA. In experiments described in the first results 
chapter, qPCR analysis was conducted using β-actin primers which were used in 
published data from our lab. In the search for suitable housekeeping controls the 
microarray dataset presented a unique opportunity to cross-check candidates for a stable 
expression profile across the dataset. β-actin was checked using GeneSpring and shown 
to be stable across the entire experiment. Literature searches of common housekeeping 
candidates and subsequent checking of microarray data found that a gene known as 
polymerase (RNA) II (DNA directed) polypeptide A (Pol2ra) was suitable (Saviozzi et al, 
2006). Expression data from microarray for both β-actin and Polr2a are shown in Figure 
5.2.1.1A. Using two housekeeping control genes  
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Figure 5.2.1.1 Validation primers for qPCR gene expression analysis of microarray hits. A. House 
keeping gene Polr2A and β-actin expression profiles from microarray data expressed as log2 
transformed, median baseline adjusted signal. Summary of qPCR primers including gene information 
(NCBI accession number), primer sequence, primer length, melting temperature (Tm) position on 
transcript, fragment length and sequence design source (published, PrimerBLAST or PrimerBank). B. 
Housekeeping controls. C. Statistically significant hits. D. Network derived hits.  
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Symbol Accession Number Description Primer sequence Length Tm Position
Fragment 
Length
Reference
Areg NM_009704.3 amphiregulin
GGTCTTAGGCTCAGGCCATTA 21 61 48-68
137
Primer Bank 
6753108a1CGCTTATGGTGGAAACCTCTC 21 60.4 184-164
Cxcl1 NM_008176.3
chemokine (C-X-C motif) 
ligand 1 
ACTGCACCCAAACCGAAGTC 20 60.04 39-58
114
Primer Bank 
229577225b1TGGGGACACCTTTTAGCATCTT 22 60.53 155-136
Mmp3 NM_010809.1
matrix metalloproteinase 
3
ACATGGAGACTTTGTCCCTTTTG 23 60.7 507-529
192
Primer Bank 
6754714a1TTGGCTGAGTGGTAGAGTCCC 21 62.9 698-678
Mmp13 NM_008607.2
matrix metalloproteinase 
13
TGTTTGCAGAGCACTACTTGAA 22 60.1 113-134
132
Primer Bank 
291463259b1CAGTCACCTCTAAGCCAAAGAAA 23 60.2 244-222
Symbol Accession Number Description Primer sequence Length Tm Position
Fragment 
Length
Reference
Rgs16 NM_011267.3
regulator of G-protein 
signaling 16
GGTACTTGCTACTCGCTTTTCC 22 60.9 23-44
151
PrimerBank 
29437173a1CAGCCGCGTCTTGAACTCT 19 62.3 173-155
Fam110c NM_027828.2
family with sequence 
similarity 110, member C
GGCCAAAGAAACCCCCAGCCAG 22 60.18 1297-1318
121
Primer-BLAST-
Primer pair 1GGCTCTGGAGTTTCAGACGCCTA 23 58.16 1417-1395
Irf1 NM_001159393.1
interferon regulatory 
factor 1
ATGCCAATCACTCGAATGCG 20 61.1 1-20
197
PrimerBank ID 
6680467a1TTGTATCGGCCTGTGTGAATG 21 60.4 197-177
Hbb-bh1 NM_008219.3
hemoglobin Z, beta-like 
embryonic chain
GAAACCCCCGGATTAGAGCC 20 62 170-189
93
PrimerBank ID 
6680179a1GAGCAAAGGTCTCCTTGAGGT 21 61.4 262-242
C.
D.
Symbol Accession Number Description Primer sequence Length Tm Position
Fragment 
Length
Reference
Polr2A NM_009089.2 polymerase (RNA) II (DNA 
directed) polypeptide A 
CCCGCTGCGCACCATCAAGA 20 60.04 39-58
117
Primer-
BLAST-
Primer pair 1GGGCGACCTCCCTCCGTTGT 20 60.53 155-136
Actb NM_007393.3 Beta actin
ACGGCCAGGTCATCACTATTG 21 60.13 810-830
101
Donev et. al. 
(2008)AGTTTCATGGATGCCACAGGAT 20 60.02 910-889
B.
A.
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improves the validity of qPCR data produced as a relative expression value can be 
calculated from the mean Ct values given by β-actin and Polr2a. 
All primers were designed as described in section 2.6.1 and the sequences along with 
summary information are shown in Figure 5.2.1.1, for housekeeping genes (B), 
statistically significant hits from microarray (C) and network derived hits from microarray 
(D). 
5.2.1.2 Mapping primers to transcripts 
To best visualize the primer pairs and their location on transcript sequences as well as 
their proximity to microarray probe sequence the sequences for each of the target genes 
were found within Ensembl MGI transcripts, where location of exons on the genomic 
material is displayed and exon sequence for each transcript variant described. Here the 
sequence along with the location of exon/exon boundaries (sites where intronic sequence 
has been removed during splicing) were used to create a colour coded sequence as 
shown in Figure 5.2.1.2, 3, 4 and 5. 
Within the sequences displayed lower case is non-coding sequence and upper case is 
coding region. Exons were alternately coloured turquoise and green by text. Start codons 
were highlighted in green and stop coloured red. Primer pair sequence locations were 
highlighted as green and the probe sequence highlighted yellow. 
5.2.1.3 Testing of qPCR primers 
These primer pairs were tested by qPCR using cDNA reverse transcribed from RNA 
extracted from CT26 cells. The protocol described in section 2.6.2 was followed to test the 
primer pairs at a standard annealing temperature of 60°C. Melt curves taken from each 
primer pair reaction were scrutinized for signs of non-specific products and irregularities. 
Melt curves for each primer pair are shown in Figure 5.2.1.6 and 7. Each curve describes 
a peak at which the predominant dsDNA PCR product, which binds the fluorescent dye 
efficiently, is shown to dissociate and result in ssDNA which does not bind the dye. The  
159 
 
 
Figure 5.2.1.2  Mapping of qPCR primers and their products onto mRNA transcript sequence for Pol2ra 
and β-actin. Transcript sequence and exon/exon boundary information taken from Ensembl database 
was arranged and 5 and 3 prime non-coding shown in lower case and coding sequence in upper case. 
Sequence was also colour coded turquoise and blue so that exons were arranged alternately. Primer 
sequences were highlighted on the transcript in red and microarray probe in yellow. Start and stop 
codons were highlighted in green and red respectively. 
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Figure 5.2.1.3 Mapping of qPCR primers and their products onto mRNA transcript sequence for Irf1, 
Hbb-bh1, Rgs16, and Fam110c. Transcript sequence and exon/exon boundary information taken from 
Ensembl database was arranged and 5 and 3 prime non-coding shown in lower case and coding 
sequence in upper case. Sequence was also colour coded turquoise and blue so that exons were 
arranged alternately. Primer sequences were highlighted on the transcript in red and microarray probe 
in yellow. Start and stop codons were highlighted in green and red respectively. 
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Figure 5.2.1.4  Mapping of qPCR primers and their products onto mRNA transcript sequence for Mmp3 
and Mmp13. Transcript sequence and exon/exon boundary information taken from Ensembl database 
was arranged and 5 and 3 prime non-coding shown in lower case and coding sequence in upper case. 
Sequence was also colour coded turquoise and blue so that exons were arranged alternately. Primer 
sequences were highlighted on the transcript in green and microarray probe in yellow. Start and stop 
codons were highlighted in green and red respectively. 
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Figure 5.2.1.5 Mapping of qPCR primers and their products onto mRNA transcript sequence for Areg 
and Cxcl1. Transcript sequence and exon/exon boundary information was taken from Ensembl 
database was arranged and 5 and 3 prime non-coding shown in lower case and coding sequence in 
upper case. Sequence was also colour coded turquoise and blue so that exons were arranged 
alternately. Primer sequences were highlighted on the transcript in green and microarray probe in 
yellow. Start and stop codons were highlighted in green and red respectively. 
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temperature of this peak is directly related to the size of the fragment but is also 
influenced by other factors such as the % GC content of the sequence. The size of 
fragment and peak temperature largely correlates well for each of the shown melt curves, 
the greater the fragment size the higher the peak melt temperature. There are however a 
few exceptions.  
Rgs16 PCR fragment of 151bp melted at 87°C which was higher than that for the 197bp 
fragment of Irf1 which melted at 84°C (Figure 5.2.1.6). The fragment generated by qPCR 
using the Rgs16 primers is rich in GC (62%) and thus has a much higher melting 
temperature compared to the Irf1 fragment which has a 50% GC. The same is true in the 
case of the fragments created by Areg and Mmp13 primers which were similar in size, 132 
and 137bp respectively, but melted at 84.5°C and 81.5°C respectively (Figure 5.2.1.7). 
The higher Areg melting temperature was because of its higher GC content of 55% as 
compared to 47% for Mmp13. Melt curves demonstrated the specificity of each of the 
primer pairs for their intended targets and indicate that there were no issues with 
unintended products. 
5.2.1.4 QPCR validation strategy 
Primary qPCR corroboration of the expression changes was performed using RNA taken 
from samples prepared in parallel to that used in hybridisation experiment. Replicate 3 
from each condition was therefore used as this was omitted from microarray analysis 
because of sample number restrictions. Control condition RNA was also replicate 3 
regardless of its previous usage. This was further corroborated by performing a secondary 
validation involving an identical, independent sublytic C experiment to that used for 
microarray analysis. One microgram of sample RNA was reverse transcribed as described 
in section 2.5.4 then diluted 1/10 in upH2O and subjected to qPCR analysis using primer 
pairs for Polr2a, β-actin and test gene specific primer pairs shown in section 2.1.2. 
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Figure 5.2.1.6 Melt curve analysis of qPCR products given by primers for housekeeping controls 
(Polr2A, β-actin) and top statistically significant changes from microarray analysis (Rgs16, Fam110c, 
Irf1, Hbb-bh1). RNA from CT26 cells under normal growth conditions was reverse transcribed and 
placed in qPCR reaction mixes  and cycling program run as described in section 2.6.2. Melt curves 
taken post cycling program assessing SYBR Green fluorescence over temperature gradient from 70-
90°C increasing by 0.3°C every second. 
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Figure 5.2.1.7 Melt curve analysis of qPCR products given by primers for network derived microarray 
hits (Areg, Cxcl1, Mmp3, Mmp13). RNA from CT26 cells under normal growth conditions was reverse 
transcribed and placed in qPCR reaction mixes  and qPCR cycling program run as described in 
section 2.6.2. Melt curves taken post cycling program assessing SYBR Green fluorescence over 
temperature gradient from 70-90°C increasing by 0.3°C every 15 seconds. 
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5.2.2 Protein Validation 
5.2.2.1 Conditioned medium (CM) preparation 
CT26 cells were seeded at 5×105 per mL in normal growth medium and placed in three 
75cm2 tissue culture flasks (23 mL per flask) and incubated for 20 hours. Cell monolayers 
were exposed to pNHS, pNHS+OmCI or left untreated as a control. Cells were incubated 
for 1 hour at 37°C, then cell monolayers were washed in serum free medium only and 7.5 
mL serum free medium added and incubated for 24 hours. Supernatant (CM) was 
centrifuged at 300×g to remove dead cells and debris then transferred to 50 mL falcon 
tubes ready for acetone precipitation of protein content. 
5.2.2.2 Whole cell extract (WCE) preparation  
Name Contents 
Whole Cell Extract (WCE) Buffer 
0.5 M Tris, 0.1 mM EDTA, 125 mM MgCl2, 
100 mM KCl, 20% (v/v) Glycerol,  1% (v/v) 
Trition-X-100, pH8 
 
Cell monolayers were washed in 10 mL ice cold PBS then cells detached using a cell 
scraper. The cell suspension was centrifuged at 300×g and the supernatant discarded. 
The cell pellet was resuspended in 1 mL WCE buffer (plus 100 mM PMSF, 1× Complete 
protease inhibitor cocktail from tablets (Roche, Welwyn Garden City, UK))  and the lysate 
incubated on ice for 5 minutes then centrifuged at 16,000×g, 4°C in a small refrigerated 
centrifuge. Supernatants were transferred to 15 mL falcon tubes ready for acetone 
precipitation of protein content. 
5.2.2.3 Acetone protein precipitation 
Conditioned media and whole cell extracts were mixed with 5× volume cold acetone and 
stored at -20°C for 1 hour. Precipitated protein was spun down by centrifugation at 
4,400×g, 4°C for 20 minutes. Protein pellets were transferred carefully using a spatula to 2 
mL screw cap eppendorf tubes then allowed to air dry. Screw caps were tightly closed to 
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prevent complete air drying of the protein pellet. Pellets were weighed by subtracting tube 
weights from that containing the pellet. Protein was resuspended in protein sample buffer 
volume relative to the least massive pellet (~100 µL- adjusting to mass in relation to 
smallest pellet).  
5.2.3 Pharmacological inhibitor preparation 
5.2.3.1 Inhibitors 
LY294002, SP600125, PD0325901, inhibitors of PI3K, MEK and JNK pathways 
respectively, were purchased from Cambridge Biosciences (Cambridge, UK). SB202190, 
inhibitor of p38, was purchased from Stratech Scientific (Suffolk, UK). Inhibitors were 
received as crystalline powders and dissolved in dimethyl sulphoxide (DMSO) to create 
stock solutions of 1000× working concentration: LY294002 10mM, SB202190 1mM, 
SP600125 5 mM and PD0325901 0.5 mM. Aliquots of 10-20 µL of each drug were 
prepared and stored at -80°C. Drug stocks were thawed on ice prior to experiment and 
stored at 4°C for no more than a month.  
5.2.3.2 Sublytic C with inhibitors 
The sublytic C experimental procedure was modified as follows: seeded cells were 
washed in serum free medium and incubated for 1 hour with 1/1000 inhibitor solutions in 
normal growth media along with a carrier only control (DMSO) so that final concentrations 
were as shown in Table 5.2.3.1. Inhibitors and DMSO were also added to 5% pNHS and 
pNHS+OmCI solutions at the same final concentrations. Sublytic C experiment was 
proceeded as before.  
Table 5.2.3.1 Pharmacological inhibitors used to investigate putative signalling cascades implicated 
by network generation. 
Inhibitor Inhibits Dose Reference 
LY294002 PI3K 10 µM (Zhang et al, 2011) 
SB 202190 p38a/b MAPK 1 µM (Manthey et al, 1998; 
Silvers et al, 2003) 
SP 600125 JNK1-3 5 µM (Bennett et al, 2001) 
PD 0325901 MEK/ERK 0.5 µM (Lin et al, 2009) 
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5.2.4 C5a, PMX53, C6D + C6 
C5a active protein was purchased from Abcam (Cambridge UK) as a lyophilized powder 
and was reconstituted to a concentration of 1 µg/mL in ice cold water containing 2.5 
mg/mL BSA. 10 µL aliquots were stored at -80°C and thawed on ice prior to experiments. 
PMX53 (a kind gift from Queensland University, Australia ) was prepared as a 100 µM in 
stock solution in upH2O and 10 µL aliquots stored at -80°C and thawed on ice prior to 
experiments. C6D serum prepared as described in section 3.3.3.5 was used as serum in 
sublytic C experiments. C6D was diluted in serum free medium to 5% and C6 added back 
at 50 µg/mL of serum. Experiments were carried out in the same way as sublytic C 
experiments described in section 2.4. 
5.3 Results 
5.3.1 QPCR validation of microarray 
Two sets of genes highlighted during bioinformatic analysis described in chapter 4, were 
brought forward for validation by qPCR. The first set were chosen as the 4 genes with the 
most statistically significant expression changes representing upregulation and down 
regulation at both 1 hour and 12 hour time points. These were Rgs16 and Fam110c which 
were upregulated at 1 hour, Irf1 which was downregulated at 1 hour and Hbb-bh1 which 
was upregulated at 12 hours. There were no genes significantly downregulated at 12 
hours. The purpose of validating such gene expression changes is to demonstrate the 
capability of microarray in distinguishing gene expression changes and to ensure that no 
technical issues occurred at any stage of the sublytic C experiment used for microarray 
analysis, such as sample switching. 
The second set of target genes were those highlighted by network analysis and therefore 
of particular interest in investigating the response to sublytic C, these were Areg, Cxcl1, 
Mmp3 and Mmp13. Validation of the expression profile of these genes was carried out to 
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confirm their involvement in the sublytic C response and provide grounds to further 
investigate these changes. 
5.3.1.1 Top statistical changes 
Upregulation of Fam110c and Rgs16 at 1 hour in response to pNHS in comparison to 
pNHS+OmCI was confirmed by qPCR in primary validation experiments with similar 
statistical significance. Expression profiles in secondary validation were largely reflective 
of microarray results for Fam110c but not for Rgs16. Although there was upregulation of 
Rgs16 after 1 hour it was also increased at 12 hours and by a greater degree suggesting 
a sustained and additive upregulation (Figure 5.3.1.1 and Figure 5.3.1.2).  
Downregulation of Irf1 at 1 hour in response to pNHS compared to pNHS+OmCI  was 
confirmed in both primary and secondary validation experiments; although in secondary 
validation the downregulation was not significant, it followed a similar trend to that outlined 
by microarray (Figure 5.3.1.3). 
Upregulation of Hbb-bh1 at 12 hours in response to pNHS compared to pNHS+OmCI was 
confirmed very successfully in both primary and secondary qPCR validations. A significant 
comparative increase at 1 hour was observed in secondary validation which was not 
found in primary validation but actually reflected a similar expression pattern to that found 
in microarray data (Figure 5.3.1.4).  
Primary validation reflected directly the expression profiles given in the microarray data, 
confirming them as true positives, and supporting the suitability of the statistical treatment. 
Despite the variability inevitable in a full biological repeat of the sublytic C experiment, the 
results of secondary validation were largely corroborative of microarray results. 
5.3.1.2 Network generated genes 
With the microarray experiment successfully validated by qPCR using a selection of key 
gene expression changes it was then possible to examine those genes highlighted as  
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Figure 5.3.1.1 qPCR validation of Fam110c expression by CT26 cells in response to sublytic C. 
Microarray=original microarray data, Primary Validation=RNA extracted in parallel with that used in 
microarray, Secondary validation=RNA extracted in a fresh sublytic attack experiment. RNA was 
reverse transcribed and Fam110c gene expression analysed by qPCR and calculated as relative to β-
actin and Pol2ra using the ΔΔCt calculation outlined in section 2.6.2 then presented as a % of 
untreated control . Results are mean n=3 +/- SEM (***p<0.001). 
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Figure 5.3.1.2 qPCR validation of Rgs16 expression by CT26 cells in response to sublytic C. 
Microarray=original microarray data, Primary Validation=RNA extracted in parallel with that used in 
microarray, Secondary validation=RNA extracted in a fresh sublytic attack experiment. RNA was 
reverse transcribed and Rgs16 gene expression analysed by qPCR and calculated as relative to β-
actin and Pol2ra using the ΔΔCt calculation outlined in section 2.6.2 then presented as a % of 
untreated control. Results are mean n=3 +/- SEM (*p<0.05, **p<0.01). 
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Figure 5.3.1.3 QPCR validation of Irf1 expression by CT26 cells in response to sublytic complement. 
Microarray=original microarray data, Primary Validation=RNA extracted in parallel with that used in 
microarray, Secondary validation=RNA extracted in a fresh sublytic attack experiment. RNA was 
reverse transcribed and Irf1 gene expression analysed by qPCR and calculated as relative to β-actin 
and Pol2ra using the ΔΔCt calculation outlined in section 2.6.2 then presented as a % of untreated 
control . Results are mean n=3 +/- SEM (ns=not significant, *p<0.05, ***p<0.001). 
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Figure 5.3.1.4 QPCR validation of Hbb-bh1 expression by CT26 cells in response to sublytic C. 
Microarray=original microarray data, Primary Validation=RNA extracted in parallel with that used in 
microarray, Secondary validation=RNA extracted in a fresh sublytic attack experiment. RNA was 
reverse transcribed and Hbb-bh1 gene expression analysed by qPCR and calculated as relative to β-
actin and Pol2ra using the ΔΔCt calculation outlined in section 2.6.2 then presented as a % of 
untreated control. Results are mean n=3 +/- SEM (**p<0.01). 
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Figure 5.3.1.5 QPCR validation of Areg expression by CT26 cells in response to sublytic C. 
Microarray=original microarray data, Primary Validation=RNA extracted in parallel with that used in 
microarray, Secondary validation=RNA extracted in a fresh sublytic attack experiment. RNA was 
reverse transcribed and Areg gene expression analysed by qPCR and calculated as relative to β-actin 
and Pol2ra using the ΔΔCt calculation outlined in section 2.6.2 then presented as a % of untreated 
control . Results are mean n=3 +/- SEM (*p<0.05) 
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Figure 5.3.1.6 QPCR validation of Cxcl1 expression by CT26 cells in response to sublytic C. 
Microarray=original microarray data, Primary Validation=RNA extracted in parallel with that used in 
microarray, Secondary validation=RNA extracted in a fresh sublytic attack experiment. RNA was 
reverse transcribed and Cxcl1 gene expression analysed by qPCR and calculated as relative to β-actin 
and Pol2ra using the ΔΔCt calculation outlined in section 2.6.2 then presented as a % of untreated 
control. Results are mean n=3 +/- SEM (*p<0.05, ***p<0.001). 
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Figure 5.3.1.7 QPCR validation of Mmp3 expression by CT26 cells in response to sublytic C. 
Microarray=original microarray data, Primary Validation=RNA extracted in parallel with that used in 
microarray, Secondary validation=RNA extracted in a fresh sublytic attack experiment. RNA was 
reverse transcribed and Cxcl1 gene expression analysed by qPCR and calculated as relative to β-actin 
and Pol2ra using the ΔΔCt calculation outlined in section 2.6.2 then presented as a % of untreated 
control. Results are mean n=3 +/- SEM (**p<0.01, ***p<0.001). 
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Figure 5.3.1.8 QPCR validation of Mmp13 expression by CT26 cells in response to sublytic C. 
Microarray=original microarray data, Primary Validation=RNA extracted in parallel with that used in 
microarray, Secondary validation=RNA extracted in a fresh sublytic attack experiment. RNA was 
reverse transcribed and Mmp13 gene expression analysed by qPCR and calculated as relative to β-
actin and Pol2ra using the ΔΔCt calculation outlined in section 2.6.2 then presented as a % of 
untreated control. Results are mean n=3 +/- SEM (**p<0.01, ***p<0.001). 
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interesting by network analysis. Network analysis (section 4.2.5.2) revealed that within a 
list of genes upregulated at 1 and 12 hours there were four co-regulated downstream 
genes which represent a possible gene expression response to sublytic C; Areg, Cxcl1, 
Mmp3 and Mmp13.  
Previously in this thesis I have described the significant interrelation of these genes 
through controlling receptor interactions, signalling cascades, transcription factors and 
biochemical interactions of the immature/mature protein products. These genes were 
validated by qPCR. 
Areg 
Areg expression data from the microarray was confirmed using primary and secondary 
validation qPCR (Figure 5.3.1.5).  Microarray data showed an upregulation of Areg in 
response to pNHS compared to pNHS+OmCI at both 1 and 12 hour time points, with the 
largest increase happening at 1 hour. Primary validation qPCR confirmed this  
upregulation and showed a significant increase of 50% at 1 hour and a small, but not 
significant, increase at 12 hours. Areg upregulation was shown to be repeatable by 
secondary validation showing upregulation by 50% at 1 hour and 100% at 12 hour. OmCI 
controls had similar expression levels to untreated controls in all experiments. 
Cxcl1 
Cxcl1 expression data from the microarray was confirmed using primary and secondary 
validation qPCR (Figure 5.3.1.6). Expression of Cxcl1 was upregulated in the microarray 
experiment at both 1 hour and 12 hours in response to pNHS compared to pNHS+OmCI. 
Upregulation was greatest at 1 hour, as with the Areg microarray data.  
Primary validation of Cxcl1 expression did not reflect this pattern. QPCR data showed no 
upregulation at 1 hour but a significant upregulation of 50% at 12 hours (Figure 5.3.1.6). 
Interestingly, although no change was detected at 1 hour between pNHS and 
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pNHS+OmCI, there was a decrease in expression of Cxcl1 in pNHS+OmCI at 12 hours 
compared to the untreated controls. This reflected a similar pattern in the microarray data. 
Secondary validation showed that expression at 1 hour increased in response to pNHS by 
comparison with pNHS+OmCI in a similar manner to the microarray data; however, at 12 
hours upregulation was far higher than that shown by microarray and primary validation 
with increases in the order of 1500% of pNHS+OmCI. Both microarray and primary 
validation qPCR data showed a decrease in Cxcl1 expression in pNHS+OmCI at 12 hours 
compared to the untreated control but primary validation qPCR showed expression levels 
were more similar across the time points. 
Mmp3 
Mmp3 expression data from the microarray was confirmed using primary and secondary 
validation qPCR Figure 5.3.1.7. According to the microarray data Mmp3 expression was 
upregulated in response to pNHS at both 1 and 12 hours compared to pNHS+OmCI. 
Primary qPCR validation supported the microarray data in that it showed an upregulation 
in response to pNHS at both time points, however, upregulation was greatest at 12 hours 
being some 75% above pNHS+OmCI compared to an increase of 30% at 1 hour. 
Secondary validation confirmed this effect in a fresh experiment in which Mmp3 was 
upregulated by 100% in response to pNHS at both time points. Expression levels in 
pNHS+OmCI compared to untreated controls remained relatively similar and constant in 
all experiments. 
Mmp13 
The expression profile of Mmp13 from the microarray data shows some similarity to that of 
Mmp3, with significant increases over controls at both 1 and 12 hours (Figure 5.3.1.7 and 
Figure 5.3.1.8). Primary qPCR validation confirmed the findings of the microarray showing 
Mmp13 upregulation in response to pNHS by 50% at 1 hour and 75% at 12 hours 
compared to pNHS+OmCI (Figure 5.3.1.8). Secondary validation qPCR data confirmed 
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the pNHS induced Mmp13 upregulation at both time points showing an increase of 100% 
at 1 hour and 150% at 12 hours compared to pNHS+OmCI (Figure 5.3.1.8). Expression 
levels in pNHS+OmCI compared to untreated controls were generally similar except for 
microarray data which showed a decrease in Mmp13 expression at 12 hours. 
5.3.2 Protein validation 
Having confirmed by qPCR that the target genes Areg, Cxcl1, Mmp3 and Mmp13 were 
indeed responsive to sublytic C as the microarray had suggested, it was necessary to 
further confirm that these changes in transcript mRNA production correlated with 
increased protein levels. To achieve this western blotting was employed to detect the 
proteins in conditioned media (CM) and whole cell extracts (WCE).  
Briefly, cells were seeded in 3× 75mm2 TC flasks and 20 hours following initial seeding 2 
flasks were removed, the cells washed then exposed to either 5% pNHS or 5% 
pNHS+OmCI as previously described (section 2.4) then incubated at 37°C for 1 hour. 
Cells were then washed, serum free media added to all three flasks and incubated for 24 
hours to allow for the accumulation of expressed proteins. CM and WCEs were prepared 
as described in sections 5.2.2.1 and 5.2.2.2 and protein content precipitated with acetone 
as described in section 5.2.2.3. Protein pellets were weighed and reconstituted in loading 
buffer so that the volume corresponded to mass thus ensuring equal concentration and 
therefore equal loading. In each case roughly 8 mg of total  protein was loaded per well. 
Samples were electrophoresed through 7.5 or 10% polyacrylamide gels (section 2.7) and 
proteins transferred to nitrocellulose membranes as described in section 2.8.1. 
Membranes were probed using anti- AR, CXCL1, MMP3 or MMP13 antibodies (section 
2.8.2), detected by HRP conjugated secondary Ab and presence of positive staining 
revealed by chemiluminescence as described in section 2.8.3.  
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5.3.2.1 AR 
Human AR is expressed as a transmembrane tethered 252 (248 murine protein) amino 
acid precursor glycoprotein. The soluble, active form is released by proteolytic cleavage 
(Plowman et al, 1990). Analysis of the multiple soluble forms of AR has demonstrated that 
the possible fragments depend on the location and sequence of cleavage (Brown et al, 
1998; MartinezLacaci et al, 1996). From a 50 kDa pro-form, cleavage at a site proximal to 
the transmembrane domain results in 43 and 36 kDa high molecular weight fragments 
together with 21, 19 and 9 kDa lower molecular weight soluble forms. In addition 28, 26 
and 16 kDa transmembrane forms can also result from cleavage (Brown et al, 1998). 
Murine AR shares a close amino acid homology with human AR and thus it is likely that 
similar active fragments are released upon cleavage. 
Figure 5.3.2.1A shows a western blot of CM and WCE from pNHS and pNHS+OmCI 
treated cells probed for AR. In the lane containing the CM sample there are two clear 
bands located near the 36 and 50 kDa markers corresponding to the reported higher MW 
soluble forms of AR. These bands appeared weakly in CM sample from control and 
pNHS+OmCI treated cells but were much stronger in samples from cells that had 
undergone sublytic complement attack (pNHS). In addition to these bands there were also 
bands at approximately 100 kDa which could be non-specific primary or secondary Ab 
binding of aggregates, something which would have benefited from the inclusion of a 
secondary control. WCE from all conditions showed no discernible bands. From the 
available data it cannot be determined whether both the detected forms at 50 and 36 kDa 
are “active” fragments. The increased levels of soluble AR in CM induced by pNHS 
treatment agrees with qPCR data and suggests that increased transcription in response to 
sublytic complement results in increased protein secretion. The lack of signal in WCE 
suggests that the synthesised protein did not accumulate in the cytoplasm and implies it 
was secreted quickly upon expression.  
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5.3.2.2 CXCL1 
The C-X-C motif ligand 1 (CXCL1) is a small cytokine of 107 amino acids. Within the 
amino acid sequence there are 4 cysteine residues of which two are separated by a single 
glutamine residue forming the C-X-C motif. Disulphide links between the cysteine residues 
of the motif with those dispersed in the sequence create a stable secondary structure 
encompassing antiparallel β-sheet with three β strands ending in C-terminal antiparallel α- 
helices, this structure couples to form homo-dimers. CXCL1 has a predicted mass of 11.5 
kDa and typically migrates to 12 kDa on SDS-PAGE (Allen et al, 2007; Jin et al, 2005).   
Figure 5.3.2.1B shows a western blot of CM and WCE from pNHS and pNHS+OmCI 
treated cells probed for CXCL1. This shows a band in CM lanes appearing at around the 
36 kDa marker which is more prominent in pNHS compared to the OmCI control. A band 
at this molecular weight does not correspond to a reported CXCL1 fragment, thus no clear 
conclusion can be drawn from this data regarding the effect, if any, of sublytic complement 
attack on CXCL1 protein production. Of note, several commercially available antibodies 
raised against CXCL1 protein react with a protein of around 36 kDa in cell extracts 
(Thermo Scientific, Ab against human CXCL1: PA5-28822).  
5.3.2.3 MMP3 
Matrix metalloproteinase 3 (MMP3) is  expressed as a single 477 polypeptide chain which 
folds to form a pro-form. Similar to other MMP proteins the MMP3 pro-enzyme contains an 
N-terminal propeptide, a catalytic domain of 180 amino acids and a C-terminal domain 
which contains the site for substrate recognition and inhibitor interaction (Becker et al, 
1995). It is secreted as a 57 kDa protein as well as a minor 60 kDa glycosylated form.  
Activation occurs by cleavage, which releases an 80 aa peptide and leaves the major 
active 48 and 45 kDa proteins (a minor fragment of 28 kDa has also been reported) 
(Koklitis et al, 1991). This information pertains to human MMP3, however cleavage and 
activation product sizes are likely to be similar in the mouse given sequence homology. 
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Figure 5.3.2.1 Protein validation of AR and CXCL1. Western blot analysis of CM and WCE of cells 
treated with pNHS or pNHS+OmCI for 1 hour, probed using antibodies raised against murine AR (A) 
and CXCL1 (B) proteins then developed using HRP conjugated secondary antibodies and the ECL 
system as described in section 2.8.  
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Figure 5.3.2.2 Protein validation of MMP3 and MMP13. Western blot analysis of CM and WCE of cells 
treated with pNHS or pNHS+OmCI for 1 hour, probed using antibodies raised against murine MMP3 (A) 
and MMP13 (B) proteins then developed using HRP conjugated secondary antibodies and the ECL 
system as described in section 2.8. 
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In Figure 5.3.2.2A, western blot analysis of CM obtained from CT26 cells exposed to 
pNHS shows increased expression of both pro-forms of MMP3 at 57 and 60 kDa, together 
with an apparent increase in the active form at 48 kDa, when compared to CM from both 
the untreated and pNHS+OmCI treated cells. WCE contained only the 60 kDa pro-MMP3 
in all conditions with no apparent difference in levels between conditions. As with the AR 
western blots, there were several high molecular weight non-specific bands which are 
likely to be aggregated protein. The data is in agreement with the qPCR validation of 
Mmp3 mRNA levels and demonstrates that for Mmp3 increased levels of transcript 
correlate with protein production and secretion under conditions of sublytic C attack. 
5.3.2.4 MMP13 
MMP13 is expressed as a 427 amino acid (60 kDa) polypeptide chain pro-form which is 
activated by cleavage and removal of a pro-peptide sequence to yield a 48 kDa active 
form (Botos et al, 1999; Knauper et al, 1996). 
Figure 5.3.2.2B shows an induction of MMP13 protein secretion by CT26 into the CM in 
response to pNHS with almost all induced protein in the 48 kDa active form while on 
exposure to pNHS+OmCI the 60 kDa pro-MMP13 predominated. Control conditions 
induced little MMP13 in either form. No MMP13 was detected in WCE suggesting the 
protein did not accumulate in the cytoplasm perhaps implying that the pro-form of the 
protein was secreted as soon as synthesised. 
In summary, western blot analysis for each of the analyses, with the exception of CXCL1, 
demonstrated that upregulation at the mRNA level induced by sublytic complement attack 
correlated with changes in secreted protein levels in CM. This was most clearly seen with 
the blots for MMP3 and AR. Another effect of sublytic complement treatment on MMP13 
protein production appeared to be an increased activation of the secreted pro-form. 
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5.3.3 Pharmacological inhibition of signalling 
In sections  4.2.4 and 4.2.5 enrichment and network analyses implied that the gene 
expression response to sublytic C, largely validated at mRNA and protein expression 
levels in sections 5.3.1.2 and 5.3.2, were co-regulated by a number of signalling 
cascades. These included the PI3K and the MAPK pathways (p38, JNK, and ERK1/2). To 
discover the contributions made by each of these pathways in mediating the gene 
expression response pharmacological inhibition of each of the four pathways was 
attempted using pathway specific small molecule inhibitors. 
The inhibitors used for investigation are shown in Table 5.2.3.1. 
LY294002 is a morpholine derivative of quercetin (2-(4-morpholinyl)- 8-phenylchromone) 
and acts as a highly specific PI3K inhibitor by competing with ATP for its binding site 
(Vlahos et al, 1994). SB202190 is a pyridinyl-imidazole (4-(4-(4-fluorophenyl)-5-(pyridin-4-
yl)-1H-imidazol-2-yl)phenol) compound shown to inhibit IL-1 and TNFα release by 
activated monocytes via inhibition of p38 kinase activity (Lee et al, 1994). SP600125 is an 
anthrapyrazolone (Anthra[1-9-cd]pyrazol-6(2H)-one) which is a kinase inhibitor capable of 
binding the ATP binding site on JNK with relative specificity for JNK1, 2 and 3. It prevents 
c-Jun mediated gene expression of inflammatory mediators including cytokines and 
MMPs (Bennett et al, 2001). PD 0325901 is benzhydroxamate (N-[(2R)-2,3-
Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide) which 
inhibits the ATP activation of MEK kinases preventing phosphorylation of ERK and 
continued transduction through the Raf/MEK/ERK pathway. It was shown to inhibit ERK 
phosphorylation in CT26 cells both in vitro and in an in vivo tumour model (Barrett et al, 
2008). 
5.3.3.1 Sublytic C experiment with inhibitors 
In order to investigate the contribution made by each of the implicated signalling pathways 
the sublytic C experiments were repeated as described in section 2.4 in the presence of 
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pharmacological inhibitors of PI3K (LY294002), p38a/b (SB202190), JNK1-3 (SP 600125) 
and MEK/ERK (PD 0325901) at the doses shown in Table 5.2.3.1. Expression of Areg, 
Cxcl1, Mmp3 and Mmp13 was assessed by qPCR and compared to the carrier control 
(DMSO). 
Figure 5.3.3.1 and Figure show the qPCR analysis of Areg, Cxcl1, Mmp3 and Mmp13 
expression response to sublytic C under treatment with DMSO, LY294002, SB202190, 
PD0325901, and SP600125. 
Areg 
Areg gene expression was significantly upregulated at both time points in response to the 
sublytic C attack in the presence of the carrier control reflecting closely the validated data 
(p<0.01, Figure 5.3.3.1A). PI3K inhibition did nothing to suppress this effect, rather, it 
accelerated the response at the 12 hour time point. P38 inhibition had the effect of 
increasing the overall expression of Areg at both time points but did not suppress the 
comparative increase induced by sublytic C. Inhibition of MEK/ERK signalling suppressed 
Areg expression in all conditions representing both a reduction in overall expression and a 
suppression of the observed upregulation in response to sublytic C. JNK inhibition had no 
influence on the Areg expression response resulting in a similar profile to that of the 
control. 
Cxcl1 
Cxcl1 gene expression was upregulated at both time points in response to the sublytic C 
attack in the presence of the carrier control although this was not significant at the 1 hour 
time point but was at 12 thus reflecting the validated data (ns, p<0.01, Figure 5.3.3.1B). 
PI3K inhibition suppressed upregulation at 1 hour, but accelerated upregulation at the 12 
hour time point suggesting a degree of redundancy in its control of Cxcl1 expression since 
PI3K inhibition could not permanently suppress an upregulatory response. P38 inhibition 
resulted in a significant (p<0.05) increase in overall expression at 1 hour and had an 
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acceleratory effect on the response to pNHS at 12 hours. However, it did not suppress the 
upregulation effect at either time point suggesting that p38 signalling has an inhibitory 
influence on Cxcl1 expression. Inhibition of MEK/ERK signalling suppressed the Cxcl1 
expression response at 1 hour but did not affect it at 12 hours indicating a possible 
redundancy in MEK/ERK influence over Cxcl1 signalling. JNK inhibition had no influence 
on the Cxcl1 expression response resulting in a similar profile to that of the control. 
Mmp3 
Mmp3 gene expression was upregulated at both time points in response to the sublytic C 
attack in the presence of the carrier control, reflecting the validated data (p<0.01, p<0.001, 
Figure 5.3.3.2A). PI3K inhibition significantly reduced expression levels for both pNHS 
and pNHS+OmCI at 1 hour but appeared not to inhibit the upregulatory response to 
pNHS. In contrast PI3K inhibition significantly reduced the upregulatory response at 12 
hours.  P38 inhibition had the effect of increasing the overall expression of Mmp3 at the 1 
hour time point but did not suppress the upregulatory response to pNHS compared to 
pNHS+OmCI at either time point. Inhibition of MEK/ERK signalling suppressed the Mmp3 
expression response at both time points but had the effect of significantly increasing 
overall expression at 12 hours. JNK inhibition did not affect the expression response of 
Mmp3 at 1 hour but significantly reduced the upregulation at 12 hours. 
Mmp13 
Mmp13 gene expression was upregulated at both time points in response to the sublytic C 
attack in the presence of the carrier control, this was significant at 1 hour time point but 
not at 12 hours, overall, reflecting the validated data (Figure 5.3.3.2B). PI3K inhibition 
significantly increased overall Mmp13 at 1 hour but did not affect either overall levels or 
the upregulation at 12 hours, perhaps indicating a regulatory role for PI3K in Mmp13 
expression. P38 inhibition had the effect of enhancing the expression response to sublytic 
C of Mmp13 at 1 hour but abolished the effect completely at 12 hours. Inhibition of  
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Figure 5.3.3.1 Effect of pharmacological inhibition of signalling pathways on Areg and Cxcl1 response 
to sublytic C attack. CT26 cells treated with LY294002, SB202190, PD0325901, SP600125 or a DMSO 
carrier control and exposed to pNHS and pNHS+OmCI for 1 and 12 hours. RNA was extracted from 
each including an untreated control. RNA was reverse transcribed then Areg (A.) and Cxcl1 (B.) gene 
expression analysed by qPCR and calculated as relative to β-actin using the ΔΔCt calculation outlined 
in section 2.6.2 then presented as a % of untreated control. Results are mean n=3 +/- SEM, statistics 
were calculated by ttest: comparing pNHS and pNHS+OmCI (displayed on comparative lines above)  
and comparing condition under inhibitor treatment with relevant DMSO control (displayed above 
individual bars) (ns=not significant *p<0.05, **p<0.01, ***p<0.001). 
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Figure 5.3.3.2 Effect of pharmacological inhibition of signalling pathways on Mmp3 and Mmp13 
response to sublytic C attack. CT26 cells treated with LY294002, SB202190, PD0325901, SP600125 or a 
DMSO carrier control and exposed to pNHS and pNHS+OmCI for 1 and 12 hours. RNA was extracted 
from each including an untreated control. RNA was reverse transcribed then Mmp3 (A.) and Mmp13 
(B.) gene expression analysed by qPCR and calculated as relative to β-actin using the ΔΔCt 
calculation outlined in section 2.6.2 then presented as a % of untreated control. Results are mean n=3 
+/- SEM, statistics were calculated by ttest: comparing pNHS and pNHS+OmCI (displayed on 
comparative lines above)  and comparing condition under inhibitor treatment with relevant DMSO 
control (displayed above individual bars) (ns=not significant *p<0.05, **p<0.01, ***p<0.001). 
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MEK/ERK signalling increased overall expression levels but suppressed the expression 
response at both time points suggesting a key role for MEK/ERK signalling in the Mmp13 
expression response to sublytic C. JNK inhibition had no influence on the Mmp13 
expression response resulting in a similar profile to that of the control although increasing 
expression levels overall. 
5.3.4 Roles of C5a and MAC 
Sublytic C experiments have so far been conducted using serum as a source of C and 
relied upon OmCI to switch off terminal pathway activation. Using OmCI in this way has 
obvious advantages that have been described in section 3.4.4 but by preventing C5 
cleavage it removes not only MAC but also the highly active cleavage product C5a from 
the system which under the conditions used with pNHS would be released during 
activation. It is therefore possible that C5a plays a significant activatory role alongside the 
MAC in mediating the observed effects on gene expression. 
5.3.4.1 C5a/C5aR axis 
Involvement of C5a in the expression response requires the presence of a C5aR 
expressed on the surface of CT26 cells. The presence of the receptor was assessed by 
detecting levels of mRNA transcript using qPCR and protein by western blot. Cells were 
cultured to 80% confluency in normal growth conditions and either RNA extracted or a 
whole cell extract (WCE) prepared. RNA was reverse transcribed as described in section 
2.5.4 and qPCR detection of C5aR performed by Dr Jack Ham (Institute of Molecular and 
Experimental Medicine Cardiff University) using a pre-existing qPCR primers and an 
optimized protocol (Figure 5.3.4.1A). WCE was prepared as described in section 5.2.2.2 
and both the pellet and supernatant analysed by western blot alongside the murine 
macrophage cell line J774.2 WCE pellet as a positive control (Figure 5.3.4.1B). Western 
blotting was conducted by Dr Carmen Van den Berg (Institute of Molecular and  
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Figure 5.3.4.1 C5aR expression by CT26 cells. A. qPCR analysis of C5aR mRNA expression using 
specific primers showing melt curve and amplification plots. B. Western blot analysis of CT26 WCE 
(supernatant and pellet) and a J774.2 WCE (pellet only) for a positive control, probed using an 
antibody raised against murine C5aR then developed using HRP conjugated secondary antibodies and 
the ECL system as described in section 2.8.   
  
1  2   3
25
150
50
37
75
100
kDa
1. CT26 WCE Supernatant
2. CT26 WCE Pellet
3. J774.2 WCE Pellet
C5aR
A.
B.
193 
 
Experimental Medicine Cardiff University) using a well established western blotting 
protocol for C5aR detection. 
C5aR expression 
CT26 were shown by qPCR analysis to express low levels of C5aR (Figure 5.3.4.1A). 
Expression level was not compared to a housekeeping or positive control instead qPCR 
analysis but was simply performed using 20 ng of cDNA (1 µg RNA reverse transcribed in 
10 µL volume; cDNA diluted in qPCR reaction mix at a final concentration of 1 ng/µL in 20 
µL). 
Melt curve analysis demonstrated a clean amplification of C5aR transcript with 
amplification curve reaching the threshold at cycle 34 indicating low level expression. 
Western blot analysis suggested that the expressed transcript for C5aR was not 
translated into detectable protein (Figure 5.3.4.1B). The pellet of WCE taken from J774.2 
macrophage cell line was clearly positive for C5aR protein giving a band between the 37 
and 50 kDa markers. This band was absent in both supernatant and pellet of CT26 WCE. 
C5aR inhibition and C5a treatment 
The role of C5a and the C5aR signalling was investigated by two opposing strategies; 
treatment of cells with the C5aR inhibitor PMX53 and treatment with commercially 
obtained purified human C5a (Abcam) (Figure 5.3.4.2). PMX53 is a low molecular weight 
cyclic peptide, AcF-[OP(D-Cha)WR], developed to improve upon larger c-terminal C5a 
peptidic inhibitors (Finch et al, 1999). PMX53 competitively binds C5aR but does not 
trigger GPCR activation as demonstrated by myeloperoxidase (MPO) release from human 
PMNs which could be effectively inhibited by PMX53 at µM concentrations (Wong et al, 
1998). Analogous to the pharmacological inhibitor experiments described in section 
5.2.3.2, cells were treated for 1 hour with or without 100 nM PMX53 in normal growth 
medium. Cells were then exposed to 5% pNHS and pNHS+OmCI treatment as before 
(section 2.4), maintaining the PMX53 dose in relevant conditions. 
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To assess the effects of C5a present in the system with the absence of terminal pathway 
activation, C5a was added back to cells exposed to pNHS+OmCI. C5a was added at final 
concentration of 0.4 µM, an excess of physiological concentration equivalent to the molar 
concentration of C5 present in serum. In addition, the effects of C5a alone were tested 
with cells incubated with complete growth medium with or without the addition of C5a to 
the same concentration. Cells were incubated in their respective conditions for 1 hour at 
37°C and RNA was extracted as before. RNA was reverse transcribed for qPCR analysis 
of Mmp3 expression response and presented as % of an untreated control (Figure 
5.3.4.2). Mmp3 gene expression response to sublytic complement was used because it 
represented a reliable readout that had been confirmed at both transcript and protein 
levels. 
Mmp3 was upregulated in untreated cells in response to pNHS treatment compared to 
pNHS+OmCI as in the validated data, though it did not reach significance (Figure 5.3.4.2). 
Under PMX53 inhibition of C5aR the effect was unaltered and upregulation in response to 
sublytic C reached significance (p<0.01). C5a added back to pNHS+OmCI condition did 
not reconstitute the upregulation observed in the pNHS condition and was not significantly 
different to pNHS+OmCI. Purified C5a added directly to medium induced a small 
upregulation compared to medium only control, though this was a much smaller increase 
compared to that provoked by pNHS and was not significant. 
Taken together the data suggests that C5a is not responsible for the observed expression 
responses to terminal pathway activation at least for Mmp3 expression. With no 
detectable C5aR protein present on the cells it is unlikely that the cells can respond to 
C5a to any significant degree. 
5.3.4.2 MAC 
In order to ascertain the role played by MAC in the observed gene expression effects, C6 
depleted serum (C6D) prepared in section 3.3.3.5 was employed. Cells were exposed to  
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Figure 5.3.4.2 The role of the C5a/C5aR axis in the observed Mmp3 gene expression changes. Cells 
were treated with or without PMX53 for 1 hour and exposed to pNHS or pNHS+OmCI conditions. 
Purified C5a at 0.4 µM was added back to a separately prepared pNHS+OmCI condition to reconstitute 
C5a. C5a was also added to normal growth medium along with a medium only control. Treatments 
were incubated for 1 hour then RNA extracted from cells monolayers. RNA was reverse transcribed 
and Mmp3 gene expression analysed by qPCR and calculated as relative to β-actin using the ΔΔCt 
calculation outlined in section 2.6.2 then presented as a % of untreated control. Results are mean n=3 
+/- SEM (**p<0.01). C5aAB statistics compare to pNHS+OmCI. 
 
Figure 5.3.4.3 The role of MAC in the observed Mmp3 gene expression changes. Cells were exposed to 
pNHS or pNHS+OmCI conditions as well as C6D serum and C6D serum with C6 added back to 50 
µg/mL of serum. Treatments were incubated for 1 hour then RNA extracted from cell monolayers. RNA 
was reverse transcribed and Mmp3 gene expression analysed by qPCR and calculated as relative to β-
actin using the ΔΔCt calculation outlined in section 2.6.2  then presented as a % of untreated control. 
Results are mean n=3 +/- SEM. 
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C6D with or without C6 reconstituted to 50 µg/mL of serum alongside pNHS and 
pNHS+OmCI conditions as a comparison with the inclusion of an untreated control. Cells 
were incubated for 1 hour at 37°C and RNA was extracted as before and reverse 
transcribed for qPCR analysis of Mmp3 gene expression ( 
Figure 5.3.4.3). C6D serum reconstituted with C6 was able to produce upregulation of 
Mmp3 compared to the C6D serum alone resulting in a similar upregulation induced by 
pNHS compared to pNHS+OmCI though neither of these effects were significant. The 
data appears to suggest that the observed gene expression responses are due to the 
formation of MAC at least for Mmp3. 
5.4 Discussion 
5.4.1 Validation of statistically significant changes 
Validation of the most significant expression changes selected allowed the microarray to 
be validated in an unbiased fashion. Genes were chosen so that upregulation and 
downregulation of the greatest significance and fold change values could be tested at 
each time point. Fam110c and Rgs16 representing upregulation at 1 hour, Irf1 
representing downregulation at 1 hour and Hbb-bh1 representing upregulation at 12 
hours, were each confirmed by qPCR analysis conducted on RNA extracted in parallel 
with that used for microarray (primary validation). In addition, qPCR was conducted using 
RNA extracted from an independent sublytic C experiment conducted in an identical 
manner (secondary validation). In all cases except for Rgs16, both primary and secondary 
validation qPCR data was in agreement with that of the microarray. This validation lends 
weight and confidence to the microarray data and the findings so far attributed to it. 
5.4.2 Validation of network analysis hits: qPCR 
Network analyses (section 4.2.5.2) suggested possible co-regulation of Areg, Cxcl1, 
Mmp3 and Mmp13 in response to sublytic C attack. Validation of these targets was 
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pursued using an identical strategy to that described above. In each case qPCR data 
confirmed the gene expression response described by microarray data i.e. an 
upregulation at both the 1 hour and the 12 hour time-points. There was some variation 
between the primary and secondary validation expression data especially for Cxcl1, and 
to some extent Areg, expression. For Mmp3 and Mmp13 both primary and secondary 
validations were in agreement. As discussed in chapter 4 their proposed interconnectivity 
and co-regulation make them interesting genes for further study given that there may be 
common mechanisms of control. Also, their roles as growth factors (Areg, Cxcl1) and 
extracellular matrix regulators (Mmp3 and Mmp13) make them possible candidates as 
tumour promoting genes expressed in response to sublytic C exposure. 
5.4.3 Validation variation 
Inevitably, there were discrepancies between microarray data and primary and secondary 
qPCR validation, most pronounced for Rgs16 and Cxcl1.  
Rgs16 expression, which was shown by microarray and primary qPCR to be significantly 
upregulated at the 1h time point but not at 12h, was shown to be upregulated at both time 
points by secondary qPCR, with the increase greatest after 12 hours. Since secondary 
validation was an independent repeat of the experiment it is likely that biological variation 
arising from unknown experimental factors is the cause. This suggests that the observed 
Rgs16 expression response to sublytic C is less robust than for the other validated genes. 
In the case of Cxcl1, array data showed a significant upregulation at both time points with 
the greatest increase at 1 hour. However, primary and secondary qPCR data showed 
upregulation of expression was most pronounced at 12 hours. In contrast with Areg 
validation, this discrepancy suggests a difference between microarray and qPCR methods 
for expression detection. Ensembl derived transcript sequences shown in section 5.2.1.2 
with labelled  microarray probes, demonstrate that Cxcl1 has no transcript variants and 
only 4 exons. If qPCR primers target this same transcript then differing levels of variants 
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cannot explain the difference between microarray and qPCR data. A more likely 
explanation is the location and proximity of the qPCR primers compared to the microarray 
probes since the two are designed to target opposite flanks of the transcript, indeed the 
forward primer is located on the 5’UTR and the probe on the 3’UTR. It has been 
demonstrated that the distance between the two is an important factor in the level of 
agreement between microarray and qPCR validation (Etienne et al, 2004). 
Though the qPCR validation of Rgs16 and Cxcl1 did not perfectly match, validation of 
Fam110c, Irf1, Hbb-bh1, Areg, Mmp3 and Mmp13 data did closely match their microarray 
counterparts, indicating the overall suitability of qPCR a validation tool. 
5.4.4 Validation at protein level 
In order to assess whether the gene expression responses led to an increase in levels of 
translated proteins western blots were carried out on whole cell extracts and conditioned 
media using antibodies against each of the network generated protein targets. Despite the 
lack of a proper loading control efforts were made to load equal quantities of protein by 
calculating the mass of precipitated protein pellets and adjusting the volume of loading 
buffer added so that 8 mg could be loaded per sample.  
AR 
There was a clear increase upon exposure to sublytic C of two high molecular weight 
forms of AR at the 50 and 36 kDa markers secreted into the medium over 24 hours. AR at 
the 36 kDa marker is likely to correspond with the 36 kDa fragment produced by cleavage 
of the preferred distal position on the membrane anchored pre-cursor (Brown et al, 1998).  
The 50 kDa AR band is likely the membrane tethered pro-form reported to be the 
dominant form by (Brown et al, 1998)). If this fragment was indeed the pro-form, its 
presence in CM suggests membrane fragment contamination which might have been 
eliminated by centrifugation or filtration. Another explanation is the release of vesicular 
bodies into CM, indeed sublytic C is known to induce production of MAC enriched vesicles 
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from mammalian cells as part of a C resistance strategy (Campbell & Morgan, 1985). In 
order to investigate whether this is the case, vesicular bodies of differing sizes can be 
isolated from the CM and run on a western blot to detect AR fragments. 
CXCL1 
CXCL1 in CM was not be seen by western blot under the described experimental 
conditions, no bands corresponded to the predicted 12 kDa mass. A higher molecular 
weight band of unknown identity at the 36 kDa marker was likely the result of non-specific 
binding or aggregates. Failure to detect the protein product suggested that abundance of 
the protein was below the limit of detection for western blot, therefore it is likely that ELISA 
would have been a more suitable method of detection.  
MMP3 
Western blotting for MMP3 showed that sublytic C attack  induced increased expression 
and greater activation of secreted protein. The two bands at 57 and 60 kDa are likely to be 
the unglycosylated and glycosylated pro-forms of MMP3 respectively. Given that the 60 
kDa form is dominant in WCE there is a possibility that, as was the case for the AR 
western blots, there were detached cells or vesicular bodies present in the CM. An MMP3 
band at 50 kDa, corresponding to the activated form, was also increased in CM confirming 
that the expression pattern described by microarray and validated by qPCR translates into 
protein production. 
MMP13 
Expression of MMP13 protein was not increased comparing pNHS with pNHS+OmCI; 
however, expressed MMP13 from pNHS-exposed cells was mostly activated MMP13 (48 
kDa) as opposed to the predominant pro-form found in control samples. Given that MMP3 
is known to be an efficient activator of MMP13 it can be hypothesised that the shift of 
MMP13 into its active form during pNHS exposure may be due to expression and 
200 
 
activation of MMP3 (Lochter et al, 1997). In the same way MMP3, MMP13 or both active 
enzymes may be responsible for cleavage and solubilisation of an active AR cleavage 
product from the membrane anchored pro-AR, indeed cleavage of pro-AR is known to be 
inhibited by treatment with metalloprotease inhibitors (Brown et al, 1998). However 
ADAM17 is well characterised as a key component for pro-AR ectodomain shedding 
(Sahin et al, 2004). 
Equality of protein loading was achieved by a crude method, less reliable than a protein 
assay or loading control such as β-actin staining. The latter was attempted but 
unfortunately failed to provide usable results within the time frame available. Obviously 
these limitations reduce the confidence in the protein expression changes. Also, again 
due to time pressures the presented blots were not confirmed by repeats, making 
interpretation of the data more difficult. This being said the data presented does provide 
some evidence that mRNA expression changes of Areg and Mmp3 are translated into 
changes in levels of expressed protein products. Interestingly, MMP13 expression was not 
increased but expressed protein was activated under sublytic C conditions. CXCL1 protein 
was not detected by WB. 
5.4.5 Pharmacological inhibition of signalling pathways  
Network analysis as described in section 4.2.5.2 implicated a number of signalling 
pathways which may co-regulate the validated responsive genes. The MAPK pathways, 
p38, JNK and MEK/ERK, as well as the PI3K pathway, were the four main implicated 
pathways. Pharmacological inhibition with small molecule drugs was used to ascertain the 
contributions made by each pathway. The results showed that overall p38 and JNK were 
not involved in the response but suggested involvement of MEK/ERK and PI3K  pathways 
in some of the observed effects.  
Areg expression was most affected by inhibition of MEK/ERK signalling. This pathway has 
been strongly associated with EGFR transactivation via the previously described 
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ectodomain shedding of pro-AR leading to proliferation (Kasina et al, 2009). The 
described response relied upon CXCL12 activation of ADAMs (or possibly MMPs) for the 
ectodomain cleavage. Given that Areg transcript expression was almost entirely knocked 
down by MEK inhibition in qPCR experiments, it may be that EGFR transactivation 
through ectodomain cleavage of an EGF family protein is responsible for the induction of 
Areg gene expression. Indeed Cxcl1 expression has been associated with EGFR 
transactivation via MMP mediated HB-EGF ectodomain cleavage, a process relying on 
MEK/ERK pathway (Bolitho et al, 2010).  
The role for CXCL1 as a trigger for EGFR transactivation is challenged by the relative 
reduction in Cxcl1 expression during MEK inhibition especially at 1 hour post exposure 
which suggests that Cxcl1 response also relies in part upon MEK activation or perhaps 
the response is indirect via an unknown mechanism, able to recover at 12 hour in a way 
that Areg did not. Inhibition of Cxcl1 at the 1 hour time point by the PI3K inhibitor and 
subsequent recovery at 12 hours suggests both pathways may be involved. Cxcl1 
expression is known to involve activation of ERK1/2 and p38 MAPK pathways (Yang et al, 
2008), however while involvement of PI3K has not previously been described in 
endothelial derived cell types (from which CT26 are derived) it has been shown to be 
involved in Cxcl1 expression by macrophages (Pickens et al, 2011).  
Potentiation of the Cxcl1 expression response by suppression of p38 suggests a role as a 
negative regulator, a phenomenon which has previously been described in hepatocytes, 
however the mechanism is as yet unclear (Wiechert et al, 2012). Areg gene expression 
response to sublytic C was also potentiated by inhibition of p38 signalling pathway. 
Precedent for p38 acting to inhibit gene expression, whilst ERK being required to activate 
it has been described during Ras activation and formation of growth factor autocrine loops 
in epithelial cells, this may explain the observed potentiation effects for both Areg and 
Cxcl1 under p38 inhibition (Pruitt et al, 2002). 
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PI3K signalling was implicated by pharmacology experiments in the sublytic C attack 
mediated Mmp3 upregulation, but not that of Mmp13. However, MEK/ERK was implicated 
in upregulation of both Mmp3 and Mmp13. EGFR activation has been shown to induce 
Mmp3 and Mmp13 via both MEK/ERK and PI3K signalling pathways in a number of 
contexts (Meierjohann et al, 2010; Shukla et al, 2006). This points to the key involvement 
of MEK/ERK and to a lesser extent PI3K in mediating Mmp3 and Mmp13 expression in 
response to sublytic C attack. 
The phosphoinositide 3-kinase (PI3K) pathway refers to a signalling pathway which 
harnesses inositol phospholipid metabolism as a means of transduction. PI3Ks are a 
family of enzymes responsible for the phosphorylation of inositol phospholipids at the 3’-
OH position. This leads to the generation of PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 
which influence activation and localisation of several proteins possessing the pleckstrin 
homology domain (PH) (Rameh et al, 1997). PH domain containing proteins are generally 
signalling molecules and include protein kinases such as Akt (aka PKB or RAC) a 
serine/threonine kinase which is associated with receptor tyrosine kinase signal 
transduction (Burgering & Coffer, 1995). It is the PI3K/Akt pathway which has been most 
often associated with cellular responses to MAC deposition such as modulation of 
apoptosis and proliferation (Fosbrink et al, 2006; Soane et al, 2001). 
The Raf/MEK/ERK MAPK pathway has previously been discussed in this thesis as being 
associated with growth factor cell activation, proliferation and protection from apoptosis 
(Mebratu & Tesfaigzi, 2009). Raf/MEK/ERK signalling has been demonstrated to be 
triggered in response to MAC deposition and was associated with a proliferative response 
in part through junD and c-fos gene upregulation (Rus et al, 1997). It has also been 
associated with the induced protection phenomenon (Kraus et al, 2001). 
Overall the data suggests involvement of MEK/ERK and PI3K as the signalling pathways 
important in mediating the responses observed of upregulation upon exposure to sublytic 
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C. Indeed MEK/ERK appears to be the most important. MEK/ERK and PI3K are both key 
pathways involved in transduction of EGFR activation where they act to promote 
proliferation and survival respectively (Aksamitiene et al, 2010). MEK is the upstream 
effector of ERK1/2 phosphorylation and during growth factor signal transduction is 
activated through RTK/Ras sequential activation which initiates the Raf/MEK/ERK 
pathway (Chang et al, 2003). EGF treatment of cells has been demonstrated to increase 
ERK activity over several hours which coincided with a number of gene upregulations 
(Mullenbrock et al, 2011). The crosstalk of PI3K with MEK/ERK activation may explain 
their co-involvement since they appear to be activated in parallel and could be co-
regulatory, indeed it could be hypothesised that PI3K promotes the MEK response 
through co-activation of Raf (Chang et al, 2003). This might explain why inhibition of PI3K 
did not fully suppress Mmp3 and Cxcl1 responses which for Cxcl1 recovered after 12 
hours, perhaps indicative of MEK/ERK overcoming PI3K inhibition. In addition whilst PI3K 
inhibition was not sufficient to suppress the upregulation completely, MEK inhibition 
universally suppressed it. 
These data provide some preliminary evidence of a central role for MEK/ERK activation in 
transduction of sublytic C induced signalling with possible involvement of PI3K. They also 
show that p38 and JNK pathways are not obviously involved. Within this a key role played 
by EGFR is suggested. Taken together, a possible hypothesis might be that EGFR is 
activated upon the event of a sublytic C attack, triggering MEK/ERK supported by PI3K 
signalling cascades. This is in agreement with the central segment of the network 
generated in section 4.2.5.2 which linked EGFR to PI3K and MEK/ERK. To confirm the 
involvement of EGFR in mediating the expression response an inhibitor of the EGFR 
receptor such as AG1478 could be used and the experiment repeated. If EGFR is a 
central effector in mediating the effects its inhibition would be expected to suppress the 
gene expression response.  
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5.4.6 C5a/C5aR axis 
5.4.6.1 C5aR expression 
Expression of the C5aR on the cell surface is required for C5a to exert influence on local 
cells. Sublytic C experiments described in this thesis have used human serum on a 
murine cell line, CT26 cells. Therefore when considering C5a/C5aR axis involvement it is 
important to consider that human C5a is known to be capable of ligating and activating 
murine C5aR (Gerard & Gerard, 1994). Expression data at transcript level suggested a 
low level expression in CT26 cells but western blot data suggested that this was not 
translated into protein. With no surface expression of C5aR it is less likely that C5a plays 
a central role in the observed sublytic C induced gene expression changes. Upon 
treatment with PMX53, a cyclical peptide inhibitor of C5aR, the repeatable expression 
response of Mmp3 was unaltered further ruling out the role played by C5aR 
5.4.6.2 C5a 
 In experiments using commercially obtained purified human C5a protein on CT26 cells, 
no upregulation of Mmp3 was observed. C5a was added at a final concentration of 0.4 µM 
which was calculated as the concentration of C5 in serum. C5a was added at huge 
excess because the concentration was calculated for neat serum but erroneously added 
as a final concentration resulting in 20 fold excess. In addition the calculated quantity was 
based upon the concentration of C5, incorrectly assuming complete cleavage of all C5, 
however, in reality only 50% of available C5 is cleaved. As a result C5a was added at 
roughly 40 fold excess to physiologically relevant levels. C5a is often used in in vitro 
experiments at a concentration of  10 nM and a dose dependent effect can be seen in 
Ca2+ release by astrocytes during C5a treatment between 0.1 and 100 nm (Gasque et al, 
1995). Given the excess of C5a added, if C5a was responsible for the changes in gene 
expression caused by pNHS, it would be expected that a significant response might have 
been observed but in reality there was little effect on Mmp3 expression. 
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Taken together the data suggests that a lack of C5aR expression on the cell surface 
prevents C5a from exerting an effect on CT26 cells under sublytic C conditions. This 
makes a role for C5a in mediating the observed gene expression responses unlikely, 
though it may contribute. Therefore the remaining terminal pathway components are 
implicated.  
5.4.7 MAC 
To further underline a role for the MAC in the observed effects C6D serum was used 
which retains the ability to activate complement, including the release of C5a, but is 
incapable of forming the MAC complex. C6D ability to form MAC was significantly reduced 
as shown in reduced haemolytic and CDC activity (section 3.3.3.5). These activities were 
reconstituted with the addition of C6. Expression data from Mmp3 showed that treatment 
with C6D serum resulted in similar expression levels to cells exposed to OmCI treated 
serum and untreated controls. This implies that the activation of C and the release of C5a 
is not enough to induce the expression response seen in pNHS treated cells. Indeed, 
upon the addition of C6 the cells responded in a similar manner to pNHS treatment and 
Mmp3 was upregulated. This is good evidence that MAC is required for the observed 
expression responses. 
5.5 Summary and conclusions 
Out of the 8 candidate genes 4 demonstrated the validity of the microarray experiment as 
a detector of expression change providing confidence in the discoveries made. The 
remaining genes were highlighted by network analysis as being possibly co-regulated and 
showing previous links in tumour progression/cancer cell growth therefore strong 
candidates for investigation. In addition to qPCR confirmation of a transcription response 
by Areg, Cxcl1, Mmp3 and Mmp13 these genes were confirmed at the protein level by 
western blot of which the response could be demonstrated for MMP3, MMP13 and AR 
protein levels and activation states but CXCL1 was not successfully corroborated. Further 
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investigation of the confirmed expression changes by pharmacological inhibition of PI3K 
and JNK, ERK and JNK MAPK pathways demonstrated that MEK/ERK and to a lesser 
extent PI3K activation were important in signalling the response triggered by sublytic C 
exposure. CT26 cells were shown to express small amounts of transcript but  lacked 
C5aR on their surface. C5aR inhibitors did not inhibit, and addition of extrinsic C5a could 
not replicate the sublytic C response to pNHS compared to pNHS+OmCI. Treatment of 
cells with C6D+C6 compared to C6D alone induced an upregulation of Mmp3 which 
closely resembled that induced by pNHS compared to pNHS+OmCI strongly implicating 
the MAC complex as the central mediator of the effects. 
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6 Discussion 
6.1 Hypothesis 
This thesis has been concerned with the effects of the terminal pathway of C on tumour 
cells and in particular its effects on gene expression. The end product of terminal pathway 
activation, the MAC, is a potent activator of cells and influence on cell fate when deposited 
on nucleated cells, with a plethora of effects, including induction of expression of 
inflammatory mediators/cytokines (Cybulsky, 1991; Morgan, 1989; Schonermark et al, 
1991), alterations in ECM components/regulators (Lueck et al, 2011; Torbohm et al, 
1990), triggering entry into the cell cycle (Rus et al, 1996) protection from apoptosis (Rus 
et al, 1996) and induction of apoptosis ((Liu et al, 2012). It is through these effects on cell 
function that C promotes tumour formation and cause it to be considered a contributor to 
disease. 
The hypothesis investigated was that tumour cells may respond to sublytic C 
membrane attack by up-regulating genes which bestow the tumour with a more 
metastatic and proliferative phenotype. 
6.2 Summary of main findings 
To investigate the above hypothesis, the murine colon carcinoma cell line CT26 was used 
as an in vitro model to study the sublytic effects of C attack. Pooled normal human serum 
was used as a C source which auto-activated on the cells, probably through the presence 
of natural antibodies; though this was never confirmed it is the most likely explanation. 
Cells were shown to be susceptible to C lysis and had a sublytic threshold, defined as that 
which caused less than 10% lysis, of 5% serum. The recombinant terminal pathway 
inhibitor OmCI, a C5-binding protein derived from the soft tick Ornithodoros moubata, 
served as a control allowing the terminal pathway specific effects to be deduced. 
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 OPN and uPA which are known to increase metastatic potential in cells which express 
them, were upregulated in response to sublytic C (Wai et al, 2005). It was shown that 
CT26 cells expressed very low levels of the terminal pathway regulator CD59a. Sublytic C 
attack on CT26 cells overexpressing CD59a resulted in only a minor suppression of the 
effect on OPN and uPA seen in control cells. This indicates that these particular gene 
expression changes were little affected by increasing CD59a expression and were thus 
unlikely to be mediated via  signalling shown previously to be caused by CD59 cross-
linking (Murray & Robbins, 1998). The evidence suggests that MAC pore is responsible 
for the observed expression change and that inhibition of its formation effectively reduces 
the effect. 
Expression of OPN mRNA by CT26 cells was then shown to increase steadily over the 
course of 12 hours exposure to sublytic C conditions. OPN upregulation by sublytic C has 
previously been reported as a marker for tubular injury in a study that suggested a key 
role for MAC (Nangaku et al, 1999). OPN expression is likely a stress response which for 
a forming tumour provides several advantages; it is capable of acting as a chemokine and 
promotes tumour-supporting local inflammation, can promote metastasis by acting as an 
adhesion molecule and can be anti-apoptotic through the ligation of receptors and 
stimulation of signalling cascades (Wang & Denhardt, 2008). 
Following the successful establishment of an in vitro model of sublytic C attack on tumour 
cells, global gene expression analysis using microarray technology was used to identify 
an expression profile of genes reactive to sublytic C. Primary analysis was performed 
using Partek software. Data were quality checked by PCA and shown to be well separated 
by experimental grouping. The separation described through PCA was a significant 
observation showing that a definable gene expression response to sublytic C could be 
detected, giving clear evidence of an effect despite the substantial influence of serum 
factors. Using ANOVA statistics, lists were generated of the most differentially expressed 
genes responsive to C. This analysis highlighted a number of genes with products 
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involved in  Ca2+, G-protein, and MAPK signal regulation, c-fos, Egr1 and Egr2 
transcription factors, Areg and Bdnf growth factors, and inflammatory signal regulators. 
Representative genes were found for upregulation and downregulation at 1 and 12 hours; 
Fam110c, Rgs16, Irf1 and Hbb-bh1, for validation. 
Pathway and network analysis was performed using a systems biology approach with 
GeneGo MetaCore software. Enrichment analysis of the data further crystallized the 
involvement of MAPK signalling. Network analysis of genes upregulated in the test 
conditions at both time points revealed four key downstream genes which were apparently 
co-regulated through a number of canonical pathways converging on the EGFR receptor. 
The four network derived genes were Areg, Cxcl1, Mmp3, and Mmp13. Network analysis 
also suggested the involvement of the MAPK, PI3K signalling cascades leading to gene 
expression control via AP-1 and NFκB. 
The data derived from the microarray analysis was in agreement with published literature 
describing the effects of MAC deposition on nucleated cells, including causing Ca2+ fluxes, 
G-protein activation together with PI3K and MAPK signalling (Campbell et al, 1979; 
Dashiell et al, 2000; Fosbrink et al, 2006; Rus et al, 1997). Further reported effects which 
could influence broad changes in gene expression include induction of expression of c-
fos, a member of the AP-1 family of transcription factors (Rus et al, 1996). Involvement of 
the EGFR in mediating intracellular signalling by MAC has been previously described, 
proposed to be by transactivation via G-protein coupled receptors (Cybulsky et al, 1999). 
Induction of Mmp3 and Mmp13 gene expression in response to sublytic C has also 
previously been reported in chondrocytes but responses involving Areg and Cxcl1 are 
novel (Wang et al, 2011). 
Microarray data were validated experimentally by qPCR analysis conducted using both 
RNA extracted in parallel with that used for the microarray experiment (primary) and an 
independent experimental repeat (secondary). Primary and secondary validation of 
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statistically significant changes and the network derived hits showed a high degree of 
agreement, confirming the biological relevance of the microarray data. The upregulation of 
Areg and Mmp3 gene expression was further examined at the protein level by western 
blotting to confirm whether the changes seen at mRNA level were translated into changes 
in levels of expressed protein. For both protein products I showed that sublytic C 
stimulated increases in protein level. Overall levels of Mmp13 protein product were not 
increased, however the balance between the pro-form and the activated form of the 
protein shifted dramatically towards the latter. Cxcl1 protein could not be detected by 
western blot with the available reagents and so the changes seen in the mRNA could not 
be confirmed at protein level. 
Various pharmacological inhibitors were used to investigate the involvement of PI3K and 
the three MAPK pathways implicated by network analysis. JNK and p38 signalling 
pathways were shown not to be involved in the observed responses, however, p38 was 
shown to have an overall inhibitory influence on gene expression of the four network 
derived genes. MEK/ERK signalling appeared to play a central role in the upregulation of 
Areg, Cxcl1, Mmp3 and Mmp13 gene expression responses with PI3K acting as a co-
activator. 
Since use of OmCI blocks release of C5a as well as MAC formation, the role of the 
C5aR/C5a axis in the observed gene expression responses was investigated. C5aR 
transcript expression was present in CT26 cells but surface expression was not 
detectable. Addition of C5a to CT26 cells had no effect on Mmp3 expression and PMX53, 
a C5aR inhibitor did not suppress the upregulation of Mmp3 in cells attacked by sublytic 
C. Therefore, C5a through the binding of C5aR, could be ruled out as the key terminal 
pathway component responsible for mediating the response.  
To further define the role of the MAC in mediating the effects seen, C6D serum was used. 
C6D is capable of C activation up to and including C5a release but lacks the capacity to 
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form MAC. The ability to produce the MAC was restored by the addition of C6. C6D serum 
failed to elicit any increase in Mmp3 expression whereas C6D with C6 added induced a 
similar increase in Mmp3 expression to those shown by pNHS when compared to 
pNHS+OmCI controls. This was compelling evidence that MAC is the key mediator of the 
observed effect and further discounted the role of C5a. 
6.3 Tumour promoting MAC 
Each of the four key genes identified during the expression studies in this thesis as 
responsive to sublytic MAC encode proteins reported to possess tumour promoting 
properties and are strongly associated with several tumorigenic disease processes. MAC 
deposition was shown here to induce the expression of Areg (AR), Cxcl1( CXCL1), Mmp3 
(MMP3) and Mmp13 (MMP13) in tumour cells, which have known roles in proliferation and 
metastatic potential. The changes in expression caused by sublytic MAC on this particular 
set of genes may thus represent a possible mechanism by which low level MAC 
deposition and the chronic inflammatory context it engenders benefits the cells of a 
forming tumour. 
Expression of AR has been shown to be increased, at mRNA and protein levels, in a 
number of human cancer tissues including breast, colon, liver, ovary and pancreas 
compared to healthy counterparts (Castillo et al, 2006; Ciardiello et al, 1991; D'Antonio et 
al, 2002; Ebert et al, 1994; Lejeune et al, 1993). AR has been shown to play a role in 
tumorigenesis via its function as a growth factor through the development of autocrine or 
juxtacrine loops in hepatocellular carcinoma (Castillo et al, 2006), colon carcinoma 
(Johnson et al, 1992), pancreatic cancer (Murphy et al, 2001) and breast cancer 
(Willmarth & Ethier, 2006) cells. AR loops are self-sustaining, self-stimulating AR 
expression which acts through the EGFR receptor to support proliferation of transformed 
cells (Castillo et al, 2006). AR stimulation can also support cell survival through protection 
from apoptosis through Akt and STAT3 pathways and upregulation of Bcl-xl (Berasain et 
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al, 2005). AR has been shown to induce increased motility and invasion as part of its 
wound healing and tissue development roles in healthy tissue through upregulation of a 
number of associated genes (Willmarth & Ethier, 2006). 
The described roles define a gene product which can bestow several advantages to 
forming tumours and indeed this translates into patient outcome and survival. (Fontanini et 
al, 1998; McBryan et al, 2008). A strong correlation between AR expression and survival 
has been demonstrated in lung, breast and colon cancers and high expression levels in 
colon carcinoma have been shown to be predictive of disease aggression and liver 
metastasis development (Fontanini et al, 1998; McBryan et al, 2008; MichiyoYamada et 
al, 2008).  
CXCL1 expression at the transcript and protein level has been shown to be increased in 
colorectal, gastric, bladder and ovarian cancers when compared to healthy tissue (Junnila 
et al, 2010; Kawanishi et al, 2008; Rubie et al, 2008; Yang et al, 2006). CXCL1 production 
at inflammatory sites is required to recruit immune cells such as neutrophils but in the 
tumour microenvironment of mouse breast cancer cells, it is capable of recruiting myeloid 
derived suppressor cells (MDSCs) which are shown to support tumour growth and 
metastasis as well as suppress the local immune response (Acharyya et al, 2012; Diaz-
Montero et al, 2009; Yang et al, 2004). CXCL1 can also exert autocrine growth signals 
directly on tumour cells via binding of CXCR2 thus promoting their proliferation (Bordoni et 
al, 1990). In addition CXCL1 can support tumour growth through directly promoting 
angiogenesis and metastasis in autocrine/paracrine loops (Acharyya et al, 2012; Strieter 
et al, 1995; Wang et al, 2006). A role in tumour self-seeding has also been proposed in 
which CXCL1 expression by tumour mass helps homing of tumour derived cells from 
circulation where they can contribute to tumour invasion and metastasis (Kim et al, 2009). 
Like AR, the tumour promoting functions of CXCL1 mean that expression by tumour tissue 
is correlated with patient outcomes. This is true for gastric cancer patients where 
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expression levels correlate with disease stage, likelihood of metastatic development and 
number of lymph node metastases (Jung et al, 2010). CXCL1 expression has also been 
shown to correlate with poorer relapse free survival in stage III colorectal cancer (Oladipo 
et al, 2011). 
Matrix metalloproteinases (MMPs) have long been associated with tumour development 
and progression primarily through their role in degrading and remodelling the ECM 
(Egeblad & Werb, 2002). MMPs contribute to tumour progression through their ability to 
promote angiogenesis, tumour invasion and metastasis (Deryugina & Quigley, 2006). In 
addition to these functions, MMPs can cleave and activate molecules in ECM with various 
tumour promoting roles such as inducing proliferation, motility and alterations in adhesion 
(Lukashev & Werb, 1998). Increased expression of MMPs is associated with poor tumour 
differentiation, increased invasiveness, poor prognosis, increased likelihood of metastasis 
and shorter survival time (Deryugina & Quigley, 2006).  
MMP3 proteolytic cleavage can release E-cadherin, L-selectin, HB-EGF and TNFα as well 
as activate MMPs, proteases and protease inhibitors (Sternlicht et al, 1999). It has been 
proposed that by releasing/activating these factors, MMP3 acts as a central mediator of 
mammary tumorigenesis as a subversion to its role during normal tissue development 
(Sternlicht et al, 1999). MMP3 can induce a stable change from an epithelial to 
mesenchymal phenotype (epithelial to mesenchymal transition (EMT)) a process which is 
closely linked to tumour development (Lochter et al, 1997). 
MMP13 in the tumour microenvironment has a number of roles in promoting tumour 
development, growth and metastasis. Activities key to this role are its collagenase and 
angiogenic activities. In a melanoma model MMP13 promoted angiogenesis, though 
expression did not to correlate with VEGF levels, suggesting an independent mechanism 
which contributed to organ specific metastasis (Zigrino et al, 2009). The angiogenic 
properties of MMP13 were investigated on HUVECs, though in opposition to the 
214 
 
melanoma model, VEGF was shown to be partly responsible for the promotion of tube 
formation and did not require protease activity, suggesting a direct and indirect influence 
(Kudo et al, 2012). In this same report MMP13 expression was shown to correlate with 
vascular density in human cancers. 
MMP13 is overexpressed at transcript and protein levels in colon and breast cancers 
(Chang et al, 2009; Mori et al, 2005; Roeb et al, 2004). MMP13 expression is also 
associated with poor prognosis in colorectal and head and neck cancer and is proposed 
as a predictive marker for patient outcome (Huang et al, 2010; Leeman et al, 2002; 
Luukkaa et al, 2006). Indeed in prostate and oesophageal cancer patients MMP13 
correlates to tumour metastasis and poor outcome, and thus may be used as a biomarker 
for metastatic spread (Morgia et al, 2005; Ye et al, 2011). 
The process of EMT is characterised by loss of cell-cell contact, disruption of epithelial cell 
polarity, cytoskeletal organization, cell adhesion and production of ECM (Turley et al, 
2008). It is associated with development and wound healing as well as disease processes 
such as driving tumour development and metastasis (Kalluri, 2009). CXCL1, MMP3 and 
MMP13 are each shown to be upregulated in, and therefore considered markers for, EMT 
(Lim et al, 2011; Radisky et al, 2005; Toh et al, 2011). The contribution made by 
upregulation of CXCL1, MMPs and EGFR ligands to EMT and metastasis may extend to 
the preparation of target organ tissue to create premetastatic niches (Kaplan et al, 2006; 
Minn et al, 2005) 
Increased gene expression of Cxcl1, Areg, Mmp3 and Mmp13 upon MAC deposition 
therefore presents a novel mechanism by which C activation may lead to tumour 
promotion through alterations to the tumour:stroma interaction, bestowing cells of the 
tumour with proliferative, anti-apoptotic and angiogenic signals as well as the capability to 
degrade local ECM and metastasise. 
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6.4 Mechanism of MAC signalling 
A great many signalling pathways have been described to be triggered upon MAC 
deposition onto mammalian cells, including Ca2+, PKC, PI3K as well as the three MAPK 
pathways; p38, JNK and ERK (Aoudjit et al, 2003; Campbell et al, 1979; Cybulsky et al, 
1995; Cybulsky et al, 1998; Niculescu et al, 1999; Rus et al, 1997).The exact mechanism 
by which MAC triggers signalling, if indeed it is specific and consistent, has eluded many 
investigators but Gαi, Gβɣ, receptor tyrosine kinase (EGFR, PDGFR) activation have all 
been implicated (Cybulsky et al, 1999; Niculescu et al, 1997; Soane et al, 2001). Evidence 
presented in this thesis from microarray analysis and pharmacology experiments, has 
pointed towards an EGFR mediated activation of MEK/ERK supported by PI3K in 
response to deposition of MAC resulting in the upregulation of Areg, Cxcl1, Mmp3 and 
Mmp13.  
Cross-talk between PI3K and MEK/ERK is a well established phenomenon but the distinct 
mechanisms and nature of this interaction are not well defined. Focussing on the 
Ras/Raf/MEK/ERK pathway an interaction with PI3K has been described post Ras-GTP 
since PI3K can bind and be activated by it (Rodriguezviciana et al, 1994). However in the 
EGFR activated Ras/Raf/MEK/ERK pathway, PI3K was shown to support activation both 
pre and post-Ras, but this was only observed under low level EGFR activation and so the 
importance of PI3K in this pathway is highly context dependent (Wennstrom & Downward, 
1999). EGF receptor signalling through PI3K and ERK may be coupled through regulation 
of Gab1 scaffold protein and this interaction has the ability to sustain MEK/ERK activation 
(Kiyatkin et al, 2006). This interaction is therefore complex and difficult to pin down with 
the available data and so is ripe for further interrogation. 
EGFR activation by MAC is hypothesised as a transactivation via ligand independent 
induction of tyrosine phosphorylation of EGFR RTK via GPCRs (Cybulsky et al, 1999; 
Daub et al, 1997; Daub et al, 1996). This transactivation may be due to Ca2+ influx, the 
well characterised first cellular response to sublytic MAC, shown to induce EGFR 
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activation of MAPK signalling in vascular endothelial cells (Campbell et al, 1979; Eguchi et 
al, 1998). 
Both MEK/ERK and PI3K pathways are associated with tumour survival and proliferation 
signals. Indeed Raf activation has been shown to induce autocrine expression of the EGF-
like growth factors including AR in sustained Raf/MAPK pathway stimulation as part of a 
tumour promoting mechanism (Schulze et al, 2001). The two pathways are also shown to 
contribute to survival through caspase 9 inactivation and inhibition of apoptosis (Cardone 
et al, 1999). 
Taken together, MAC induced EGFR transactivation, possibly via Ca2+ influx, mediating 
activation of MEK/ERK alongside PI3K is a compelling explanation for the observed gene 
expression responses. This may be the initial trigger for Areg upregulation which goes on 
to form a feedback loop sustaining activation and promoting the upregulation of Cxcl1, 
Mmp3 and Mmp13. MAC stimulation of EGFR-Ras/Raf/MEK/ERK can therefore be 
considered a possible mechanism of tumorigenesis driven by sublytic C.  
6.5 Future work 
To investigate the role of the EGFR triggered activation of the PI3K and MEK/ERK 
pathways, vector expressed siRNA transfected for specific knock down of early and late 
pathway members could be used to determine their roles in signalling. This has an 
advantage over pharmacology in that it is highly specific and controlled so that effects on 
phosphorylation of downstream controllers such as ERK can be quantified using western 
blot stained using phosphorylation state specific antibodies. Furthermore, transcription 
factor activity could be assess using EMSA or CHiP techniques. 
The work described in this thesis demonstrates a mechanism by which activation of the C 
terminal pathway might promote tumour development and metastasis. To confirm the 
impact of the gene upregulation cell motility and invasiveness as measurements of 
217 
 
metastatic potential, a transwell experiment could be performed using a matrigel insert. 
Cells exposed to pNHS and pNHS+OmCI would be placed in the upper chamber and 
serum used as a chemoattractant. Cells exposed to sublytic C would be expected to have 
increased capacity to degrade and migrate through the matrigel by virtue of upregulated 
MMP3 and 13 expression. Conditioned medium used in place of serum, as the 
chemoattractant would demonstrate whether expression of CXCL1 influences the 
migratory potential, this could be performed with or without matrigel. Proliferation could 
also be measured to ascertain the influence of Areg and Cxcl1 upregulation on growth 
potential. 
The work presented in this thesis makes use of a murine cell line, CT26 colon carcinoma 
cells. These were used in anticipation of using them to create an animal model to confirm 
the in vitro results in vivo. CT26 cells would be injected into WT and C3, C6 or C5 
knockout BALB/c mice and tumour growth monitored over ~30 days (Current knockout 
mice held at Cardiff animal house are C57BL/6 and so it may be necessary to use the B16 
cell line instead of CT26). Tumours would then be resected and analysed for Areg, Cxcl1, 
Mmp3 and Mmp13 gene expression by qPCR and protein expression assessed by 
immunostaining of fixed tissue. It would be expected that tumour promoting gene 
expression would occur in increased tumour growth rate and reduced survival in C 
sufficient mice compared to C knockouts. Tumours could also be assessed for tumour 
infiltrating leukocytes including the possible presence of MDSCs using FACS analysis. In 
addition to primary tumour analysis the formation of lung metastasis could be quantified 
and assessed for gene expression. Metastatic nodes would be expected to be more 
frequent in C sufficient WT mice and their tumour cells would be expected to be higher 
expressors of the four genes.  
The described model could also be used to test the efficacy of therapeutic strategies. 
Using C6 anti-sense oligonucleotides (RNAi) delivered via a lentiviral system C6 could be 
knocked down in the tumour cells and used in the WT mice in an injectable model. 
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Treatment would be compared to a nonsense oligo and readouts repeated as above. 
Also, an available anti-C5 reagent BB5.1, commonly used in C driven disease research, 
could be used in the WT injectable model and compared to an IgG control. The mouse 
mAb BB5.1 binds mouse C5 and prevents it’s cleavage, effectively blocking terminal 
pathway activation. Treatment with BB5.1 would determine the effect of MAC and C5a on 
tumour development in vivo and may provide information on the relationship between the 
two and whether this is additive or synergistic. BB5.1 is homologous to the human mAb 
eculizumab which will be discussed in the following section. C intervention would be 
expected to reduce gene expression responses in tumour cells and reduce development 
and metastasis formation in a manner homologous to KO models. These investigations 
would inform treatment regimens which could be adapted for cancer patients. 
A confounding factor in KO, RNAi and inhibitor treatment experiments is the expression of 
terminal pathway components by the injected cells. This would result in C sufficiency in 
the tumour microenvironment serving to make the KO/RNAi/inhibitor  strategy ineffectual 
in the relevant context. In order to address this problem it might be necessary to perform 
additional experiments in which terminal pathway component expression by injected cells 
is knocked down using RNAi. This could be performed in the same way as described for 
above experiments in WT and KO mice as well as RNAi knock down and inhibitor 
treatments, providing information on the importance of local vs. systemic sources of C 
terminal pathway components. 
6.6 Treatment strategies 
The findings of this thesis have demonstrated the pro-tumour role for C and shown that 
low level activation can be a contributor to tumour development, growth and metastasis. 
This forms part of the contribution to tumorigenesis made by inflammation. Importantly the 
use of anti-tumour mAb in immunotherapy which harness C activation for efficacy may 
require cautious administration since sub-effective doses, analogous to antibiotic 
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resistance, may promote tumour development and resistance to treatment through 
sublytic levels of MAC.   
Treatment of cancer patients using C therapeutics to reduce this contribution might target 
C terminal pathway activation. Eculizumab could be used, a humanized monoclonal anti-
C5 antibody which binds to C5 and prevents it’s cleavage. Eculizumab is licensed for use 
in paroxysmal nocturnal haemoglobinuria (Hillmen et al, 2006). This prevents release of 
C5a and formation of MAC. In addition to reduction in MAC mediated effect, C5a release 
would be reduced, shown to have potential pro-tumour roles through recruitment and 
activation of suppressive MDSCs to the tumour micro-environment (Markiewski et al, 
2008).  
Alternatively, to inhibit MAC formation alone a soluble form of CD59 (sCD59) which is able 
to tether to membrane could be used, a strategy which has been developed for use in 
PNH (Hill et al, 2006). An alternative to this would be systemic knockdown of C6 using 
anti-sense oligonucleotides (RNAi) delivered by viral vector system to the liver (Fluiter et 
al, 2011). Removal of MAC formation would prevent any pro-tumour influence of MAC 
deposition but leave the remaining C functions intact including opsonization and 
anaphylatoxin release. Ability to control infection would be retained but increased 
susceptibility to Neisseria infection would necessitate monitoring. 
Since tumours often express high levels of membrane bound C regulatory proteins 
(mCregs), tumour localised sublytic C may be the result of robust activation on well 
protected cells (Fishelson et al, 2003; Jurianz et al, 2001). Evidence for which is shown by 
the deposition of C products and increased activation characteristics (Niculescu et al, 
1992). It might be possible to reduce CD59 expression through tumour cell targeted 
knockdown (Shi et al, 2009). By removing regulation during immunotherapy perhaps C 
activation could shift towards lytic levels and become anti-tumour. 
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Strategies to prevent tumour promoting sublytic C effects would best be deployed in the 
early stages of development. Recently transformed or pre-malignant cells may require 
certain triggers for transition and C activation may be a key component in this switch. 
Indeed the pre-malignant state might itself be assisted through inflammatory processes as 
is the case in breast cancer and mesothelioma (Dostert et al, 2008; Lochter et al, 1997).  
6.7 Concluding remarks 
A role for C in tumour promoting inflammation has only very recently gained substantive 
recognition. The work presented in this thesis provides evidence to suggest that MAC 
deposition which does not result in cell lysis is a potent tumour cell activator leading to 
significant changes in gene expression. Indeed the work suggests that a gene expression 
response might be indicative of a shift in tumour behaviour through induction of 
proliferative, migratory and survival pathways. The work also suggested that sublytic MAC 
may trigger the EGFR system. This phenomenon has been shown before but by exploiting 
microarray technology and systems biology this work provides more evidence of its role 
and the possible consequences of this activation. A role for sublytic MAC in tumour 
development therefore presents a therapeutic opportunity which no doubt could benefit 
from the C terminal pathway targeting drugs currently available. 
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